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Abstract 
 
Constraints of cell supply indicate that proliferating cell lines are likely to 
be essential components of Bio-Artificial Liver support devices (BAL) for 
the treatment of acute liver failure. The Liver Group BAL employs clones of 
cells derived from the HepG2 cell line, which in common with many tumour 
derived cells, are predominantly dependent on anaerobic glycolysis for 
energy supply, leading to production of lactate within the bioreactor. The 
BAL system requires prolonged culture of alginate encapsulated HepG2 
cells, and lactate accumulation presents a potential hazard in this system: at 
~15 mM, accumulated lactate becomes toxic to the cells in the bioreactor, 
and also compromises alginate bead integrity by chelating the calcium ions 
necessary for alginate polymerisation. Furthermore, the tumour lineage of 
the cells could prove a potential threat to patient safety should any HepG2 
DNA enter the patient’s system. 
 
It was hypothesised that inclusion of immobilised Lactate oxidase (LOx) to 
catalyse degradation of lactate into pyruvate could offset these limitations 
whilst simultaneously providing a potential energy source utilisable by 
HepG2 cells. In a similar fashion, immobilised Deoxyribonuclease I 
(DNase I) could be utilised to remove non-patient DNA during the treatment 
phase of the BAL system. 
 
Here it is demonstrated that functionalised glass beads are a feasible method 
of immobilising LOx and DNase I. Enzymatic activity was retained even 
after prolonged incubation at 37°C in the presence of human plasma, 
offering a means of reducing lactate levels during HepG2 culture, and 
potentially removing circulating DNA below practically detectable levels, 
thus facilitating cellular performance and BAL efficiency as a safe and 
effective potential therapy for acute liver failure. 
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1. General Introduction 
The scope of this study falls into a rather niche and specialised field and so 
it is necessary to thoroughly establish the context, background and 
ultimately the relevance of this work to the scientific community. The 
physiology of the human liver will be discussed, followed by the aetiology 
and treatment of liver failure conditions, particular emphasis being placed 
upon current liver-assist device development; it is at this point where the 
process of enzyme immobilisation and the potential use of said enzyme 
systems in a clinical application will be explored. 
 
1.1.  The Liver 
The human adult liver is located in the upper right quadrant of the 
abdominal cavity and is, by mass, the second largest organ of the body, 
weighing on average around 1.5 kg and thus contributing approximately 2% 
of the total body mass. The liver is a highly metabolically active organ and 
thus receives a seemingly disproportionately large percentage of oxygen 
rich blood from the hepatic artery – up to 25% of the total cardiac output - 
and is also supplied via the portal vein. Both then subdivide into a network 
of capillaries to supply the four lobes of the liver, which can be further 
subdivided into lobules, the functional units of the liver (1). The lobule has a 
hexagonal structure, comprised of between 1 x 10
5
 and 2 x 10
5
 hepatocytes, 
arranged in arrays one or two cells thick around the central vein. Between 
two arrays are specialised blood vessels, termed sinusoids, which are lined 
with sinusoidal cells and connect the portal venous system to the systemic 
venous system. Between four and six portal triads surround the lobule, 
themselves comprising the terminus of portal vein and hepatic artery 
branches, and a bile duct. Small bile ducts are also found between two 
hepatocytes, whilst the space between hepatocytes and sinusoidal cells is 
termed the Space of Disse. 
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Figure 1-1– Representation of the liver lobule. 
Arrays of hepatocytes surround the central vein, from which sinusoids extend 
radially. Portal triads are found at the lobule periphery, comprising the terminus of 
portal vein and hepatic artery branches and a bile duct. Hepatocytes, Kupffer cells, 
sinusoidal and stellate cells are found in the lobule unit.  
 
http://php.med.unsw.edu.au/embryology/images/0/02/Liver_structure_cartoon.jpg 
 
 
1.1.1. Structure and function of the liver 
Benefiting from such an extensive blood supply assists the liver in 
performing its “cleansing” roles; the liver is responsible for detoxifying 
molecules which would otherwise prove hazardous to health, in addition to 
its role as a centre of metabolism and molecular synthesis. In terms of 
synthesis, the liver is the site of production of bile acids, which are essential 
for digestion (1). Other molecules to be produced by the liver include 
proteins such as blood clotting factors, heparin, cholesterol, albumin, 
oestrogen and somatomedins (2;3). In addition to synthesising bile acids and 
cholesterol, the liver is also responsible for their filtration and detoxification 
(4), along with bilirubin, hormones and ingested drugs and poisons. The 
liver also serves as a filter for the removal of amino acids, dead blood cells 
and Immunoglobulin A (5).  
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Multiple cell types comprise the liver (6), including sinusoidal cells, 
Kupffer cells, hepatic stellate cells and hepatocytes Mitochondria-rich 
hepatocytes account for 60% of the liver cells and are responsible for many 
metabolic functions including bile production (up to 15 ml/kg/day in healthy 
humans) (6) and glycogen synthesis. The liver has the ability to convert 
lactate back into glucose by means of gluconeogenesis, which if not 
immediately required as an energy source, can be converted and stored in 
the liver cells as glycogen. As would be expected of such a metabolically 
active and productive organ, the number of genes expressed in the liver is 
second only to the brain (7). The majority of these genes are transcribed in 
the hepatocyte, but in disease, the increase in gene expression is mostly 
undertaken by other cell populations such as stellate cells. It is worth noting 
that the liver is unique among mammalian organs in that, extraordinarily, it 
is able to regenerate back to its original size from as little as 25% of its 
initial mass (8). 
 
Taken together, it is evident from the physical and functional complexity of 
the liver why maladies of this organ can have such devastating 
consequences. These can range from the effects of inborn metabolic 
disorders such as the lysosomal storage disorders, Gaucher Disease and 
Fabry Disease, to infectious diseases such as viral Hepatitis C, to 
autoimmune conditions (e.g. Autoimmune Hepatitis, Systemic Lupus 
Erythematosus (SLE)), drug (commonly by N-acetyl-p-aminophenol 
(Paracetamol)) related damage and lifestyle induced conditions as seen in 
fatty liver disease and alcoholic liver disease. The implications of liver 
failure will be discussed in the following section. 
 
1.2.  Liver Failure 
An estimated 1-2 million people worldwide die each year from hepatic 
failure (9). There are two basic types of liver failure, chronic and acute. 
Chronic liver failure is defined as the deterioration of liver function over a 
prolonged period of time, whereby functional hepatocytes are replaced by 
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the processes of cirrhosis and/or fibrosis. Acute liver failure (ALF) results 
following the death of liver cells within a short period of time and is 
characterised by the rapid loss of liver function, including a decrease in 
Factor V levels and the onset of jaundice and hepatic encephalopathy (9). 
ALF represents one of the liver maladies with the poorest prognoses, with 
orthotopic liver transplantation being the most widely and successfully used 
method of treatment. Whilst viral infection, particularly with Hepatitis E, is 
the principal cause of ALF in the developing world (10), drug-induced liver 
failure is more commonly described as the causative agent of ALF in 
Western countries. However, the cause of this malady is not always evident 
and furthermore it can arise as a complication of an underlying liver 
condition such as cirrhosis, referred to as acute-on-chronic liver failure. 
Following the onset of symptoms, the condition of ALF patients rapidly 
declines; mortality can occur after only a matter of days with a particularly 
rapidly progressive form of liver failure, fulminant liver failure, if not 
treated appropriately (11), with brain edema and intracranial hypertension 
being the leading causes of death (9). It is thus necessary that in addition to 
a rapid diagnosis, there is a mode of treatment which is readily available. 
Therefore, in recent years great emphasis and effort has been invested 
within the medical and scientific community to develop an alternative to 
organ transplantation. 
 
1.3.  Liver Failure Treatment Strategies 
Currently, if the patient’s liver is unable to regenerate following the insult, 
transplantation is the treatment of choice for liver failure. There are two 
types of transplant methods, which use either material from deceased or 
living donors. Unfortunately, the situation is far from ideal as the demand 
for transplantations far outnumber the availability of donor organs. Data 
from 2007 shows that in the United States there were some 17,500 patients 
on a waiting list for liver transplantation; yet annually typically just 6,000 
transplantations take place with more than 1,700 patients dying whilst on 
the waiting list (12). The most recent UK data published by the NHS for the 
four quarter period 2011/2012 shows that there were 764 liver/lobe 
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transplant operations (726 deceased donor, 38 living donor) yet a further 
507 patients still awaiting a transplantation (excluding those temporarily 
suspended from the waiting list) (13). Furthermore, a recent study revealed 
that the proportion of unused donor livers has risen drastically since 2004 
(14), with organs being deemed unsuitable due to poor liver condition. This 
phenomenon has been hypothesised to be linked to an increasing incidence 
of obesity and an ageing population. In addition to the challenges presented 
by resource scarcity, patients in need of liver transplantation must also 
contend with the fact that after transplantation they will be subjected to an 
immunosupression programme for the duration of their life in order to avoid 
the new liver being rejected by the immune system. 
Therefore it is apparent that an alternative treatment to transplantation be 
developed, which can be readily made available when and as required, 
whilst keeping side effects to a minimum. 
 
1.3.1. Biological approaches 
The use of non-human organs for transplantation has been practised globally 
when no suitable human equivalent can be obtained. The caveat here is the 
risk of immune rejection and also the potential for the transmission of 
zoonoses and cross-species pathogens, in particular of endogenous 
retroviruses (15). However, a small study on patients linked 
extracorporeally to porcine kidneys detected no measurable level of pig 
endogenous retro-virus (PERV) in the patients following treatment (15). 
 
The transplant of isolated liver cells to support liver function in acute and/or 
fulminant liver failure patients is an active area of research since the idea 
was first proposed in the 1970s (16). Although primary human hepatocytes 
would be preferable they are infamously difficult to proliferate in culture 
and are heavily reliant on cell-cell contacts and the extracellular matrix (17). 
In an attempt to overcome the challenges presented by the use of primary 
hepatocytes other human cell lines have been explored, including 
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pluripotent stem cells and embryonically derived stem cells, both of which 
proliferate well (18). However, apart from the obvious ethical issues this 
raises, there is also the consideration that these highly proliferative cells 
may pose a tumorigenic risk to the patient. Moreover, to date, there is no 
suitable and readily available stem cell derived hepatocyte line. 
 
Encapsulating non-human xenografted or human allografted liver cells 
within a synthetic membrane prior to transplantation reduces the likelihood 
of rejection by the patient’s immune system as the contained cells do not 
come in to contact with cellular components of the immune system although 
there remains a body of evidence to suggest that an inflammatory response 
may still be triggered (19;20). However, this approach must ideally be used 
only following the clearance of plasma toxins induced by liver failure 
(21;22), as such substances have a profoundly detrimental effect on the 
survival and function of the transplanted cells (23). Moreover, the synthetic 
membrane prevents normally secreted proteins from entering the 
circulation; with a molecular cut-off of 70,000 kDa the membrane would 
prevent diffusion of large proteins, such as fibrinogen (340,000 kDa). 
 
1.3.2. Artificial liver support strategies 
Artificial liver support devices serve to remove toxins from the patient’s 
blood, a role which the failing liver is no longer able to adequately perform. 
This is critical, as otherwise an accumulation of products such as ammonia 
will have a detrimental effect upon the body, often leading to sepsis and / or 
multiple organ failure, which are common complications of untreated liver 
failure. Several systems have been explored to fulfil this role, the most 
prominent of which will be briefly discussed. Generally speaking, these 
methods fall into one of three categories: those which remove toxins based 
upon their charge; those which remove toxins by binding to albumin; and, 
those which involve plasma exchange to remove harmful substances from 
the patient’s system. 
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Bio-Logic DT utilises the key principal of sorbent technology to remove 
toxins from the patient’s circulation, which were commonly believed to be 
the principal cause of liver failure associated complications (24). However, 
this has been shown to not be the case, with a multitude of other entities, 
including endotoxin, mediators of the inflammatory immune response and 
other signalling molecules, also playing fundamental roles in the 
progression of liver failure symptoms. Many of these molecules cannot be 
removed by simple haemodialysis or adsorbed via charcoal, thus explaining 
why such approaches have shown little or no benefit in clinical applications 
(9). 
 
Prometheus® passes blood through an albumin permeable hollow-fibre 
filter before it enters a series of two resin cartridges, following which the 
blood is haemodialysed before being returned in a purified state to the 
patient (25). The rationale is that molecules bound to the patient’s albumin 
will be sequestered by albumin in the filter, thus effectively cleansing the 
patient’s albumin. Although this combination of strategies permits the 
removal of both water soluble toxins and also albumin bound substances 
(25;26) there is to date limited clinical evidence that Prometheus® improves 
the prognosis of liver failure patients (27); a recent study showed no 
significant improvement of survival rates between acute-on-chronic liver 
failure patients treated with the Prometheus® device compared to those 
receiving the standard medical therapy (28). 
 
Molecular Adsorbent Recirculating System (MARS)® is an albumin 
dialysis based method of performing the blood purification functions of a 
failing liver, comprising of a dialyzer, a charcoal column and an ion 
exchange column. It utilises an albumin containing solution to dialyse and 
remove both albumin bound (bilirubin and bile acids) and soluble molecules 
(such as urea and ammonia) from the patient’s blood across a high flux 
membrane (29;30). However, ultimately MARS® is only capable of 
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removing toxins from the liver failure patient’s blood and is unable to 
support the failing metabolic or synthetic functions of the liver. 
 
A further use of activated charcoal to remove blood toxins has been 
employed whereby the charcoal particles are encapsulated within an inert 
polymer casing (31), forming an artificial cell which can then be 
administered to the patient. This method has advantages in that it can be 
used when standard dialysis methods are not suitable, and also avoids the 
damaging effect of embolizing particles on cells which occurs when 
bioadsorbants are used in isolation. Furthermore, in clinical trials this 
approach successfully saw Grade 4 Hepatic Coma patients recover 
consciousness (32;33).  
 
1.3.3. Bio-Artificial liver devices 
The development of a Bio-Artificial liver device (BAL) would represent a 
major advance in improving the prognosis of patients suffering from acute 
liver failure (34;35). Such a device would serve to perform short term liver-
specific functions such as protein synthesis, detoxification and synthetic and 
metabolic homeostasis, allowing sufficient time for the liver to regenerate 
and recover, or in extreme circumstances, serve as a bridge to liver 
transplantation. This would be of great significance, as currently there is an 
insufficiency in the number of donor organs available and a dismally high 
number of liver failure patients expire whilst on the transplantation waiting 
list. Furthermore, a biological approach to cleansing the blood has an 
advantage over carbon based adsorption therapies, as the latter 
indiscriminately bind molecules, including those which are beneficial to 
patient health. There are currently several BAL devices being developed, 
which will be briefly described in this section. 
 
Technically a hybrid of artificial and Bio-Artificial approaches, treatment 
with HepatAssist
TM 
involves the separation of cellular and plasma 
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components of blood by plasmapheresis, whereupon the plasma phase 
passes through a charcoal filter and then warmed and oxygenated before 
entering a hollow fibre chamber housing some 6 x 10
9
 porcine cells (36-38). 
The charcoal filtration pre-treatment of plasma promotes the efficacy of the 
treatment as toxic substances which would have detrimental effects on 
cellular growth and performance, are purged before reaching the cells 
(37;38). A logical explanation for the lack of success of this method can be 
attributed to the simple insufficiency of cells; only 6 x 10
9
 cells were 
utilised, representing just 6% of the hepatocyte population in a healthy 
75 kg human adult; it has been demonstrated that liver resection procedures 
are only successful when the postoperative liver volume is at least 35% of 
the original mass (39). 
 
The Extracorporeal Liver Assist Device (ELAD) also utilises a hollow fibre 
chamber, although here the cell line of choice is C3A, derived from a human 
hepatoblastoma (HepG2) line. Although early trials showed no 
improvement in the outcome for patients compared to the standard mode of 
treatment for liver failure (40) safety was demonstrated (particularly 
important in this application as the use of human carcinoma cells had not 
previously been used in a clinical setting) and the ELAD system continues 
to be developed and trialled. However, this approach suffers from the poor 
mass transfer of nutrients and metabolites, owing to the structure of the 
hollow fibre chamber. Inevitably, this compromises the efficacy of this 
system, and prevents the possibility of cryopreserving the chamber. 
 
1.3.3.1. The Liver Group BAL 
The BAL currently under development by the Liver Group (LG) at the 
Royal Free Hospital Campus, UCL Medical School, is an extracorporeal 
device, where the plasma phase of the liver failure patient’s blood would 
enter a double circuit system and pass through a chamber containing three-
dimensional spheroids of HepG2 cells which would perform the normal 
liver functions of detoxification and substance metabolism and synthesis. 
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The cells are encapsulated within alginate, a non-toxic material, and 
contained within a fluidised bed bioreactor (FBB). The advantages of using 
this type of chamber to culture cells are well known (41) but, succinctly, 
have the benefit of utilising microgravity principles to promote the growth 
of multicellular spheroids. As spheroids, HepG2 cells have improved cell-
cell contacts (34) which are critical for their growth and performance, thus 
enhancing efficiency of the BAL device. It is accepted that a greater degree 
of complexity is given to the structure and function of the liver by the effect 
of the location and microenvironment on the cells of the liver. It is well 
documented that the metabolic, synthetic and genetic transcript profile of 
hepatocytes, stellate cells, sinusoidal endothelial and Kupffer cells all vary 
depending on their specific location within the liver (42) and thus the local 
concentration gradients of oxygen saturation. By culturing the HepG2 cells 
as spheroids in a microgravity environment, the mass transfer of metabolic 
products and metabolites, including oxygen, is optimised, permitting the 
maximum productivity of the cells and hence efficacy of the treatment. 
Furthermore, another advantage of using a micro-gravity method of cell 
culture rather than, for example, growth in a hollow-fibre support matrix, is 
that the potential failure of the device due to pore blockage is eliminated. 
 
The BAL system utilises alginate bead encapsulated HepG2 cells (34), a 
human hepatoblastoma line derived from a 15 year old Caucasian male. 
Primary human hepatocytes would seem to be the ideal candidates for use in 
the BAL, as it is this cell type which accounts for the majority of the liver 
mass (6). However, a number of limitations including a difficulty with 
expanding cell number in culture (43), restricted availability of cells and a 
loss of transcription of liver specific genes throughout the isolation and 
culture process precludes their use. HepG2 cells are currently the best 
available human cell line for use in the LG BAL (34), as HepG2 cells 
maintain several properties typical of hepatocytes, including the synthesis of 
albumin and clotting factors (44-46). Furthermore, being of human origin, 
HepG2 cells are not subject to the safety and biocompatibility concerns 
associated with the use of xenogenic cell lines. Although this BAL has not 
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yet reached clinical trials, in vitro studies have shown that encapsulated 
HepG2 cells show good protein synthesis (demonstrated by an increase in 
albumin, clotting factors and alpha-1 antitrypsin production) and 
detoxification of bilirubin (34) when perfused with human liver failure 
plasma. Additionally, the use of HepG2 spheroids encapsulated in uncoated 
alginate beads allows greater mass transfer of metabolites and nutrients, and 
it is possible to make a sufficiently accurate calculation of cell number and 
hence viability and efficiency of the BAL system, a feat which is not 
possible with hollow fibre based methods, for example. 
 
However, the utilisation of HepG2 cells is not without some drawbacks; this 
cell line lacks some detoxification functions, including high Cytochrome 
P450 activity (47;48) and there is a lack of ammonia metabolism. Whereas 
these issues can be ameliorated, if not completely overcome, by adjusting 
the growth media of the cells or by genetic manipulation, there are other 
problems associated with the use of HepG2 cells which must be addressed if 
they are to be successfully incorporated into a clinically approved BAL 
device. Among these is the potential threat of circulating HepG2 DNA to 
the patient; it has been proposed that any DNA released from dead HepG2 
cells may trigger an immunogenic response from the patient’s immune 
system. Another key concern is with regards to the high levels of lactate 
produced by HepG2 cells as a result of aerobic glycolysis, a common 
phenomenon in many cancer cell lines (49). In addition to having the 
potential to compromise cellular performance (low pH can be detrimental to 
enzyme integrity and trigger caspase-induced apoptosis), the Liver Group 
laboratory investigations have shown that concentrations of lactate in excess 
of approximately 15 mM cause a loss of alginate bead integrity by chelating 
the calcium ions required to stabilise the alginate hydrogel. If this occurs, 
the cell spheroids could break free and become free-flowing within the 
BAL, jeopardising the efficacy and safety of the treatment. In order to best 
understand the potential threat lactate and DNA pose to the BAL, the 
following sections will discuss the nature of these molecules in more detail.  
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1.4.  Lactate 
The Liver Group BAL incorporates HepG2 cells encapsulated within 
sodium alginate (NaC6H7O6) beads. Alginate is a non toxic, biocompatible 
anionic polymer (50) which is polymerised to form a stable hydrogel by the 
interaction between carboxyl groups and divalent ions such as calcium (50-
52). However, this process is reversible and the integrity of the beads is 
compromised when divalent ions are removed (53) as occurs when lactate 
levels accumulate within the FBB. Furthermore, lactate has been shown to 
increase the proportion of free calcium in solution (53) and is believed to 
achieve this by chelating the divalent ions from insoluble calcium (54). 
 
Lactic acid (C3H6O3) is a carboxylic acid with a dissociation constant (pKa) 
of 3.86 which when in solution dissociates to form its conjugate base, 
lactate. It is a chiral molecule, having both an R- and L- form, the latter 
being the predominant stereoisomer in the human body. It is found in human 
blood at a base level of 1-2 mmol/L, although this can rise 10-fold during 
periods of strenuous exercise. A product of glycolytic respiration in oxygen 
limited conditions or when energy demand is elevated, lactate is produced 
from the reduction of pyruvate, itself the product of glucose oxidation. 
Although only two molecules of ATP are generated per glucose molecule 
instead of the 36 during full aerobic respiration, only the glycolytic pathway 
is utilised which has far fewer reaction steps and so a more rapid glucose to 
ATP turnover is possible. The cell line utilised in the BAL, HepG2, favours 
the glycolytic pathway for the generation of ATP, consequently generating 
lactate, and therefore highlighting the requirement to establish a means of 
reducing lactate concentration in the FBB to acceptable levels. 
 
1.5.  Deoxyribonucleic Acid 
Deoxyribonucleic Acid (DNA) contains the hereditary genetic information 
of an organism, found mostly in the nucleus of eukaryotic cells and in the 
cytoplasm of prokaryotes. 
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1.5.1. DNA structure 
The structure of DNA was famously discovered by James Watson and 
Francis Crick in 1953 although the molecule had been identified in the late 
19
th
 century. One of four bases (adenine (A), cytosine (C), thymine (T) and 
guanine (G)) is joined to a pentose sugar, 2-deoxyribose, and a phosphate 
molecule to form a nucleotide, the monomer of DNA (55). Polymerisation 
of these monomers links adjacent deoxyriboses via phosphodiester bond 
formation, generating an external “back bone” to the DNA strand. The bases 
are classified by their molecular structure as being a purine (A and G) or a 
pyrimidine (C and T) molecule; a purine binds with a pyrimidine (A-T and 
G-C) via hydrogen bonds thus forming “rungs” between two strands of 
DNA. These two strands are arranged around each other to form a 
hexagonal coiled-coil, with the complimentary strands running anti-parallel 
to each other, the phospho-sugar backbone being external, the base pairs 
internal to the structure. The spaces between strands are referred to as the 
major and minor grooves, the width of which is 22 Å and 12 Å respectively 
(56). Proteins such as transcription factors are able to bind to exposed 
nucleotides in the major groove (57). 
 
There are approximately three billion bases in the human genome, a copy of 
which is present in the nucleus of every cell. In order for such an expanse of 
material to be contained within such a small space, DNA undergoes several 
organisational modifications to become more compact. First, the double 
strands can be more closely twisted around each other, or supercoiled. The 
strands are wrapped one - to - three times around an octomer of histone 
proteins to form 10 nm nucleosomes (representing a seven-fold 
condensation factor) and are then linked by histone H1 to from a 30 nm 
coiled rope-like structure (a further six-fold condensation factor), termed 
chromatin. Chromatin fibres are then further condensed by forming looped 
structures along a non-histone protein scaffold, which can in turn be further 
condensed to form chromosomes during cell division (58). 
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1.5.2. Forms of eukaryotic DNA  
As mentioned earlier, DNA is most often located in the nucleus of the cell, 
but can also be found in the mitochondria and the cytoplasm. Like 
chromosomal DNA, mitochondrial DNA (mtDNA) is double stranded and 
comprised of the bases A, C, G and T, but differs from chromosomal DNA 
in that it is circular rather than forming a double helix. Another difference is 
that whereas each cell contains just two molecules of chromosomal DNA, 
there can be thousands of copies of mtDNA within a single cell. Once 
external to the cell DNA is termed cell-free circulating DNA (cfcDNA). 
DNA found in plasma is predominantly double stranded (59) and cfcDNA is 
usually complexed to lipids or protein. 
 
1.5.3. DNA as the carrier of genetic information 
The identity of the mechanism by which genetic material is inherited was 
under debate for some time, with chromosomal protein also being thought to 
play a role; it wasn’t until the 1940s that DNA was finally shown to carry 
the genetic code (60). Genes are the units of hereditary information, regions 
of the DNA sequence which encode proteins by way of their amino acid 
constituent parts. Each of the twenty amino acids are represented by a three 
base codon (e.g. TGG encodes tryptophan) with the majority of amino acids 
being represented by more than one codon. Messenger RNA (mRNA) is 
synthesised during transcription of a gene on the sense strand of DNA, 
forming a strand of complimentary sequence. This is later translated into 
amino acids by the action of transfer RNA (tRNA), forming a polypeptide 
polymer which constitutes the target protein. The target protein may then 
undergo further post-translational modifications such as the addition of 
functional groups (e.g. phosphate, lipids or carbohydrates) the formation of 
disulfide bridges or phosphorylation. Thus, a functional protein is 
synthesised and can affect its environment depending upon its nature and 
specific function. 
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1.5.4. Extraneous DNA as a potential risk to the patient 
The use of cells from a non-patient source will never be without risk; 
induction of an immunological response could occur by either the cells 
themselves or by their secreted proteins. It has also been postulated that 
DNA and / or other constituents from the cells may invoke a secondary 
disease situation. It is therefore necessary to protect the patient from any 
circulating DNA of HepG2 origin by removing extraneous DNA from the 
BAL. 
 
Assessing the risk that extraneous cell lines pose to the patient is however 
not straightforward. First of all, there is no absolute maximum value of non-
patient DNA which is deemed tolerable by the regulatory bodies, including 
the US Food and Drug Administration (FDA). Secondly, it has been 
reported that only trace levels of DNA can be found in the circulation (61), 
with levels in healthy individuals reported at 34 +/- 34 ng/ml (62), and so 
identifying an analysis method with sufficient sensitivity to detect these 
levels also poses a challenge. To demonstrate this point, a recent study on 
the use of encapsulated porcine cells in a BAL observed that upon applying 
the supernatant from cell culture to a population of human hepatocytes, Pig 
Endogenous RetroVirus (PERV) was found to have infected the hepatocytes 
(63). Conversely, however, a study undertaken by the AMC-BAL 
(Academic Medical Centre – Bio-Artificial Liver) group which utilises 
porcine cells in their BAL system, detected no measurable levels of PERV 
in chronically immunosuppressed patients having undertaken treatment with 
the device (64).  
 
Usually restricted to the cell nucleus, DNA is released into the extracellular 
environment following apoptosis or necrosis, or “metabolic” DNA can be 
actively secreted by cells (65). In healthy individuals levels of between 
59 ± 15 ng/ml of DNA can be detected in the plasma (66), the vast majority 
of which is cleared by a process of inter-nucleosomal fragmentation (67). 
As the BAL utilises a large cell population there is the potential for non-
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patient DNA, in the form of cfcDNA, to be transferred from the BAL 
chamber circuit into the patient. The relative risk this would then pose is a 
cause for contention, with relatively little information being available on the 
potential for extraneous DNA to cause harm to the host. That withstanding, 
there is evidence to support the theory that cfcDNA can be incorporated into 
eukaryotic host cells (68;69). The process by which circulating DNA could 
enter a host cell could be via the toll receptor pathway (70). By initiating a 
DNA damage repair response, these DNA fragments can become 
incorporated into the host genome by a process of homologous 
recombination. A recent example of this was demonstrated in a study where 
the plasma from colon cancer patients with a k-ras mutation was applied to 
mouse fibroblasts, after which the k-ras oncogene sequence was detected 
within the mouse cells (71). This finding is of particular importance as the 
BAL utilises HepG2 cells which are of a tumour lineage; it is quite obvious 
that a risk of geno-metastasis to liver failure patients can not be permitted. 
 
It is also plausible that circulating DNA could initiate an immune response 
in the patient, where it is the double stranded nature of DNA which is 
recognised (72). This stimulates transcription of genes for the major 
histocompatibility complex (MHC) and interferon regulating factors, which 
then eventually lead to the transcription of pro-inflammatory factors such 
NFκβ and chemokines (73) which can be linked to causing tissue damage. 
Mitochondrial DNA and degraded formidyl peptides have also been 
suggested to initiate a pro-inflammatory response (74). Another mechanism 
by which circulating DNA can trigger an immune response is via proteins 
such as IF116 (75) and DAI (76) which bind cfcDNA and recruit 
transcription factors, resulting in the expression of IFNβ. Moreover, it has 
been demonstrated that cfcDNA can evoke an inflammatory response by 
stimulating IL-6 production in monocytes (77;78). Together, these data 
demonstrate that measures must be taken to minimise the potential for 
HepG2 DNA to enter the patient’s circulation during treatment with the 
BAL device. 
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Although physical filtration is an option for DNA removal, as is 
supplementation / exchange of the culture media to limit the effects of 
lactate, there exists a more elegant solution, utilising the natural catalytic 
activity of specific enzymes to convert these detrimental entities into 
harmless, or even potentially useful, molecules. This would provide a 
solution which can be “in line” with the BAL, enabling a continually 
working closed circuit system and therefore forming the basis of a safer and 
more time efficient device. 
 
1.6.  Enzyme Immobilisation 
The catalytic activities of enzymes have long been exploited, dating back to 
antiquity when enzyme rich media were used, for example, in the 
preparation of leather, or the use of rennin in cheese production. Today, the 
applications of enzyme technology are plentiful, covering a multitude of 
disciplines ranging from the food industry, to the manufacture of cleaning 
products and pollutant neutralisation strategies. There is also a growing area 
of research into the field of enzymes as therapeutics, whereby enzymes are 
administered to patients in order to replace the function of their nonexistent 
or non-functional native enzyme. This is referred to as enzyme replacement 
therapy (ERT). The majority of investigations have used enzymes in 
solution to be administered either orally or as an injectable, with relatively 
few studies into the use of immobilised enzyme complexes as a potential 
therapeutic agent. However, the process of immobilisation may facilitate the 
use of enzymes in a therapeutic context, as it has been reported that this 
strategy can bestow many beneficial properties onto both the activity and 
stability of the enzyme. This will be discussed further in this section. 
The first recorded account of enzyme immobilisation was in 1916 by Nelson 
and Griffin who noted that invertase adsorbed onto a charcoal and Al(OH)3 
artificial support retained its catalytic activity (79). However, it was not 
until the 1950s that the potential for immobilised enzyme technology was 
recognised, highlighted by a steady increase in enzyme immobilisation 
research (80). The immobilisation of enzymes has received a great deal of 
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interest in recent years, for use in the pharmaceutical, diagnostic and food 
production industries amongst others. 
 
1.6.1. Benefits of immobilisation 
Regardless of specific application, usually the primary aim of 
immobilisation is to stabilise the enzyme, facilitating reuse in multiple 
procedures (thus lowering running costs). The ways in which an 
immobilised enzyme is stabilised varies depending on the method used, but 
among the mechanisms of stabilisation are molecular confinement (81) 
whereby the enzyme is less readily unravelled as a consequence of thermal 
denaturation, or by adding stability through the formation of new bonds 
during covalent binding (82). Some methods also confer an increased level 
of enzymatic activity; the action of multi-point attachment between enzyme 
and support can result in the enzyme being held in a permanently active 
conformation (83). 
 
Additionally, for enzymes intended for a therapeutic application, there is the 
advantage that an immobilised enzyme is far less likely than the free 
enzyme to initiate an immune response (84). In support of this, studies have 
demonstrated that compared to the free enzyme, immobilised enzymes 
provoked the formation of either fewer antibodies or deleterious 
downstream effects, such as invoking an immunological response or having 
a toxic effect upon the organism (85;86).  
 
1.6.2. Immobilisation considerations 
There currently exists a wide variety of immobilisation techniques, with the 
requirements of the target enzyme dictating which method should be applied 
for optimal effect (87). A particular consideration is that the coupling 
reagent and the support matrix together can potentially contribute to the 
enzyme’s microenvironment, (for example, affecting pH, ionic strength and 
the hydrophilic-lipophilic balance (88),) which can influence substrate 
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interaction and product formation. During the immobilisation process the 
enzyme must be in its active state. The requirements of each application to 
utilise immobilised enzymes will obviously vary, as will the particular 
conditions in which an enzyme will function; a system can only be 
described as “robust” when both the enzyme function and method of 
immobilisation work effectively for that particular application (89). For use 
within a biological system, as will be the case with the Liver Group BAL, 
there are additional criteria to consider when selecting an immobilisation 
method; for example, as well as binding the enzyme in its active state, the 
support matrix must be bio-compatible, neither being itself degraded nor 
causing damage, for example, to blood constituents (e.g. by inducing 
haemolysis or thrombosis) and must also be composed of non-toxic or 
carcinogenic materials (80). 
 
1.6.3. Solid support based immobilisation strategies 
The majority of immobilisation procedures involve physically or chemically 
anchoring the enzyme to a support matrix. The benefits associated with this 
include the ability to control more precisely the duration and location of an 
enzymatically catalysed reaction. Also, stabilisation of the immobilised 
enzyme is frequently observed. The most common and significant modes of 
immobilisation are summarised in the following sections; however, it is to 
be noted that several methods which have been allocated a separate heading 
may under certain conditions and applications overlap with other methods. 
This highlights the growing complexity and ingenuity behind the designs 
and protocols for enzyme immobilisation.  
1.6.3.1. Adsorption & immobilisation via ionic interactions 
Often regarded as the simplest means of immobilising an enzyme, 
adsorption requires very little in the way of chemical modification or pre-
treatment of the enzyme/support surface. However, the bonds formed are 
relatively weak in inorganic solvents and thus leaching of the enzyme is not 
an uncommon phenomenon (90). Although stronger than adsorption, ionic 
fixation of an enzyme to a carrier is by nature a reversible process and so 
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leaching of the enzyme is still a potential hazard. Nevertheless, various 
groups have utilised ionic interactions to assist binding of the enzyme to the 
support, namely orientating the enzyme active site into a position whereby it 
can achieve optimal functionality i.e. ensuring that the enzyme is not 
immobilised via a residue located in/near to the active site. 
 
Due to the reversible nature of these interactions no further consideration 
will be given to either of these methods for use in the immobilisation of 
enzymes in the LG BAL. 
 
1.6.3.2. Covalent attachment 
For many applications where leaching of the enzyme cannot be tolerated, 
the use of irreversible covalent methods of immobilisation are preferred. In 
addition, conformational flexibility and as a consequence thermal vibrations 
are reduced, serving to stabilise the protein structure. Enzymes are typically 
bound at multiple points, strengthening the interaction between protein and 
support. Frequently the ε-amino group of lysine is used to form the covalent 
bond between enzyme and epoxide groups on the support (91;92), owing to 
the tendency of lysine to be found on many enzymes and located on the 
protein surface. There are a plethora of cross-linking reagents available for 
mediating the covalent attachment of enzymes to a support, in addition to a 
wide variety of methods of activating and functionalising the support 
surface (see sections 3.1.3 and 4.1.3 for further information). Furthermore, 
there exist multiple commercial supports which can be acquired ready-
functionalised, common examples being Eupergit (Evonik) macroporous 
spheres and Sepabeads (Resindion), which contain surface fissures and thus 
provide a degree of protection to the immobilised enzyme from shear stress. 
However, the decrease in flexibility often associated with covalent binding 
may also hinder enzyme-substrate interactions and hence significantly lower 
the rate of enzyme activity. When seeking to immobilise an enzyme by 
means of covalent attachment to a solid support, the choice of support and 
cross linking reagent is often the result of a compromise between stability 
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and enzyme activity. For example, although shorter linking groups confer 
greater stability by limiting vibrations and increasing rigidity, longer linking 
groups may be necessary to overcome the problems with steric hindrance 
associated with shorter linking groups. 
 
1.6.3.3. Nanoparticle attachment 
The use of nanoscale structures such as spheres, fibres and tubes is one of 
growing popularity and interest owing to recent advances in 
nanotechnology. In theory, use of nanosized supports should make optimal 
use of the available surface area, thus maximising enzyme loading 
efficiency. Silica based matrices have been used to encapsulate enzymes 
within nanoparticles (93), the benefits associated with silica including 
formation under mild environmental conditions, good stabilisation of the 
immobilised enzyme, variable morphologies and variable pore sizes. An 
elegant method of this approach utilised the R5 peptide, a synthetic 
derivative of a silica precipitating protein found in Cylindrotheca fusiformis, 
which was inserted into the protein sequence without obvious detriment to 
the enzyme to yield an enzyme encapsulated within a silica nanoparticle 
(mean diameter of ~500 nm) synthesised in situ. Other molecules are also 
capable of catalysing silica formation, such as polyethylenimine (PEI), 
although there have been reports that the potentially hydrophilic 
environment created by this particular molecule may limit availability of 
hydrophobic substrates, a particular problem for lipases. Electrospun 
polymer nanofibres (reviewed by Wang et al. 2009 (94)) are another option 
utilising nanotechnology for the immobilisation of enzymes. Advances in 
reducing the difficulties associated with the recovery and handling of 
nanoparticles have been addressed for example by means of magnetic 
microspheres (93). However, it is crucial for the LG BAL application of 
immobilised enzymes that no particles such as cell debris are able to enter 
the patient. For this reason, a 0.5 µm filter is an essential component of the 
LG BAL system, but this would become subject to an unacceptably high 
back pressure were any nanoparticles to escape and become trapped behind 
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the filter. For this reason, the use of nanoparticles for enzyme 
immobilisation will not be given further consideration within this study. 
 
1.6.3.4. Entrapment 
Sol-gel technologies are amongst the most frequently used methods of 
immobilising enzymes using an entrapment strategy, wherein a chemical 
solution (“sol”) is gradually evolved to from a solid network or polymer 
structure (“gel”). The composition of a sol-gel can vary greatly in material, 
pore size and mesh network structure, all of which significantly affect their 
enzyme immobilisation properties. Mesoporous silica remains a popular 
medium for entrapment owing to the controllability of pore size 
(mesoporous denotes a pore size of 2-50 nm; microporous <2 nm, and 
macroporous >50 nm) especially given that the diameter of the majority of 
enzymes lies between 3 to 6 nm. This quality of mesoporous silica has been 
successfully used for a range of biomolecule retention and release 
applications (95) What is more, sol-gels are chemically inert, physically 
stable and optically transparent, facilitating their use in a wide range of 
applications. The amine group of the sol-gel theoretically plays a role in 
maintaining pH and preventing protonisation of enzyme functional groups, 
thus demonstrating the importance of selecting an appropriate sol-gel for 
entrapping the chosen enzyme in the required working conditions.  
Furthermore, sol-gel entrapment has frequently been observed to increase 
the stability and reusability of the enzymes (96-98). 
 
However, problems with low loading efficiencies are common and there is 
some concern that the relationship between properties of a sol-gel and the 
subsequent enzyme activity rates is poorly understood. It stands that there 
are very few generic sol-gels, each one necessitating refinement and 
development of both structure and composition for each enzyme studied.  
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1.6.3.5. Encapsulation 
The act of sealing enzymes within a polymer encasing has the significant 
advantage of conferring protection to the enzymes from their external 
environment (99;100), permitting their use in a biological context, as they 
will evade detection and rejection from immune system components 
(99;101). Furthermore, entrapment methods protect the enzyme from the 
external environment thus lowering the impact of many physical phenomena 
such as the effects of gas bubbles and sheer stress. An early experiment to 
address the need for a liver failure treatment involved the encapsulation of a 
myriad of liver enzymes within a nylon-polyethylenimine shell (102) to 
form an artificial cell. Although not tested at a biological level, the artificial 
cells were demonstrated to reduce ammonia and urea concentrations in 
solution by converting them into the essential amino acids of leucine, 
isoleucine and valine, the metabolism of which is often aberrant in 
fulminant liver failure (103). 
 
Zhang et al. reported a procedure whereby a silica shell was used to encase 
a liquid alginate core containing β-glucuronidase, thus encapsulating the 
enzyme (104). The resulting sphere was resistant to swelling and enhanced 
enzyme stability and activity. Unfortunately, there exists the disadvantage of 
limited diffusion potential, leading to issues with mass transfer, e.g. 
substrate availability through the encapsulation shell (90). 
 
1.6.4. Support-free methods of immobilisation 
Recently, there has been growing research into support-free modes of 
enzyme immobilisation. These systems alleviate the situation whereby the 
support matrix can typically account for 90-99% of the volume of the 
immobilised catalyst (84;105) thus potentially allowing for a more efficient 
system. 
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1.6.4.1. Spherezymes 
The term “spherezyme” denotes a multi-enzyme structure whereby enzymes 
are anchored to each other without the assistance of a carrier (90). It has 
been demonstrated that in four lipases and laccase the formation of a 
spherezyme leads to a higher activity rate than that observed in the native 
enzyme (87;90). Protein cross-linkers were utilised in a water-in-oil 
emulsion of aqueous enzyme solution to form individual spheres of 
0.5-10 µm but which tended to form aggregates of approximately 100 µm. 
These structures were robust enough to be collected by centrifugation and 
filtration, permitting their reuse. Initial problems were encountered with a 
loss of activity following cross-linking with glutaraldehyde, although these 
were resolved by adding the substrate to the aqueous enzyme solution, 
resulting in an activity rate higher than that of the native enzyme. Addition 
of ethylenediamine (EDA) increased activity further, likely due to increased 
linker chain length. From this technology co-immobilisation becomes 
possible, where one enzyme could theoretically protect a second, more 
sensitive enzyme beneath it. This configuration would also allow for multi-
step reactions, whereby multiple enzymes are immobilised in close 
proximity and thus facilitating a more rapid interaction between catalysts 
and substrate(s). 
 
1.6.4.2. Cross-linking of enzymes 
Typically, a di-functional agent (e.g. glutaraldehyde) is used to covalently 
bind enzymes together, acting as their own carrier. Cross-linked enzyme 
aggregates (CLEAs) are formed by aggregating and then cross-linking the 
enzymes. The procedure benefits from relatively facile preparation steps and 
negates the use of expensive supports (93), a disadvantage of carrier based 
methods of immobilisation. Self-immobilised enzymes (CLEA, cross-linked 
enzyme crystals (CLEC) etc) typically show 10-1000 times higher 
volumetric activity (catalytic activity observed within a defined reaction 
volume (84)) than carrier bound immobilised enzymes. However, problems 
have been reported with poor reusability for CLEAs. Furthermore, cross-
linking is highly likely to be affected by the ability of the enzyme to resist 
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chemical cross-linking (93), and mass-transfer limitations may become 
problematic if large aggregates of CLEAs are formed. 
 
1.7.  Hypothesis & Aims 
HepG2 cells offer high proliferative capacity and are capable of performing 
many of the liver functions when in 3D culture (44) such as synthesis of 
albumin and clotting factors whilst retaining viable metabolic and synthetic 
functions (106-108). Furthermore, it has been demonstrated that the 
presence of plasma does not have a negative impact upon HepG2 cells; 
indeed, an increase in proliferation and amino acid uptake rates was 
observed (109). 
 
However, HepG2 cells lack some key liver functions (48) including 
ammonia metabolism (110) and furthermore there is a very small risk of 
tumour metastasis in a patient receiving BAL treatment should the tumour 
cells enter the patient’s circulation, due to the lineage of the cells. 
Additionally, there is a body of evidence to imply that cfcDNA has the 
potential to trigger an immunological response. 
 
Another obstacle posed by the hepatoblastoma origins of HepG2 cells is 
their tendency towards glycolytic respiration (111), leading to elevated 
levels of lactate production. In addition to the effects on pH, increased 
lactate levels within the BAL are problematic as lactate is able to chelate 
calcium and so compromises the integrity of the alginate beads used to 
encapsulate HepG2 cells. In order to optimise encapsulated HepG2 cell 
proliferation and function it would therefore be logical to modulate the 
lactate concentration within the FBB. Although this could simply be 
removed by repeated media changes, a more elegant approach would be to 
convert this problematic molecule into an entity which could be utilised by 
the cells.  
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The hypothesis of this thesis is that lactate oxidase and Deoxyribonuclease I 
can be immobilised in order to address the issues of lactate clearance in the 
bioreactor and the effective elimination of the potential threats from non-
self DNA attributed to HepG2 utilisation in the LG BAL. 
 
Consequently, the following aims are proposed: 
 
 Reduce lactate concentration in FBB media to levels which do not 
compromise either cell proliferation or alginate bead integrity. 
 
 Identify a method of DNA removal to be incorporated into the BAL 
device, which can function under physiological conditions reminiscent 
of the patient’s body, for the duration of the proposed treatment period. 
 
 Develop methods of immobilising suitable enzymes to assist in the 
reduction of lactate and DNA concentrations. The enzyme used must not 
have any detrimental effects on either the cell population or on the 
patient, nor should the mode of immobilisation. If this is not the case, 
acceptable measures must be taken to negate said risks. 
 
The following chapters will discuss the strategies and findings generated as 
a consequence of addressing these aims. 
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Chapter 2. General Materials & Methods 
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2.  General Materials & Methods 
This section outlines the methodology and materials required to conduct the 
majority of experimental investigations described in the following chapters. 
Experiment specific procedures will be described within the relevant 
chapter. Unless otherwise stated, all reagents were purchased from Sigma-
Aldrich UK. 
 
2.1.  HepG2 Cell Culture 
HepG2 cells were originally acquired from the European Collection of Cell 
Cultures (ECCC) and a cell line has since been maintained by the Liver 
Group for use within the BAL project. All cell culture work was performed 
in Class II Microbiological Safety Cabinet using sterile, disposable plastic 
ware in order to maintain sterile working conditions. 
 
2.1.1. Complete medium preparation 
Materials: 
 α-MEM with ribonucleosides and deoxyribonucleosides (Invitrogen 32571) 
10% Foetal Calf Serum (Hyclone CH30160-03) 
100 U/ml Penicillin with 0.1 mg/ml Streptomycin (Lonza DE17-603E) 
50 µg/ml Linoleic Acid Bovine Serum Albumin  
9.5 µg/ml Insulin (Actrapid 8-0201-01-203-3) 
1.25 µg/ml Fungizone (Gibco 15290-026) 
0.04 µg/ml Hydrocortisone  
0.04 µg/ml Thyroid Releasing Hormone   
0.002 µg/ml Sodium Selenite 
 
All additives were pooled in a 50 ml centrifuge tube and filtered through a 
0.2 µm mesh filter prior to adding to the α-MEM. 
 
2.1.1. Fresh frozen plasma media preparation 
Materials as listed above, but with the foetal calf serum replaced by human 
FFP. 
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2.1.2.  Preparation of human plasma aliquots 
Materials: 
Human plasma 
40 IU/ml heparin (Multiparin, CP Pharmaceuticals) 
 
When the experimental conditions called for the enzymatic reactions to be 
performed in the presence of human plasma, bags of human plasma of the 
same blood type (AB positive) were pooled and centrifuged at 1000 g for 
20-minutes to remove cellular debris. The plasma was then aliquoted and 
stored at -20⁰C until required. When acquired the plasma had already been 
treated with sodium citrate to prevent the clotting process. However, prior to 
use, plasma aliquots were treated with 40 IU/ml heparin to replace any loss-
of-function caused by the freeze-thaw process of storage, to discourage the 
process of clot formation. 
 
2.1.3. Monolayer cell culture 
This section describes the process by which the HepG2 cell line was 
maintained and grown prior to experimental application. 
Materials: 
Complete culture medium 
T175 Nunclon surface tissue culture flasks (Nunc) 
 
HepG2 cell suspension was seeded in 30 ml complete culture medium at an 
approximate density of 2x10
6
 cells/ml in a T175 flask (Nunclon surface, 
Nunc). Cells were incubated in a humidified incubator at 37⁰C under 
95% air and 5% CO2 until the monolayer reached approximately 
80% confluency. The medium was replaced 24 hours after seeding and 
every 48 hours thereafter until the monolayer was deemed to be sufficiently 
confluent for use or reseeding. 
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2.1.4. Passage of HepG2 cells 
Materials: 
Liver Group Trypsin: 
0.25 g/l Trypsin 0.1 g/l EDTA (Invitrogen, 15400-054) 
1 g/l glucose in citrate saline (4.4 g/l trisodium citrate.2H2O, 10 g/L KCl) 
 
Complete culture medium 
HBSS (without calcium and magnesium) 
T175 Nuncon surface tissue culture flasks (Nunc) 
Sterile 21G syringe and needle 
 
Confluent T175 flasks of HepG2 monolayer cells were rinsed three times in 
10 ml calcium- and magnesium-free HBSS solution before adding 10 ml of 
Liver Group Trypsin. Cells were incubated for six minutes in a humidified 
incubator at 37⁰C under 95% air and 5% CO2 to promote trypsin activity,  
after which 20 ml warmed complete medium was added to inactivate the 
trypsin. Cell detachment was further promoted by tapping the sides of the 
flasks. The suspension of detached cells were transferred to 50 ml centrifuge 
vials and centrifuged at room temperature at 300 g for four minutes. The 
supernatant was discarded and the resulting cell pellet gently re-suspended 
in a small volume of complete medium, any clumps being dispersed by 
gradually passing through a 21G needle no more than three times. This 
suspension was then used to seed flasks for monolayer growth, the volume 
of which depending upon the desired seeding cell density. 
 
2.2.  Determination of Cell Number 
Cell viability and numbers were determined by the Trypan Blue method of 
excluding non viable cells. 
Materials: 
Hanks Balanced Salt Solution (HBSS) - (without calcium and magnesium) 
2% Trypan Blue in PBS 
Haemocytometer 
 
A sample of 20 µl of the previously described HepG2 cell suspension was 
mixed with an equal volume of Trypan Blue (2% in PBS) and 160 µl of 
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calcium- and magnesium-free HBSS and incubated at room temperature for 
two minutes. Of this solution, 9 µl was loaded onto a haemocytometer and 
viable (unstained) and non-viable (blue stained) cells counted under 10 x 
magnification. Counts were performed five times in order to obtain mean 
and standard deviation values. The percentage viability was determined by 
the ratio between living and dead cells. 
 
2.3.  Cell Viability by Fluorescence Microscopy 
Propidium iodide (PI) is an intercalating agent and fluoresces in the red 
spectrum when bound to DNA. As it is unable to pass through the cell 
membrane, only damaged, i.e. non viable cells will take up the dye. 
Fluorescein diacetate (FDA) when hydrolysed by esterases within the 
cytoplasm of metabolically active cells is converted to fluorescin which 
emits a green fluorescence. The cell membrane is permeable to FDA, and so 
viable cells will be positive for this stain. 
 
Materials: 
1 mg/ml FDA (Sigma F7378-5G) in DMSO 
1 mg/ml PI (Sigma 70335-5ML-F) in water 
1x PBS containing calcium and magnesium 
Microscope slides 
Tissue 
Coverslips 
Nikon Eclipse microscope 
DX1200 camera 
FDA filter block (excitation filter 465-495 nm, emission filter 515-555 nm) 
PI filter block (excitation filter 510-560 nm, emission filter 590 nm) 
 
Approximately 500 µl of ELS beads from Day 11 of a FBB experiment 
were transferred to a 2 ml microcentrifuge tube. The residual culture 
medium was aspirated and the beads washed in 1 ml PBS solution (with 
Ca
2+
 and Mg
2+
). The beads were allowed to settle, whereupon the wash 
solution was aspirated and the process repeated. For the final wash the beads 
were suspended in 500 µl PBS solution, to which 10 µl FDA (Note: FDA is 
light sensitive and so must be protected from light and stored at 4⁰C) and 
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20 µl PI were added. The mixture was incubated at room temperature for 
90 seconds, inverting the tube to mix. The supernatant was aspirated and 
washed in 1 ml PBS as before, with the beads then being suspended in 
500 µl PBS to provide an adequate liquid volume to transfer the beads to a 
microscope slide. A glass coverslip was gently lowered onto the beads 
taking care not to damage them. Samples were imaged immediately 
afterwards using Lucia imaging software with a DX1200 camera on a Nikon 
Eclipse microscope. Images were taken at 4 x on phase contrast, live FDA 
and dead PI settings, protecting the specimens from light. 
The density of fluorescence was determined on the Lucia software using the 
following macro specifications: 
Fluorescein Diacetate Macro: 
ClearBinary();  
WaitText(3,"Click on areas omitted by macro to add them, then right click 
and click OK");  
DefineThreshold(0,106,14,13,255,216,7);  
_DefineThreshold();  
Threshold();  
MeasureField();  
_FieldData();  
 
 
Propidium Iodide Macro: 
ClearBinary();  
WaitText(3,"Click on areas omitted by macro to add them, then right click 
and click OK");  
DefineThreshold(106,8,6,255,61,18,7);  
_DefineThreshold();  
Threshold();  
MeasureField();  
_FieldData(); 
 
The viability of cells was calculated according to the equation: 
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2.4.  BCA Assay 
The bicinchoninic acid (BCA) assay is used to determine total protein 
present within a sample, and is indicated by a colorimetric change from 
green to purple, which when measured by absorbance spectrophotometry at 
the 570 nm wavelength, can be compared to a standard curve to deduce 
protein concentration. 
 
Materials: 
0.5% TritonX 100 in PBS 
 
Reagent A: (in 100 ml MilliQ H2O, adjusted to pH11.25 with 10 M NaOH): 
1 g sodium bicinchoninate (Sigma, D8284) 
2 g sodium carbonate (BDH, 102404H) 
0.16 g sodium tartrate (Sigma, S4797) 
0.4 g sodium hydroxide (BDH, 102524X) 
0.95 g sodium bicarbonate (BDH, 102474V) 
 
Reagent B: 
0.4 g cupric sulphate 5-hydrate (BDH, 3312-3) 
 
Standard BSA solution (1 mg/ml): 
1 ml of 2 mg/ml BSA standard solution (Sigma, P0834-10X-1ML) 
1 ml MilliQ H2O 
 
A series of BSA standards (1000 µg/ml – 31.25 µg/ml) was prepared by a 
1:2 serial dilution of the 1 mg/ml BSA solution in a solution of 0.5% 
TritonX 100 (in PBS). 
A working solution was prepared by mixing 50 parts reagent A to 1 part 
reagent B (e.g. 50 ml reagent A and 1 ml reagent B). To each well of a 
96-well plate, 200 µl of this working solution was added. 
A sample of 250 µl encapsulated HepG2 cells were combined in a 2 ml tube 
with 1.6 ml 16 mM EDTA and incubated at 37ºC for 10 minutes to dissolve 
the alginate. The resulting solution was centrifuged at 13,200 g for five 
minutes and the cell pellet was first washed in 2 ml PBS and then 
centrifuged at 13,200 g for 2.5 minutes to separate the pellet from the wash 
solution. To the dry pellet, 1 ml 0.5% TritonX 100 (in PBS) was added and 
then vortexed before incubating for 10 minutes at 37⁰C. To each well, 20 µl 
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of each standard (in triplicate) was added, including a blank consisting of 
0.5% TritonX 100 (in PBS) alone, or 20 µl of each sample in triplicate. The 
plate was placed on a shaker for 30 seconds, then wrapped in cling-film to 
prevent evaporation, and incubated at 37°C for 30 minutes. The plate was 
allowed to cool before the absorbance was measured on a plate reader 
(Anthos HTCII) at 570 nm. 
 
2.5.  MTT Viability Assay 
Metabolically active cells reduce methylthiazolyldiphenyl-tetrazolium 
bromide (MTT) to insoluble formazan by the mitochondrial and microsomal 
reductases. The formation of dark blue formazan crystals is directly 
proportional to cell activity and can be quantified by measuring absorbance 
at the 570 nm wavelength. 
 
Materials: 
0.75 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(Sigma, M5655) in PBS 
16 mM EDTA in 0.15 M NaCl 
PBS 
4 mM HCl in Isopropanol 
96 well clear flat bottomed culture plate 
Orbital plate shaker 
 
A sample of 250 µl of encapsulated HepG2 cells were combined in a 2 ml 
tube with 1.6 ml 16 mM EDTA and incubated at 37ºC for 10 minutes to 
dissolve the alginate. The resulting solution was centrifuged at 13,200 g for 
five minutes and then washed twice in PBS. The supernatant was aspirated 
and 500 µl 0.75 mg/ml MTT solution was added to each tube at incubated at 
37ºC for three hours, until blue crystals had visibly formed. The crystals 
were mixed to homogenously resuspend and then 50 µl of this was 
transferred to 200 µl acidified isopropanol in each well of a 96 well plate. 
The plate was sealed with a plate sealer and agitated for 30 minutes on an 
orbital shaker to dissolve the crystals. The absorbance was read using a 
spectrophotometer at 570 nm. 
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2.6.  Alpha-Fetoprotein ELISA 
The production of alpha-fetoprotein (AFP) was used as a marker of liver-
specific protein function, making use of an enzyme linked immunosorbent 
assay (ELISA) to detect the presence of said target protein. The principle is 
based upon the binding of target protein specific antibody, which is then 
itself bound by a secondary antibody which catalyses the breakdown of a 
precursor molecule to generate a coloured compound. The intensity of the 
coloured compound formed is therefore directly proportional to the quantity 
of protein in the sample. 
 
Materials: 
96 well Immuno coated plates (HiBind, Nunc, DIS-971-030J) 
Tween-20 (Sigma, P1379) 
2 M sulphuric acid (H2SO4) (Analar, 102760B) 
o-phenylenediamine (OPD) tablets (Dako, s204530) 
Sodium carbonate (Na2CO3) Analar (102404H) 
Sodium hydrogen carbonate (NaHCO3) (Analar, K38347229.805) 
Sodium chloride (NaCl) (Analar, 27810.364) 
Potassium chloride (KCl) (Analar, 26764.232) 
KH2PO4) (Analar, 102034B) 
Di-sodium hydrogen orthophosphate 2-hydrate (Na2HPO4.2 H2O) (Analar, 
103834G) 
Hydrogen peroxide (H2O2) (VWR, 23615.261) 
MiliQ H2O 
Non-fat milk powder (Marvel) 
2 mg/ml α Alpha-1-Fetoprotein (Abcam, Ab10071) 
Capture antibody (Abcam, Ab10072) 
Plate washer 
Plate reader 
 
10 x PBS (in 500 ml H2O): 
40 g NaCl 
1 g KCl 
7.2 g Na2HPO4.2 H2O 
1 g KH2PO4 
 
Coating Buffer (pH 9.6, in 200 ml dH2O): 
0.318 g Na2CO3 
0.586 g NaHCO3 
 
Wash Buffer: 
1 L 1 x PBS 
500 µl Tween-20 
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Blocking buffer: 
5% dehydrated non fat milk in Wash Buffer 
 
OPD Solution: 
2*OPD tablets 
12 ml distilled water 
Before use, add 6 µl H2O2 
 
The primary antibody was diluted 1 in 1000 in coating buffer to give a final 
antibody concentration of 2 mg/l. 100 µl of this solution was transferred into 
each well of a 96 microwell plate using a multipipette and the plate was then 
wrapped in cling-film and left overnight at 4
o
C. 
A plate washer was used to rinse the plate three times with Wash Buffer and 
aspirated before adding 100 µl blocking buffer to each well, incubating at 
room temperature for one hour. Samples, the QC and AFP standards (1:1 
serial dilution from 200 mg/ml to 6.25 ng/ml) were diluted in medium. 
After first swirling the plate to dislodge any sediment of blocking buffer, 
100 µl of each sample, standard and QC was added to each well in triplicate. 
The plate was then covered and incubated at 37
o
C for 90 minutes, followed 
by again using the plate washer to rinse three times with Wash Buffer. The 
secondary antibody (Ab10072) was diluted 1 in 7000 in blocking buffer and 
100 µl of this was added to each well using a multipipette. The plate was 
again covered and incubated at room temperature for one hour, after which 
it was washed five times with Wash Buffer and the supernatant aspirated. 
To start the colorimetric assay, 100 µl OPD solution was added to each well 
at timed intervals and the plate covered with foil and left to incubate at room 
temperature for approximately five minutes or until sufficient colour had 
developed. To stop the reaction, 50 µl of 2 M sulphuric acid was added at 
timed intervals. Finally, the plate was transferred to a plate reader and the 
absorbance intensity read at 492 nm. 
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2.7.  HepG2 DNA Extraction 
To obtain high molecular weight human DNA for use in DNase I 
experiments, the following protocol was utilised, modified from Laird et al. 
(112): 
 
Materials: 
Lysis Buffer: 
100 mM TrisHCl 
5 mM EDTA 
0.5% SDS 
200 mM NaCl 
 
Proteinase K (lyophilised, from Tritirachium album; Sigma-Aldrich, P6556) 
100% Isopropanol 
 
T175 flasks of 80% confluent HepG2 cells were washed twice in 50 ml PBS 
(at room temperature) discarding the supernatant. 10 ml of lysis buffer with 
1 mg Proteinase K was then added and the cells incubated for four hours at 
37˚C, after which the dislodged cell suspension was removed and mixed 
with an equal volume of isopropanol and gently inverted for 10 minutes to 
precipitate genomic DNA. The supernatant was aspirated from the resulting 
pellet which was allowed to air dry briefly before being transferred to an 
initial volume of 1.5 ml PCR grade DNase free water (BioLine). 
 
2.8.  Proteinase K Treatment of Samples 
Prior to applying plasma-based samples to PCR analysis it was necessary 
that they were first treated with Proteinase K to remove intrinsic plasma 
proteins which could otherwise interfere with the PCR readings. 
 
Materials: 
5 x TTE buffer (50 mM Tris Base, 1 mM EDTA) 
2.5% Tween-20 
Double distilled H2O (dH2O) 
Proteinase K (lyophilised, from Tritirachium album; Sigma-Aldrich, P6556) 
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For each sample, 20 µl was applied to 16 µl lyophilised Proteinase K re-
suspended in 20 µl 1 x TTE buffer (For 10 ml 1 x TTE: 2 ml 5 x TTE stock, 
7.75 ml dH2O, 250 µl 20% Tween-20) and the resulting solution incubated 
at 50⁰C for 45 minutes. Samples were then mixed with 160 µl 1 x TTE 
buffer and heated at 95⁰C for 10 minutes to inactivate the Proteinase K. 
Protein debris was removed by centrifugation at 13,000 g for 10 minutes, 
the supernatant being carefully aspirated and utilised in further assay 
protocols. 
 
2.9.  Q-PCR 
Quantitative Real Time Polymerase Chain Reaction (Q-PCR) analysis was 
chosen to measure DNA content of samples owing to its well documented 
sensitivity (67;113), being able to detect and amplify trace levels of the 
targeted amplicon. The Alu tandem repeat consensus sequence was targeted 
by using a 115 base pair (bp) primer pair first utilised by Umetani et al. 
(114) to target DNA released from apoptotic cells containing this 115 bp 
consensus sequence. It is to be noted that apoptotically cleaved DNA is 
typically 180-200 bp in length. The Alu repeat is found abundantly in the 
human genome, representing approximately 10.8% of the genome, and is 
species specific. 
 
Materials: 
2x Hot StarTaq® Polymerase (comprising 2x PCR Buffer, 1.5 mM MgCl2, 
200 μM dNTP’s and 1.25 U Taq Polymerase) (Qiagen, 203645) 
28 mM MgCl2 
DNase- and RNase-free PCR grade H2O (BioLine, BIO-37080) 
100 µM 115bp Primer (Sigma, bespoke order) 
 FORWARDS: CCTGAGGTCAGGAGTTCGAG 
 REVERSE: CCCGAGTAGCTGGGATTACA 
10 000 x SybrGreenI (Sigma, S9430) 
200 ng/µl certified human genomic DNA (BioLine, BIO-35025) 
0.2 ml PCR microcentrifuge tubes (Corbett, Qiagen, 0030 125.215) 
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1x PCR mix: (Reaction volume = 20 µl (15 µl PCR Mix + 5 µl sample)) 
10 μl Hot StarTaq® Polymerase 
0.5 μl 1/1000 SYBR Green I 
1 μl 10 μM Forward Primer (final concentration: 400 nM) 
1 μl 10 μM Forward Primer (final concentration: 400 nM) 
2.5 μl 28 mM MgCl2 (final concentration: 5 mM) 
 
A standard curve was created and run within each Q-PCR experiment, using 
standardised human genomic DNA in a five point range of concentrations 
from 0.01 pg to 10 pg DNA per 20 µl Q-PCR reaction volume. 
Samples were run using the RotorGene 3000 (Corbett) with the following 
cycle programme: 
95 °C  5 minutes 
95 °C  15 seconds 
64 °C  30 seconds 
72 °C  30 seconds 
72 °C  10 minutes 
 
This was run for 40 cycles. The melt curve data was acquired from 45⁰C to 
95⁰C at a rate of 1⁰C per minute. 
 
2.10.  PicoGreen® Assay 
The Quanti-iT
TM
 PicoGreen® reagent is a fluorescent stain for double 
stranded DNA (dsDNA), which has been shown to detect and quantify 
dsDNA in concentrations ranging from 0.25 ng/ml to 150 ng/ml (115). 
 
Materials: 
Quanti-iT TM PicoGreen® dsDNA Assay Kit (Invitrogen, P7589) 
PCR Grade H2O (Invitrogen AM9935) 
DNase free 0.2 ml PCR microcentrifuge tubes (Corbett, Qiagen) 
RotorGene 3000 (Corbett) 
 
As an alternative method of DNA detection to PCR, the Quanti-iT TM 
PicoGreen® assay was adapted for the required application. This method 
detects dsDNA fragments less than 500 bp in length and may have an 
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advantage over PCR based methods of detection as it does not require the 
presence of a specific consensus sequence to detect DNA. To prepare the 
samples, 100 µl of PicoGreen® reagent (1 x PicoGreen® diluted in 1 x TE 
buffer (diluted with PCR grade H2O from a 20 x TE buffer stock solution) 
from 200 x PicoGreen® stock reagent) was added to an equal volume of 
sample, giving a total reaction volume of 200 µl per PCR microcentrifuge 
tube. A total of 15 endpoint fluorescence measurements were taken at 37⁰C 
for each sample using the RotorGene software and PCR machine. Standards 
were produced using bacteriophage λ DNA (diluted to a 2 µg/ml stock with 
1 x TE buffer from the 100 µg/ml stock solution supplied with the 
PicoGreen assay kit) to give a 6-point range of final DNA concentrations 
from 0 – 1 µg/ml. 
 
2.11. DNA Quantification – NanoDrop  
It was necessary to quantify the concentration of HepG2 DNA prior to 
enzymatic degradation. NanoDrop instrumentation and software was used to 
gain data values using the nucleic acid absorbance assay (performed as per 
manufacturers’ protocols). A range of serially diluted samples were used in 
all situations to allow for DNA solubility and hydration limitations which 
may occur at higher DNA concentrations. 
 
2.12. DNA Gel Electrophoresis 
Materials: 
2% agarose 
0.004% 10 mg/ml ethidium bromide 
HyperLadder III (500 bp, Bioline, BIO-33055) 
Gel electrophoresis tank (BioRad) 
10 x TAE buffer (to 500 ml, in dH2O): 
24.2 g TrisBase 
5.71 ml acetic acid 
10 ml 0.5 M EDTA 
 
Samples were run at a constant current at 90 volts for 10 minutes (unless 
otherwise stated) on a 2% agarose gel stained with ethidium bromide in 
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1xTAE buffer (stock diluted 1:10 in dH2O). An appropriate molecular 
weight ladder was used to identify product size. Gels were viewed and 
images taken using UVP Gel Doc software. 
 
2.13. Preparation of Enzyme Aliquots 
In order to gain usable and reproducible concentrations of enzyme solutions, 
thus minimising intra-experiment variability, each batch of lyophilised 
enzyme was aliquoted. 
Materials: 
Deoxyribonuclease I (Type II from bovine pancreas; Sigma D4527) 
TrisHCl buffer: 
50 mM TrisHCl pH7.4  
1 mM CaCl2 
1 mM MgCl2 
 
Lactate oxidase (lyophilised, from Pediococcus sp.; Sigma LO638) 
Phosphate buffer: 
10 mM potassium phosphate 
0.01 mM FAD 
 
Polypropylene microcentrifuge tubes 
 
A vial of 20 KU Deoxyribonuclease I was re-suspended in 28.5 ml TrisHCl 
pH7.4 buffer to give a concentration of 0.2 mg/ml enzyme. Aliquots were 
made on ice of a combination of 10 µl, 100 µl and 1 ml and stored at -20⁰C 
until required. Care was taken to minimise shear stress as DNase I is 
notoriously sensitive to denaturation by physical stress (i.e. vortexing). 
 
Lactate oxidase was suspended in 10 mM potassium phosphate buffer to 
give a concentration of 2 U/ml. This was divided into aliquots, lyophilised 
and stored at -20⁰C until required. 
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2.14. Solution Lactate Concentration Determination 
Analox® GM7 was used to measure the lactate content of supernatant 
solutions. The detection method utilises an enzymatic biosensor which, 
upon substrate binding, catalyses the conversion of lactate to generate 
hydrogen peroxide as a by-product. This is detected by an electrode sensor 
and a read-out is generated, proportional to the concentration of sample 
substrate. 
 
Materials: 
Analox® GM7 direct glucose and lactate sensor 
Lactate Reagent Kit (Analox, GMRD-093) 
Positive displacement pipette (10 µl, Rainin, MR-10R) 
MilliQ H2O 
 
The machine was flushed with lactate oxidase reagent for eight cycles prior 
to calibration by injecting 7 µl 8 mM lactate standard using a positive 
displacement pipette. The pipette was rinsed between calibration and each 
sample reading in MilliQ H2O. 
 
2.15. Statistical Analysis 
Where appropriate the unpaired Student’s T-test or a one-way ANOVA 
followed by the Tukey-Kramer test was used to determine significance of 
the data generated. 
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Chapter 3. Lactate Clearance 
 
 
In this chapter modes of Lactate oxidase immobilisation and the efficacy of 
the systems to reduce lactate concentration in physiologically relevant 
conditions is experimentally investigated.  
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3.  Lactate Clearance 
 
3.1.  Introduction 
Lactate is produced as a consequence of oxygen deficient respiration and 
can be used as an energy source when glucose is unavailable to the cell 
(116). Yet many cancer cell lines, including HepG2 cells, respire primarily 
through aerobic glycolysis (49), generating lactate, a shift in the mode of 
metabolism referred to as the Warburg Effect (117). However, elevated 
lactate concentrations can impede cell growth and proliferation by lowering 
the pH (118). Furthermore, as a potent chelator of calcium (53;119), lactate 
levels in the fluidised bed bioreactor (FBB) should be regulated to below 
10 mM in order that the integrity of the HepG2 containing alginate beads is 
maintained. This is particularly critical during the cell proliferation stage, 
when encapsulated HepG2 cells are cultured in the FBB prior to their use 
within the functional BAL, as any decrease in proliferation rate would 
inevitably lead to fewer viable cells capable of performing the required 
therapeutic liver cell functions. 
 
The enzyme lactate oxidase (LOx) is an appealing candidate to address the 
problem of lactate accumulation within the BAL; not only does it catalyse 
the clearance of lactate but by doing so pyruvate is generated (120;121) 
which could potentially be used as an energy source for the encapsulated 
HepG2 cells. In its favour is that unlike lactate dehydrogenase, which also 
breaks down lactate in vivo, lactate oxidase has been demonstrated to restore 
cytoplasmic pH levels following an increase in lactate concentration 
(121;122). 
 46 
 
Figure 3-1 - Schematic depiction of the action of Lactate oxidase and Catalase 
 
 
3.1.1. Lactate oxidase 
The (approximately) 98 kDa (123) tetrameric (121) enzyme belongs to the 
a-hydroxyacid oxidase family, sharing their β8/α8 barrel structure (121) and 
is functional in the presence of the cofactor, flavin adenine dinucleotide 
(FAD), a member of the flavin mononucleotide (FMN) group. It is a highly 
specific enzyme, discriminating between L-lactate and glycolate (121). 
Studies of the crystal structure of Aerococcus viridians LOx have proposed 
a mechanism of lactate catalysis involving an interaction between lactate, 
the cofactor and amino acid moieties of the enzyme’s active site. 
Specifically, Arg268, His265, and Tyr40 are absolutely required in the 
active site domain for successful catalysis where they interact with the 
cofactor FAD; His265 and Tyr40, along with Tyr146, Tyr215 and Lys211, 
are also required for the correct orientation and chirality of lactate, 
facilitating an interaction with, and the consequent reduction of, the FAD 
cofactor and the degradation of lactate. 
 
LOx has been putatively identified in the inner membrane space of rat liver 
mitochondria (122) where it is implicated in the conversion of administered 
L-lactate into pyruvate and hydrogen peroxide (H2O2) (120;121), a potent 
oxidising agent which has been demonstrated to induce apoptosis due to 
oxidative stress (124;125). 
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Therefore, application of immobilised LOx for use within the FBB may also 
require a similar incorporation of catalase in order to convert the produced 
H2O2 to water and oxygen, should the innate catalase activity of HepG2 cell 
spheroids be insufficient. 
 
3.1.2. Existing methods of LOx immobilisation 
Previous strategies for the immobilisation of LOx have generally been for 
use within or as a biosensor device. Although some methodologies may be 
transferable between a biosensor design and an application such as the BAL 
there are a number of different considerations which must be acknowledged. 
It is an absolute requirement that the materials used for immobilisation of 
the enzyme must be able to withstand an effective sterilisation method and 
furthermore that the material can function sufficiently under the perfusion 
conditions, including compatibility with plasma/growth medium 
constituents and functionality under flow rates of between 2-600 ml/min. 
The most relevant methods undertaken for the immobilisation of LOx are 
summarised in the following sections.  
 
3.1.2.1. Nylon net 
In this approach discs of nylon net were surface-modified and lysine used as 
a spacer by which lactate oxidase from Mycobacterium smegmatis was 
covalently tethered to the discs (126). These were then used to coat the tip 
of a pO2 oxygen electrode probe. A specific activity of 50 nmol min
-1
 cm
-2
 
was obtained when 1 mg of protein was loaded onto the nylon net and tested 
at 25⁰C in 0.1 M citrate buffer at pH6 (126). This technology was shown to 
function well as a simple electrode sensor for lactic acid in blood serum 
samples (127) and, furthermore, was also shown to be operational for up to 
two months when stored in 0.1 M citrate buffer, although it is to be noted 
that serum samples were diluted 1:20 or 1:50 in citrate buffer prior to taking 
readings. Despite such encouraging results, the incorporation of a nylon net 
based method of LOx immobilisation into the BAL is probably unfeasible, 
if only as a consequence of space limitations within the FBB and the large 
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surface area of nylon net support that would be required to encompass a 
sufficient quantity of LOx enzyme. Moreover, this may also act as a binding 
surface for the proteins secreted by the biomass, meaning the benefit of 
these to the patient could be drastically reduced. 
 
3.1.2.2. Covalent attachment onto Immobeads 
Previous experiments undertaken by the Liver Group sought to immobilise 
LOx onto Immobeads150 (ChiralVision, The Netherlands). The beads have 
a diameter of 150-300 µm and comprise a macroporous cross-linked 
polymer of methacrylate carrying oxirane groups which bind lysine groups. 
Beads were pre-treated with 40 mM glutaraldehyde for four hours before 
cross-linking to LOx. However, enzyme activity remained low and active 
site analysis of A.viridians LOx revealed a lysine residue (Lys 241) in close 
proximity which, although not involved directly with the active site, is 
required for the correct orientation of FAD, the cofactor. This was 
unexpected as lysine residues have been frequently targeted to immobilise 
LOx as they are found on the periphery of the molecule and so can be 
utilised for binding without altering the active enzyme conformation (128). 
This could be accounted for by species variation of LOx enzyme; 
Pediococcus LOx was used in this study rather than the characterised 
A. viridians LOx orthologue.  
 
3.1.2.3. Functionalised glass 
In their investigation into the effects of the coupling reagent on the 
immobilisation of enzymes, Tiller et al. (128;129) demonstrated a number 
of methods for immobilising Pediococcus LOx onto NH2 functionalised 
glass. An ultrathin (in the range of hundreds of nanometres) layer of SiO2 
was applied to the tip of glass rods by the Pyrosil technique (128-130) and 
following exposure to atmospheric humidity for 1-2 hours polymerised SiO2 
films were formed. These were then treated with 3-aminopropyl 
triethoxysilane in toluene. A total of thirteen different coupling reagents 
were investigated, each used in excess, for support activation, to avoid any 
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cross-linking of the matrix. Variable amounts of cross-linking may result in 
a variable degree of swelling of the support which can affect the outcome of 
immobilisation. The activated support was incubated at 4°C for 16 hours in 
0.1 ml enzyme solution (1 mg enzyme/litre) to immobilise the enzyme. It 
was found that the enzyme was stabilised compared to the native enzyme, in 
particular that the most suitable method for high activity was coupling via 
1,3-benzenedisulfonyl chloride and 4,4’-biphenyldisulfonyl chloride onto 
NH2-glass (330 and 339 mU/cm
2
; Km 0.37 mM). This becomes more 
relevant when it is considered that glutaraldehyde, a frequently used and 
popular choice in coupling reagent, yielded enzyme activities of only 
175 mU/cm
2
; Km 0.4 mM (Km of the free enzyme, 0.57 mM). However, 
one great disadvantage encountered with this immobilisation method was 
that LOx could not be stabilised against thermal stress; the enzyme lost 60% 
of its activity after only 30 minutes at 45°C (128). 
 
Other successful attempts to tether LOx onto a modified glass surface 
include the use of zirconia coated alkylamine glass beads (131). A 
Pediococcus derived LOx was cross-linked to the glass support using 
glutaraldehyde to yield 3.2 mg of protein per gram of support, showing 
maximum activity at pH 6.5. Of note is that complexes prepared in this 
manner showed excellent retention of activity and were then applied to 
human serum to monitor lactate concentrations, indicating that this approach 
would have had the potential to be applied to the BAL; unfortunately, it was 
not possible to obtain the highly specialised glass beads for this study. 
 
3.1.2.4. Freely circulating enzyme 
In complete contrast to the immobilisation strategies discussed above, Bohm 
et al. incorporated a matrix-free method of lactate clearance which did not 
entail the immobilisation of LOx (132). Instead free enzyme was housed 
within a section of semi-permeable dialysis tubing with a wall width of 
50 µm and a molecular weight cut-off of 20 kDa. This prevented leakage of 
LOx whilst permitting diffusion of substrate analytes, namely lactate and 
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oxygen into the enzyme solution and the efflux of hydrogen peroxide and 
pyruvate. The system enabled a continuous flow method in a biosensor 
application, with the advantage that LOx could be used at any desired 
concentration, even in excess, as no enzyme activity/yield reducing 
immobilisation steps were required. However, enzyme kinetics data was not 
investigated in the study, thus the possibility remains that the lack of 
physical support and stabilisation offered by immobilisation may have had a 
negative impact upon the activity and lifespan of the free enzyme. 
 
The following section will address the hypothesis outlined in the main 
introduction chapter, namely, whether LOx can be immobilised in order to 
prevent the accumulation of lactate in the FBB. To do this, a variety of 
immobilisation strategies will be investigated and their suitability for use 
within the FBB determined. In order to be deemed a feasible option, an 
immobilisation method must fulfil the following criteria: 
 
 Lactate concentration must be reduced from 15 mM to under 10 mM 
following treatment with the enzyme preparation 
 
 The immobilisation strategy must yield enzymes which function in 
physiologically relevant conditions 
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3.2.  Materials & Methods 
 
3.2.1. Lactate oxidase activity assay 
To determine the activity of LOx following immobilisation and also for the 
free enzyme positive control conditions, a simple and well documented 
colorimetric assay was used (133), the principle of which is outlined below. 
  
             
   
                 
                 
   
                          
 
(http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/General_Information/2/lac
tate_oxidase.Par.0001.File.tmp/lactate_oxidase.pdf) 
 
Materials: 
Reaction mix 
150 µl 200 mM 3,3-Dimethylglutaric acid buffer (adjusted with NaOH to 
pH 7.4) (Sigma-Aldrich, 98% D4379-25G) 
75 µl 15 mM 4-aminoantipyrine (4-AAP) (A4382-10G) 
75 µl 24 mM lactate solution (pH7.4) 
75 µl 50 U/ml peroxidise, type II from Horseradish (Sigma, P8250) 
225 µl dH2O 
 
0.2% (v/v) N,N-Dimethylaniline solution (DMA) (ReagentPlus®, 99%, 
515124) in dH2O 
0.25% (w/v) dodecylbenzenesulfonic acid (DBS) (Aldrich 522953) in dH2O 
 
Phosphate Buffer (pH 7.4): 
10 mM potassium phosphate 
0.01 mM Flavin Adenine Dinucleotide, disodium salt (FAD) (Sigma F6625 
- ≥95% (HPLC), powder) 
 
0.2 U/ml LOx (Sigma, L0638) (in phosphate buffer) 
 
To each well of a 96-well plate 80 µl of the reaction mix and 20 µl DMA 
was added, followed by the addition of the sample (20 µl 0.2 U/ml LOx 
solution for standards and free LOx samples, 20 µl of post-immobilisation 
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supernatants or 20 µl potassium phosphate buffer (pH 7.4) when assaying 
immobilised LOx, unconjugated glass beads or for taking blank 
measurements). The reaction was quenched by the addition of 20 µl DBS 
after incubation at 37ºC for 10 minutes. 
 
3.2.2. Immobead enzyme immobilisation 
Materials: 
Immobead 150 (Sigma, ChiralVision, 94129) 
4 U lyophilised LOx (Sigma-Aldrich UK Sigma, L0638) 
40 mM glutaraldehyde 
 
Immobeads have a diameter of 150-300 µm and comprise a macroporous 
cross linked polymer of methacrylate carrying oxirane groups which bind 
lysine groups. 4 U LOx was re-suspended in 10 µl 40 mM glutaraldehyde 
solution and incubated for two hours at 4°C, before adding 100 mg of dry 
beads and incubating for 48 hours at 4°C. 
 
3.2.2.1. NaBH3CN quenching of glutaraldehyde 
Materials: As above, but also: 
10 mM NaBH3CN (Aldrich 156159) in 10 mM potassium phosphate buffer 
 
For NaBH3CN quenching experiments, 100 mg Immobeads and 370 µl 
10 mM potassium phosphate buffer was added to the enzyme solution and 
incubated at 4°C for 24 hours followed by two hours incubation with 1.5 ml 
10 mM NaBH3CN (final concentration of 8 mM). 
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3.2.3. NH2 functionalised glass beads immobilisation 
Materials: 
Glass beads (750-1000 µm diameter, Kisker-Biotech, PGB-075) 
Methanol 
Isopropyl alcohol 
Sonicator 
1,3-benzenedisulfonyl chloride (97%, Aldrich, 444642) 
Toluene, anhydrous (99.8%, Sigma-Aldrich 244511) 
Cyanuric chloride ( 99%, Sigma-Aldrich, C95501-5G) 
N,N-dimethylacetamide (DMAd) (≥99.5%)Sigma-Aldrich, 38840) 
10 mM phosphate buffer 
Ethanol 
 
3- aminopropyltriethoxysilane (≥98%, Sigma A3648) 
Ceramic mortar 
Plate shaker 
Miniature blow torch 
0.1 mg/ml LOx in 10 mM phosphate buffer 
 
A protocol for the functionalisation of glass was adapted from Tiller et al. 
(128) for the treatment of glass beads. 100 mg beads were sonicated in 
isopropyl alcohol for five minutes and then rinsed in 2 ml isopropyl alcohol 
followed by a rinse with 2 ml methanol. The beads were left to dry for 
30 minutes at 80°C. The beads were then treated with a procedure adapted 
from the Pyrosil technique used by Tiller et al; the beads were placed in an 
autoclaved ceramic dish on a plate mixer and exposed to the oxidising tip of 
a flame from a miniature blow torch. The flame treatment consisted of two 
seconds exposure to the flame followed by a five seconds pause. This was 
repeated three times to give a total of six seconds flame treatment per batch 
of beads. 
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Treated beads were allowed to cool in air overnight before incubating in a 
20% solution of 3- aminopropyltriethoxysilane in dry toluene (Figure 
3-2, 1), incubated with stirring at room temperature for two hours. 
Following this, the beads were rinsed first with 2 ml toluene, followed by 
2 ml 1:1 toluene:methanol solution and finally with 2 ml methanol. Beads 
were dried in air overnight (Figure 3-2, 2). For the cross linking stage, the 
beads were treated with 100 mg of either 1,3-benzenedisulfonyl chloride or 
cyanuric chloride, dissolved in 10 ml DMAd at room temperature for 
15/5 minutes respectively (Figure 3-2, 3). Beads were washed three times 
with 10 ml ethanol and rinsed in 10 ml chilled 10 mM phosphate buffer 
(pH7.4) before incubating with 100 µl of 0.1 mg/ml LOx (in buffer, cooled 
to 4°C) for 16 hours (Figure 3-2, 4)). Finally, the functionalised beads were 
rinsed three times in 500 µl 10 mM potassium phosphate buffer before 
being re-suspended in 10 ml of the same buffer solution. It was calculated 
  
  
1) 
 
 
 
2) 
 
 
 
 
 
 
 
 
 
 
3) 
 
 
 
 
 
 
 
 
 
 
4) 
 
 
 
 
 
 
 
 
 
 
 
Drying 
overnight 
Beads applied to 
100 µl of 
0.1 mg/ml LOx 
for 16 hours. 
 
Figure 3-2 - Schematic representation of the NH2 functionalisation process for 
glass beads. 
1) = beads in 3- aminopropyltriethoxysilane solution; 2) = beads air drying; 
3) = beads immersed in cross-linker solution; 4) = functionalised beads applied to 
LOx solution. 
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that four beads would be required for each individual assay to represent the 
0.004 U LOx used in the positive control assay conditions (based on an 
equal distribution of the total 10 µg LOx used onto 100 mg of glass beads). 
 
3.2.3.1. Immobilised LOx for lactate clearance in FFP media:  
Materials: 
Immobilised LOx beads, as described previously 
FFP culture medium 
Heparin (5000 IU/ml, Wockhardt UK Ltd) 
1 M HEPES (pH 7-7.6, Sigma, HO887) 
200 mM lactate (~98%, Sigma L7022) 
 
Heparin was added to the FFP medium to prevent clotting, at a final 
concentration of 2 U heparin/ ml of 10% FFP in complete DMEM culture 
media. A final concentration of 10 µl/ml HEPES was used to buffer the 
media solution to pH 7.4. 100 mg of beads were used for each experimental 
condition. 20 µl of the 2 ml solution was replaced with 200 mM lactate 
solution to spike the media. For the 11 day experiment, the following 
modification to the lactate spiking protocol was used: 
Table 3-1 – Lactate spike administration schedule and protocol. 
DAY 200 mM lactate added (µl) Final concentration (mM) 
1 0 0 
2 10 0.1 
3 5 0.5 
4 9 0.9 
5 14 1.4 
6 19 1.9 
7 15 1.5 
8 21 2.1 
9 31 3.9 
10 24 3.1 
11 0 2.4 
 TOTAL 25.3 
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3.2.4. PVDF membrane immobilisation of LOx 
Materials: 
Polyvinylidene fluoride (PVDF) membrane (AnalaR NORMAPUR 
081160502) 
Methanol 
dH2O 
96-well plate (Nunc 735-0291) 
0.2 U/ml LOx (in 10 mM phosphate buffer, pH 7.4) 
 
PVDF membranes are typically used in the Western Blotting procedure 
whereby proteins separated by polyacrylamide gel electrophoresis are 
transferred to the PVDF membrane. This membrane can then be treated with 
antibodies to allow the detection and identification of bound proteins. The 
protein binding property of the membrane could provide a means of 
physically retaining LOx protein to a designated location within the FBB for 
lactate clearance. 1.5 mm x 1.5 mm square sections of PVDF were first 
activated by soaking in methanol for five minutes followed by rinsing in 
distilled water. Sections were transferred individually to vacant wells in a 
96-well plate where they were incubated in 80 µl 0.2 U/ml LOx solution for 
two hours at 4°C. Sections were then rinsed in 10 mM potassium phosphate 
buffer before being applied to the LOx activity assay reagent mix for 
analysis. Modifications to this protocol included varying the incubation time 
with LOx from the original two hours, to six and 24 hours. 
 
3.2.5. Dialysis tubing for enzyme containment 
Materials: 
Sodium bicarbonate solution (100 ml): 
2 g sodium bicarbonate 
200 µl 0.5 M ethylene-dinitrilo-tetraacetic acid (EDTA) 
 
0.2 U//ml LOx in phosphate buffer (pH 7.4) 
Polypropylene 1.5 ml and 2 ml microcentrifuge tubes (Appleton Woods, 
KC024) 
Dialysis tubing (Spectra/Por™ 10 KDa, 128106) 
Dialysis tubing consists of a synthetic membrane with pores of controlled 
size. By using a membrane with a suitable molecular weight cut off, it is 
possible to create a physical barrier between LOx and the circulating 
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system, thus avoiding release of LOx into the FBB, without resorting to 
immobilisation and the resulting decreased activity rates often associated 
with the procedure. Dialysis membrane sections were activated by boiling 
for 10 minutes in sodium carbonate solution. Sections were rinsed in 
double-distilled water. A cassette to house the LOx solution was constructed 
from a 15 mm x 15 mm section of dialysis membrane sandwiched between 
the lid section of a PCR tube (Figure 3-3). 
This cassette was placed base down within the lid section of a 2 ml 
centrifuge tube containing the LOx activity assay reagent cocktail. This 
solution was used for the subsequent colorimetric assay. 
 
3.2.5.1. LOx thermostability 
0.2 U/ml LOx solution was incubated at 37°C for 24 hours prior to either 
application to the cassettes or directly to the reaction mix. All other 
methodology was as previously described. 
a) 
b) 
Figure 3-3 – Schematic diagram depicting the assembly of the dialysis membrane 
cassettes. 
(a) The lid section of a PCR tube containing 20 µl 0.2 U/ml LOx solution, covered 
by a section of activated dialysis membrane, forming the cassette. (b) The cassette 
was placed membrane face-up within a centrifuge tube “chamber” which 
contained 120 µl LOx activity assay reagent (section 3.2.1). 
 
Dialysis membrane 
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3.3.  Results & Discussion 
3.3.1.  Immobead immobilisation 
As a preliminary experiment it was necessary to ascertain the storage 
stability and reusability of free, non-immobilised LOx, to provide a standard 
against which the activity of immobilised enzyme could be measured. 
Simultaneously to this, immobilisation with glutaraldehyde was carried out 
and the beads stored in 10 mM potassium phosphate buffer at 4°C. Samples 
of beads were taken from this stock every 24 hours and assayed for LOx 
activity. Activity of immobilised LOx was compared against free LOx 
solution (0.2 U/ml). The same re-suspended aliquot of LOx was used for the 
initial immobilisation and also for the analysis of “Free LOx” throughout 
the time course of the experiment. The data shows that whereas LOx is 
suitably stable for one week at 4°C, immobilised LOx activity falls rapidly 
from an initial rate of 0.02 mM lactate cleared in 10 minutes on Day 1 to 
0.01 mM by Day 3, representing a fall from around 7% to 2% the rate of 
lactate clearance of Free LOx (Figure 3-4). Indeed, from Day 3 onwards the 
amount of lactate cleared was significantly lower (P<0.05) than that on 
Day 1, indicating a fall in enzymatic activity. The amount of lactate cleared 
by LOx immobilised onto Immobeads was significantly (p<0.005) lower 
than that of free LOx at all times, indicating that enzymatic activity is 
reduced following immobilisation onto Immobeads. 
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Figure 3-4 - Stability of LOx immobilised onto 100 mg Immobeads. 
Free LOx stock was re-suspended on the day of immobilisation and subsequently 
stored at 4ºC. Data for Immobeads are magnified in 3-4b). Activity determined 
from colorimetric absorbance at a wavelength of 565 nm. For each day, n=6, error 
bars depict +/- SD. The extent of lactate clearance between all days from Day 3 
onwards is statistically different from that of Day 1. * p<0.05 
 
To investigate whether the cross-linking stage could be optimised to gain 
better levels of lactate clearance using LOx immobilised onto Immobeads, 
two approaches to the glutaraldehyde pre-treatment of Immobeads were 
pursued. These were as follows: a) 10 µl 40 mM glutaraldehyde was used to 
re-suspended 4 U LOx and incubated at 4°C for two hours, before adding 
390 µl 10 mM potassium phosphate buffer and 100 mg Immobeads for a 
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further 48 hours at 4°C; b) 10 µl 40 mM glutaraldehyde was applied to 
100 mg Immobeads and 380 µl 10 mM potassium phosphate buffer and 
incubated at 4°C for two hours, before adding 4 U LOx in 10 µl 10 mM 
potassium phosphate buffer and incubating for 48 hours at 4°C. 
A Students T-test of the data suggests that there is no difference between the 
two glutaraldehyde treatment conditions, as both yielded activity levels of 
around 2% that of the free LOx enzyme. 
 
Quenching of the glutaraldehyde cross-linking reaction was investigated in 
order to determine whether over-binding of the enzyme was limiting the 
activity of immobilised LOx. A final concentration of 8 mM NaBH3CN was 
incubated with 100 mg of glutaraldehyde cross-linked LOx Immobeads for 
two hours at 4⁰C, prior to assaying the beads as before with the LOx activity 
assay. 
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Figure 3-5 - Comparison between two methods of immobilisation of LOx with 
100 mg Immobeads. 
Method A – 10 µl glutaraldehyde pre-incubated with 4 U LOx prior to addition of 
100 mg Immobeads. Method B – 10 µl glutaraldehyde pre-incubated with 100 mg 
Immobeads prior to addition of 4 U LOx. No significant difference (n/s) was 
calculated between the methods (Students T-test) n=6 +/- SD 
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Figure 3-6 – Effect of quenching glutaraldehyde cross-linking on LOx activity. 
“Quenched” condition: LOx immobilised onto 100 mg Immobeads with 10 µl 
glutaraldehyde as previously described, but 8 mM NaBH3CN added immediately 
after the immobilisation period in order to quench any further glutaraldehyde cross-
linking. “Un-quenched” samples were prepared exactly as previously described, 
and incubated in phosphate buffer whilst the “Quenched” samples underwent the 
additional quenching step. Error bars = +/- SD, n=6, *= significant difference 
(p=0.007). 
 
LOx beads which had been quenched were shown to have cleared less 
lactate than the unquenched beads (Figure 3-6), implying that excessive 
glutaraldehyde cross-linking, if it occurs, does not have a detrimental effect 
on immobilised LOx activity. As the quenched LOx Immobeads had 
reduced activity, the NaBH3CN treatment itself may be having a negative 
impact upon LOx activity. 
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3.3.2. NH2 functionalised glass beads immobilisation 
The initial immobilisation of LOx onto functionalised glass beads with 
1,3-benzenedisulfonyl chloride was encouraging, yielding activity levels of 
between 10 and 13% that of the free enzyme. 
 
Figure 3-7 – Lactate clearance by LOx-conjugated Immobeads or glass beads. 
Activity determined by applying immobilised LOx to the LOx activity assay. 
Volume of bead suspension / number of beads used per assay was based upon the 
theoretical quantity of LOx beads required to represent 0.004 U LOx, assuming 
100% binding efficiency. Hence, 20 µl Immobead suspension, 4 glass beads and 
20 µl Free LOx were used per well. Error bars = +/- SD, n=6. * = significant 
difference (P= 2 x 10-6 (T-test)). 
 
Moreover, the extent of lactate clearance by LOx immobilised onto glass 
beads was greater than that achieved when using an equivalent quantity of 
LOx-bound Immobeads (Figure 3-7). This was also true when using 
cyanuric chloride as the cross-linking molecule, but a similar level of 
activity was also observed in the absence of a cross linker, suggesting a 
degree of non-covalent binding of LOx to the functionalised glass bead 
(Figure 3-8 a). 
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Figure 3-8 – Effect of Cross-linking on Immobilised LOx activity. 
a) Initial LOx activity b) LOx activity following freeze/thaw. Activity determined 
by applying four glass beads (or 20 µl Free LOx) to the lactate oxidase activity 
assay. n=6 +/- SD. * = p = 0.001; ** = p = 0.0003. 
 
To test whether cross-linking confers any stability to immobilised LOx, and 
hence be advantageous over non-covalently bound LOx, the beads were 
frozen for 48 hours, thawed, refrozen for 24 hours, thawed and assayed for 
enzyme activity. Figure 3-8b shows that although LOx activity levels had 
fallen in all conditions, the greatest decrease was observed in the absence of 
any cross-linking reagent. Whereas no significant difference was observed 
between cross-linked and non-linked beads initially, activity after 
freeze/thaw of the non cross-linked LOx beads were significantly lower 
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(p<0.005) than both the cross-linked LOx conditions. This implies that cross 
linking confers some stability to LOx, which has practical implications 
should the immobilised enzyme be incorporated into a cartridge to be used 
within the FBB, and necessitate mid- to long-term storage. As the greatest 
activity levels were observed when 1,3-benzenedisulfonyl chloride was used 
to immobilise LOx, this molecule was utilised in subsequent LOx 
immobilisation experiments with the glass bead support. 
To identify which point in the bead preparation process was promoting the 
non-covalent binding of LOx, a series of experiments were carried out 
omitting various components of the functionalisation process. In brief, the 
conditions comprised all permutations of the three stages of bead treatment 
– flame treatment, NH2 group introduction and cross-linker inclusion, plus 
or minus LOx as required, generating a total of nine conditions. All 
reactions were commenced at the same time to allow for a fair comparison 
between samples, taking into account, for example, any possible 
degradation of silanol groups on the surface of the flame treated beads over 
time. 
It is shown in Figure 3-9 that there is a significant (p<0.001) difference 
between the amount of lactate cleared by beads treated with NH2 and LOx 
compared to those which had not. Although LOx activity was  obsereved in 
the absence of a cross linker, data from Figure 3.8 demonstrates the 
advantage and requirement for cross linking the enzyme to the 
functionalised support. There was not a significant difference between 
conditions which had not involved any NH2 group surface modification, 
indicating that NH2 functionalisation is critical for LOx binding to glass 
beads. 
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Figure 3-9 – Determining the Critical Step for LOx Immobilisation. 
Table shows combinations of treatments administered. LOx activity of each 
treatment is illustrated in the corresponding graph. NH2 treated beads have 
significantly greater lactate clearing properties (determined by the LOx activity 
assay as described in Materials & Methods) than other treatment protocols. n=6, 
+/- SD. * = Conditions which, as a group, are statistically different to the other 
treatment conditions. p<0.05, ANOVA. 
 
3.3.2.1. Optimisation of LOx immobilisation 
In order to increase the activity of immobilised LOx, a comparison was 
made between static incubation with LOx solution and gentle continuous 
rotation of the reaction vessel during the immobilisation process. The data 
indicated no advantage in terms of enzymatic activity to immobilising in a 
rotating chamber (Figure 3-10). Although non-significant, the P-value was 
calculated to be 0.055 and so for simplicity it was decided to continue using 
the static mode of LOx immobilisation. 
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Figure 3-10 – LOx immobilised onto glass beads by static / rotating incubation. 
Incubation was carried out at 4°C for 16 hours. T-test value P = 0.055. n=6, +/- SD. 
 
Another measure to increase the activity of the LOx immobilised glass 
beads was to vary the concentration of LOx enzyme used for each 
immobilisation. An initial experiment using a ten-fold increase in total LOx 
protein generated beads which exhibited an approximate 50% decrease in 
total lactate conversion. The experiment was expanded to include two 
additional LOx concentrations, with the aim of establishing how close the 
standard protocol was to the optimal enzyme loading capacity. All steps 
were performed as originally described except for incubation with LOx 
solution; the total amount of LOx used was either 0, 0.001, 0.005, 0.01 or 
0.1 mg per 100 mg glass beads. All subsequent steps remained as described 
in the original protocol. 
The results obtained (Figure 3-11) show that the current dose of 0.01 mg 
LOx per 100 mg beads is in fact already close to optimal, conferring almost 
30% of the activity of the control LOx solution. Furthermore, as there was 
no significant advantage to increasing the quantity of LOx used, it is more 
cost efficient to use the original loading mass of protein. 
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Figure 3-11 – Effect of varying the concentration of LOx used for immobilisation 
on the activity of functionalised glass beads. 
All LOx concentrations yielded levels of activity significantly different (*p<0.05) 
to the un-conjugated (Free) enzyme and the negative control (no LOx added to 
glass beads). The 0.01 and 0.001 mg conditions were also significantly different 
from each other at the same level. n=6, +/- SD. 
 
In order to determine the suitability of the beads as a surface for LOx 
immobilisation, the variability, in terms of lactate clearance, between 
batches of immobilised enzyme-bead complexes was investigated. Glass 
beads were prepared as per the original method, in duplicate under identical 
conditions simultaneously. Again, LOx was applied in a 100 µl volume to 
all batches of beads, and incubated at 4⁰C for 16 hours, after which beads 
were rinsed three times in 500 µl 10 mM phosphate buffer before being 
assayed by the colorimetric lactate assay described in section 3.2.1. The data 
indicated that there was no difference between the extent of lactate 
clearance by batches of immobilised LOx. It can be concluded that the 
method of immobilisation is highly reproducible in terms of the quantity of 
LOx immobilised and the resulting activity of the enzyme. 
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Figure 3-12 – Variability Between Immobilisations. 
Four beads were assayed per sample for enzymatic activity using the lactate 
oxidase activity assay. +/- SD, n=3. No statistical difference was found between 
LOx bead immobilisations (T-Test, p=0.992) 
 
Furthermore, it was shown in a separate experiment (Figure 3-13) that the 
relationship between lactate clearance rates (an indicator of LOx activity) 
and bead number is linear, confirming that there is a fixed amount of LOx is 
attached to any given bead in an immobilisation process.  
 
Figure 3-13 – Effect of bead number on the rate of lactate clearance. 
Immobilised LOx beads were prepared as previously, and either two, four or eight 
beads applied to the lactate oxidase activity assay (total reaction volume per well 
was 120 µl). All conditions were found to be statistically different from one 
another (p<0.05) n=6, +/- SD. 
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As it seemed that a limit had been reached for the amount of LOx activity 
that could be yielded from a batch of beads treated with LOx solution, it was 
investigated whether the remaining supernatant after the immobilisation 
period could be reused on freshly prepared beads in order to maximise 
efficiency. For this series of experiments, the LOx solution remaining after 
the 16 hour incubation period was aspirated and transferred to a batch of 
freshly prepared beads, which were then incubated with the solution for 
24 hours. This was repeated over the course of four days. All other 
methodology was as described in the original protocol. 
While the initial batch of beads on Day 1 exhibited activity levels around 
20% that of freshly prepared LOx solution, beads which were treated with 
the “left over” LOx in the supernatant from Day 1 demonstrated very 
similar activity levels, around 18% that of freshly prepared LOx (Figure 
3-14). However, by Day 3 (the second reuse of the supernatant) LOx 
activity had fallen dramatically to little over 3.5% that of freshly prepared 
LOx. By Day 4 LOx activity on treated glass beads was negligible. Free 
LOx activity had also diminished by Day 4, indicating that a reduction in 
the activity of the enzyme used for immobilisation was also responsible for 
the reduced immobilised LOx activity, rather than simply the depletion of 
available LOx due to previous immobilisations. 
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Figure 3-14 – Reuse of the LOx solution supernatant for subsequent 
immobilisation reactions. 
Samples stored at 4°C between readings taken at 24-hour intervals. Lactate 
clearance by beads cross-linked with Day 2 and Day 3 LOx supernatants are 
significantly different (*p<0.05) n=6, +/- SD. 
 
3.3.2.2. Immobilised LOx activity under physiological conditions 
Having determined the parameters for a successful immobilisation of LOx 
onto the glass bead support, it was necessary to determine how the activity 
of the enzyme was affected by the presence of plasma, if at all. Glass beads 
were prepared and incubated with LOx and then rinsed as described 
previously (section 3.2.3). Beads were then incubated at either 37⁰C with 
2 ml solutions containing a 20 mM lactate spike in either buffer or 100% 
human fresh frozen plasma (FFP). Samples were taken initially and then 
hourly for a duration of five hours. Sample analysis was performed using 
Analox instrumentation. The beads themselves were retained after the time-
course experiment, washed and then assayed for residual activity using the 
colorimetric assay as described in section 3.2.1. 
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Figure 3-15 – Lactate clearance by immobilised LOx over a five hour period. 
Samples of plasma (100% FFP) or buffer (10 mM phosphate buffer) were spiked to 
a concentration of 20 mM lactate and incubated at 37˚C. Samples were taken 
hourly for five hours, and analysed using Analox. n=3. 
 
 
Figure 3-16 – LOx activity after five hours incubation. 
Each condition applied to the LOx activity assay after five hours incubation with 
lactate spiked buffer or FFP at 4⁰C or 37⁰C. Extent of lactate clearance was 
significantly different between the indicated conditions (*p<0.05). n=6, +/- SD. 
 
After incubation for five hours, immobilised LOx reduced the lactate 
concentration in all conditions compared to the negative control (Figure 
3-15). Of particular interest is that the rate of lactate degradation by 
8 
10 
12 
14 
16 
18 
20 
0 1 2 3 4 5 
L
a
c
ta
te
 c
o
n
c
e
n
tr
a
ti
o
n
 (
m
M
) 
Time (hours) 
No LOx 
plasma 37 
Plasma 37 
Buffer 37 
-0.01 
0 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
0.07 
0.08 
Control (-LOx) Buffer 37⁰C Plasma 4⁰C Plasma 37⁰C 
L
a
c
ta
te
 C
le
a
re
d
 (
m
M
 /
 1
0
 m
in
u
te
s)
 
Condition 
  
72 
 
immobilised LOx in FFP was increasing with time, more so than in buffer.  
It may be thus concluded that this method of LOx immobilisation is suitable 
for use in human plasma. However, the residual activity of immobilised 
LOx exposed to plasma was significantly lower than that of identical beads 
incubated in buffer (Figure 3-16). Moreover, there was a significant 
difference between LOx activity following incubation in plasma at 37⁰C and 
4⁰C, suggesting that a component of plasma is having a detrimental effect 
upon immobilised LOx after exposure for just five hours. As the 
immobilised LOx beads will be required to reduce lactate concentrations 
over a much longer period of time than the five hours tested (up to 11 days), 
a second experiment was conducted, incubating immobilised LOx beads 
with lactate spiked FFP / buffer for a duration of 24 hours. The conditions 
also included samples incubated at 4⁰C and at 37⁰C; compromised over 
extended periods of time at physiological, rather than storage, temperatures. 
 
Figure 3-17 – Effect of temperature and plasma on immobilised LOx 
activity over 24 hours. 
Immobilised LOx beads were incubated in either 100% FFP (Plasma) or 10 mM 
phosphate buffer (Buffer) at 4⁰C or 37⁰C for 24 hours. Control consisted of glass 
beads only in spiked plasma at 37⁰C. All conditions were spiked with 15 mM 
lactate and samples taken hourly for seven hours, then finally after 24 hours. 
Samples assayed using ANALOX. 
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The results demonstrated that the rate of lactate clearance by immobilised 
LOx is temperature sensitive, but not compromised by exposure to 
physiological temperatures (Figure 3-17). Rather, the extent of lactate 
clearance was greater and more rapid at the higher temperature; as would be 
expected based on rate of reaction principles. 
Interestingly, analysis of the immobilised enzymes after this section of the 
investigation revealed that although the beads in plasma out-performed 
those in buffer, after 24 hours the immobilised LOx in buffer was able to 
reduce lactate levels by a greater extent in the colorimetric assay (Figure 
3-18). This could be interpreted to imply that a component of FFP has a 
detrimental effect upon the functional lifespan of immobilised LOx; 
although initially functioning at a greater rate, immobilised LOx in plasma 
lost catalytic activity over time, a phenomena which could have been 
masked by the initial rapid reduction in lactate concentration 
 
Figure 3-18 – Activity of immobilised LOx beads following incubation in a range 
of media. 
Samples from each condition were applied to the LOx activity assay after 24 hours 
incubation with lactate spiked buffer / FFP at 4⁰C / 37⁰C. Free LOx = enzyme 
resuspeded from the same aliquot as used for the immobilisation and stored at 4⁰C 
until the final asctivity assay. Fresh LOx = enzyme resuspended immediately prior 
to assay. Extent of lactate clearance was significantly different between the 
indicated conditions (*p<0.05). n=6, +/- SD. 
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The residual activity of immobilised LOx in all conditions was very much 
reduced after 24 hours, but less so for LOx which had been in buffer, 
particularly at 4⁰C. One interpretation of this could be that the stability of 
LOx is affected by plasma components; thus, by increasing temperature and 
consequently the thermal (and hence kinetic) energy of molecules, although 
an increased rate of lactate clearance was possible, the rate of degradation of 
LOx by plasma proteases was also increased. Consequently, less LOx would 
be degraded in plasma at 4⁰C than at 37⁰C. Although true after five hours 
incubation (Figure 3-16), there was no significant difference in residual LOx 
activity between plasma conditions after 24 hours (Figure 3-18), suggesting 
that by this point, there had been adequate time for substantial proteolysis 
even at the lower temperature. There was no significant difference at the 
p<0.01 level between residual LOx activity in the buffer conditions.  
Ultimately, however, it is sufficient to know with some certainty that 
immobilised LOx can and will reduce lactate levels in physiologically 
relevant conditions, i.e. at 37⁰C and in the presence of plasma components, 
thus permitting this method of immobilisation to be utilised within the BAL. 
In the BAL FBB, the LOx beads will be required to function in 10% FFP 
medium rather than the 100% FFP used in previously described 
experiments, which have served as an extreme test of whether plasma 
constituents ameliorate LOx activity; that the immobilised LOx beads have 
reduced lactate concentrations in the presence of so much plasma provides 
an indication that they will continue to function in BAL relevant conditions.  
However, as it was observed that immobilised LOx beads were more active 
in 100% FFP than in buffer, it could follow that their activity may not be as  
high in media containing just 10% FFP. Therefore, the activity of LOx 
beads in either 100% FFP or 10% FFP culture medium was investigated.  
Furthermore, as lactate production in the FBB will be a continuous, not an 
initial event, the media received a second lactate spike in a preliminary step 
to address this issue. 
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Figure 3-19 – Lactate clearance by immobilised LOx in 10% FFP. 
Immobilised LOx beads incubated for 24 hours in either 10% or 100% FFP, spiked 
at T=0 and T=2 hours with 15 mM lactate. Samples were taken hourly for the first 
7 hours, and then a final sample after 24 hours. Control = Glass beads without 
LOx, incubated at 37⁰C in 10% FFP culture medium. Lactate concentration 
determined by ANALOX analysis. n=3. 
 
Following incubation at 37⁰C for 24 hours in lactate spiked conditions, LOx 
beads were observed to clear lactate at comparable rates in 100% and 10% 
FFP (Figure 3-19). It can be concluded therefore, that this immobilisation 
strategy is, in principle, compatible for use within both the FBB and the 
BAL device. It is to be remembered, however, that the encapsulated HepG2 
cells are cultured for a total of 11 days; if immobilised LOx is to be 
successfully utilised in this context it must be determined whether it can 
continue to function for a period of time in excess of the 24 hours here 
tested. If plasma components, such as proteases, are responsible for the drop 
in activity of immobilised LOx, a method of protecting the enzyme from 
degradation should be explored. For this reason, an alternative 
immobilisation support was investigated. 
 
3.3.2.3. Effect of the glass support on LOx activity 
The activity of an immobilised enzyme relies upon a plethora of factors, 
significantly the physical and chemical profile of the matrix utilised as a 
support for immobilisation. By carefully selecting the support, the success 
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of the immobilisation, in terms of enzyme loading efficiency, activity of the 
immobilised enzyme and enzyme stability, can often be greatly increased. 
Previous experiments addressed immobilisation of LOx onto glass beads 
with a mean diameter of 750 µm. It was hypothesised that by maintaining 
the same quantity of enzyme and mass of beads as previously, but using a 
larger, porous bead, a greater total surface area would be available for 
enzyme attachment. Furthermore, immobilising LOx within pores could 
potentially provide some protection from proteolysis, by physically 
shielding the enzyme or even excluding proteases from the pore. Moreover, 
another advantage of using a porous support could be seen if previous rates 
of lactate clearance were limited by the availability of binding sites (an 
explanation for why so much LOx remained in the post immobilisation 
supernatant). Increasing the surface area of the support by the inclusion of 
pores could allow a greater proportion of LOx to bind and thus result in a 
greater binding efficiency between enzyme and the support. Additionally, a 
larger bead would be easier to both manipulate during preparation and also 
recover from the FBB environment. 
Two bead sizes were compared; the 750 µm diameter glass beads and a 
larger, porous glass bead with an average diameter of 4 mm. Both beads 
were prepared as previously described in section 3.2.3. The LOx incubation 
volume was increased to 200 µl to ensure that all beads were fully 
submerged. After incubation for 16 hours, the supernatants were aspirated 
and retained for analysis of LOx activity. Beads were rinsed as previously 
described, before being applied to 2 ml 10% FFP culture medium, spiked to 
give a concentration of 15 mM lactate, and incubated at 37⁰C for 24 hours. 
Samples were taken at 0, 2 and 24 hours, snap frozen and stored at -80⁰C 
until analysed by ANALOX.  
Analysis of the post immobilisation supernatants revealed that LOx enzyme 
remained to some extent in the supernatants of all immobilisation conditions 
(Figure 3-20). There was, however, far less lactate cleared by the post-
immobilisation supernatant used on the 4 mm glass bead, indicating that 
little LOx remained in this solution and hence more LOx had been bound to 
the beads. ANALOX readings of the samples taken throughout the 24 hour 
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time course (Figure 3-21) revealed that 4 mm glass beads had lactate 
clearing capabilities only fractionally greater than the negative control 
condition. Only LOx immobilised onto 750 µm glass beads brought about a 
reduction in the lactate concentration. 
 
Figure 3-20 – Activity of post-immobilisation supernatant. 
Graph depicts activity of the post-immobilisation supernatant (the unbound LOx 
remaining, in the immobilisation solution) for each LOx immobilisation treatment. 
“Free LOx” is un-tethered LOx in the immobilisation buffer. Results show mean 
* = significant difference by T-Test (p=0.0016) +/- SD, n=3. 
 
 
Figure 3-21 – Lactate Clearance by LOx immobilised onto glass beads. 
Readings taken at initially, at two and 24 hours after incubation of beads-only or 
immobilised LOx beads with lactate spiked 10% FFP culture medium at 37⁰C. 
Lactate concentrations determined by ANALOX analysis. n=3. 
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Poor recovery of enzyme in the post immobilisation supernatant would 
imply that the majority of the enzyme had bound to the support surface. 
However, this was not quite the phenomenon observed when LOx was 
conjugated to the larger glass beads; although less enzyme remained in the 
post-immobilisation supernatant, the LOx beads showed negligible activity. 
One interpretation of this could be that the enzyme was inaccessible to 
lactate when tethered within the pores, explaining why little LOx was in the 
post immobilisation supernatant and yet subsequent activity was so low. It is 
conceivable also that the enzymatic activity of LOx immobilised onto 4 mm 
beads was compromised by the presence of cross linking molecules, 
essentially trapping LOx within the bead pores, or, by binding so much 
enzyme that each molecule was too densely packed to undergo the 
conformational changes necessary to participate in the formation of a 
successful enzyme-substrate complex. 
In light of these results, subsequent LOx immobilisations were performed 
using the original smaller glass bead as a support. 
 
3.3.2.4. LOx activity in FBB relevant models 
In order to establish the suitability of immobilised LOx beads for use within 
the FBB it is critical to answer the two previously posed questions; namely, 
can immobilised LOx beads continue to function in conditions reminiscent 
of the FBB (presence of plasma, at 37⁰C and for a period of up to 11 days), 
and whether the catalytic activity of the immobilised enzyme decreases over 
time. Spiking the reaction media at multiple time points with lactate and 
then assessing the activity of immobilised LOx would serve to investigate 
the latter point, whilst the first point will also be studied if physiologically 
relevant conditions are implemented. 
Previous experiments demonstrated that immobilised LOx can reduce 
lactate levels from 10% FFP culture medium spiked initially and after two 
hours with lactate. As ELS will be producing lactate throughout their 
culture, rather than just at one time point, it was necessary to establish 
whether the immobilised LOx beads are capable of removing lactate from 
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an environment where the levels of lactate will be constantly replenished. 
For the 24 hour experiment, 20 µl of the 2 ml 10% FFP solution was 
replaced with 1 M lactate solution and again after two, four and six hours 
(the negative control received an extra spike after two hours only, in order 
to remain within the LoD of the lactate detection method (Analox)). 
Samples (20 µl) were taken hourly for seven hours and again after 24 hours. 
 
Figure 3-22 – Lactate clearance by immobilised LOx in 10% FFP culture medium 
at 37⁰C. 
Media was spiked with 10mM lactate solution; at 0 and 2 hours for the negative 
control and at 0, 2, 4 and 6 hours for the condition with immobilised LOx. 
 
A reduction in lactate concentration was observed in the presence of 
immobilised LOx beads, as shown in Figure 3-22. Over a period of 24 hours 
the sample containing LOx beads had a lactate concentration of just over 
17 mM despite having received a total of four 10 mM lactate solution doses.  
In contrast, the negative control sample, spiked twice with 10 mM lactate 
but not treated with LOx, showed no reduction in lactate concentration. The 
rationale behind the difference in lactate spiking regimes for these two 
conditions was that in the absence of LOx activity the lactate concentration 
would otherwise rise to levels exceeding the limit of detection for the 
analysis method (ANALOX) employed. 
To further investigate the activity of immobilised LOx in the presence of 
10% FFP, the rate of lactate clearance inbetween each hourly sample for the 
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24 hour experimental period was examined (Figure 3-23). This revealed that 
lactate clearance (mM/hour) dropped sharply in the first five hours of 
incubation from 1.8 to 0.4 mM/hour. The average rate after five hours 
appeared to stabilise at approximately 0.4 mM/hour. The data could support 
a hypothesis that the reduced rate of lactate clearance could be a 
consequence of the effects of substrate depletion. A relatively rapid initial 
rate of lactate clearance would have removed a substantial proportion of 
lactate from the reaction volume, thus decreasing the lactate concentration 
and therefore reducing the probability that an immobilised enzyme (which 
by its very nature will itself have reduced mobility) will encounter a 
substrate molecule. However, if the process of immobilisation does have a 
negative effect on the probability of an interaction between substrate and the 
active site, providing that this does not have an effect upon the total 
proportion of lactate removed in the conditions found in the FBB, then a 
compromised rate of reaction can be tolerated. Additionally, the data could 
suggest that the immobilised LOx had become less effective, for example as 
a consequence of inactivation accredited to prolonged exposure to a higher 
temperature. 
 
Figure 3-23 – Rate of lactate removal by immobilised LOx. 
Study conducted in 10% FFP culture media spiked four times to 10 mM (final 
reaction volume concentration) lactate, incubated at 37⁰C with rotational mixing. 
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3.3.2.5. Activity of immobilised LOx; time-course study 
To investigate the functional lifespan of immobilised LOx, a similar 
experiment was prepared in 10% FFP media buffered with HEPES to pH7.4 
and at 37°C, but conducted for a total of 11 days. The lactate spikes 
administered were calculated to represent the concentrations of lactate 
produced by encapsulated HepG2 cells within the FBB on a typical day-to-
day basis (see section 3.2.31). Samples of 20 µl were taken every 24 hours 
when possible. 
 
Figure 3-24 – Lactate clearance by immobilised LOx over a period of 11 days. 
Lactate spikes were administered to 10% FFP culture medium, maintained at 37⁰C 
for eleven days to mimic daily lactate production in a typical FBB experiment. 
Mean data values plotted, n=3. 
 
As shown in Figure 3-24, whereas overall lactate concentrations in both the 
negative control and LOx bead samples rose throughout the experimental 
time course, samples taken from media with LOx beads were consistently 
lower in lactate concentration, with a 50% decrease in lactate concentration 
compared to the negative control by day 11.  
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3.3.3. PVDF membrane immobilisation 
Samples were prepared as described in section 3.2.4 and applied to a lactate 
containing phosphate buffer solution. Regardless of treatment time, the 
activity levels of LOx supposedly bound to PVDF membrane were 
miniscule, to the extent that the values fell below the reliable scope of the 
instrument used. Therefore, this method was no longer investigated as a 
potential means of immobilising LOx for use within the FBB. 
 
3.3.4. Dialysis tubing for enzyme containment 
Preparation of apparatus and LOx was conducted as described in section 
3.2.5. LOx was re-suspended to 0.1 mg/ml in 10 mM phosphate buffer and 
placed within a cassette-like chamber, such that the enzyme was physically 
contained by a selectively permeable membrane, through which the lactate 
solution could pass. The cassettes were directly applied to the LOx activity 
assay in wells of a 96-well plate. The apparent lower activity rate of LOx 
contained within the cassette (Figure 3-25) is likely the result of altered 
rates of reaction owing to substrate/product diffusion rate limitations. 
Allowing the reaction to continue for a greater time period could potentially 
see a greater extent of lactate clearance by this immobilisation method; 
however, the FBB requires a mode of lactate removal that is both effective 
and sufficiently rapid to remove lactate from the system as it is produced, 
before the growth and proliferation rates of cultured HepG2 cells can be 
compromised. Any strategy, including the one described here, which does 
not meet such criteria would simply be impractical. Additionally, the scaling 
up of this approach would be particularly challenging, as incorporating a 
sufficiently large section of dialysis tubing into the FBB to remove lactate 
would restrict the space available in the FBB for cell culture. 
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Figure 3-25 – Lactate clearance by LOx contained within dialysis membrane. 
“Free” LOx = LOx enzyme re-suspended but not contained within a dialysis 
membrane cassette. A cassette, or free LOx, was applied to the LOx activity assay. 
n=6, +/- SD. 
 
3.4.  Summary 
3.4.1. Immobead experiments 
It is generally accepted that immobilisation tends to confer stability to an 
enzyme, and so it was surprising that over the 24 hour experimental period 
the immobilised LOx lost activity but the unbound enzyme did not. An 
explanation for this could be that unquenched glutaraldehyde residues were 
continuing to react with lysine groups on the enzyme, leading to over-
binding and thus compromising the ability of LOx to interact with lactate. 
However, an assay was conducted with the addition of NaBH3CN to quench 
un-reacted glutaraldehyde chains, which lead to a decrease rather than an 
increase in immobilised LOx activity, indicating that another factor is 
responsible for this phenomenon. An alternative theory could simply be that 
physically tethering LOx to the Immobead surface modifies in some way the 
tertiary structure of the enzyme leading to a decrease in stability. A third 
possibility is that the drop in activity was an artefact of low level activity, 
itself the result of an inaccurate method of bead administration. However, 
there remains the issue that Immobeads retain the dye which is the indicator 
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of activity in the assay – therefore it is highly likely that the activity levels 
have been underestimated, although by what extent remains to be deduced. 
Nevertheless, having regarded the lactate clearing ability of LOx 
immobilised onto glass beads (Figure 3-7), the Immobead method was no 
longer perused; not only are the glass beads more effective at lactate 
removal, but also their larger size makes them easier to manipulate and 
contain within a designated area of the FBB, and therefore less likely to 
cause a blockage in the FBB circuit. 
 
3.4.2. NH2 functionalised glass beads immobilisation 
Following two cycles of freeze/thaw, activity of LOx immobilised onto 
functionalised glass beads had dropped by an average of 65%, and almost 
90% for the no-cross linker condition. This suggests that although not 
absolutely necessary for LOx immobilisation, a cross linker is required to 
confer greater storage stability to the immobilised enzyme 
It was hypothesised that perhaps part of the functionalisation process is 
making the glass beads susceptible to protein binding, thus accounting for 
levels of LOx activity in the absence of a cross linker molecule. To address 
this point, LOx was added to conditions representing a permutation of the 
functionalisation steps. The data indicated that it is the addition of 
3-aminopropyltriethoxysilane, the “NH2 functionalisation” step, which leads 
to non-covalent binding. Although this could be further investigated to 
identify a protocol to minimise these effects, a small proportion of LOx 
binding directly to the support is not of major concern, providing that LOx 
and only LOx is binding in a stable fashion, that the majority of LOx is 
bound correctly and is active, and that the process doesn’t lead to a loss of 
newly synthesised proteins from the BAL when it is used in the patient 
treatment phase. This is highly unlikely since the concentration of plasma 
protein is so high, but this will be investigated in a following chapter  
(Chapter 6). 
Following an increase in the amount of LOx used for immobilisation, the 
activity seen for 0.01 mg LOx was comparable to previous experiments, but 
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a ten-fold increase in LOx concentration saw roughly a 50% loss in 
subsequent glass bead activity. The reason for this is unclear; it could be 
that all potential binding sites on the beads are taken, resulting in 
overcrowding and thus causing a degree of steric hindrance and so 
preventing optimal enzyme function. 
On the theme of enzyme loading and whether there is a maximum amount 
of protein which can be cross-linked to the glass bead, the data suggests that 
the LOx solution can be reused from a previous immobilisation to yield 
beads with an activity level not dissimilar to those produced by the previous 
immobilisation. This again suggests that not all the LOx present in the 
solution is binding to the beads, despite a decrease in total protein used 
leading to a lower final activity level. This could perhaps imply that it is the 
bead itself rather than LOx which is the limiting factor in the amount of 
active LOx which can be immobilised. To test this theory it would be 
beneficial to further investigate the effects the flame treatment in particular 
is having on bead structure. Visualisation of the bead surface before and 
after treatment would be one possible approach, possibly using 
environmental scanning electron microscopy technology. Importantly, 
however, the immobilisation method was shown to be reproducible, with 
separate batches of immobilised LOx having very similar activity levels. 
 
The data from the lactate clearance experiments demonstrate that 100 mg of 
immobilised LOx beads are sufficient to lower lactate concentration within 
a 2 ml volume of 10% FFP media by 50% over a period of 11 days when 
incubated at 37°C under constant rotation of the beads, as would be the case 
in the FBB. Although encouraging, there is the issue that by day 8 the 
lactate clearing activity of immobilised LOx was becoming compromised. 
Identifying the cause for this would be beneficial for optimising the 
treatment protocol; for example, if the decreased clearance rates are due to 
enzyme denaturation then immobilisation methods which may confer a 
greater degree of thermal protection could be investigated. Nevertheless, the 
data suggests that this is a promising method for addressing the issue of 
lactate clearance in the FBB. The scaled-down model of lactate production 
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in 10% FFP culture media indicates that with the addition of LOx 
immobilised onto glass beads, lactate concentrations can be reduced to 
around 6-8 mM, levels which are below the 15 mM danger level for 
encapsulated HepG2 integrity, growth and function. Moreover, eight days of 
activity may well be sufficient since there is relatively little lactate present 
during the first few days of HepG2 cell culture; it is as cell number rises 
with increased culture time that lactate accumulation becomes a greater 
concern. 
 
3.4.3. PVDF membrane immobilisation 
The results obtained using PVDF membrane as a scaffold for LOx 
immobilisation were disappointing, rendering further investigation into this 
technique as somewhat superfluous. Further analytical work would be 
required to establish why this method was so ineffective; initial explanations 
include (1) the possibility that LOx was binding primarily to the plastic 
container used as an incubation vessel rather than to the PVDF membrane, 
and (2) the maximum amount of protein which could be bound to the 
section of membrane had already done so, but that this was too low an 
amount to be detectable or indeed of use. 
 
3.4.4. Dialysis tubing for enzyme containment 
Despite low conversation of lactate, the use of a cassette incorporating a 
section of dialysis tubing could still be a potential approach for use within 
the FBB. Although higher activity levels for immobilised LOx were 
obtained using other methods, it still remains to be seen whether this 
strategy could remove a sufficient quantity of lactate given more time for 
diffusion. If that is the case, there could be a number of potential advantages 
to using this method over other support-based methods of harnessing LOx 
activity. For example, as there is no immobilisation required, there is no risk 
of altering the tertiary structure of the enzyme which may lead to 
compromised catalytic activity. Also on this theme, without the burden of a 
physical link between enzyme and the support matrix, there is less scope for 
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steric hindrance effects in terms of substrate access to the enzyme’s active 
site. However, this method would also forfeit the advantages often 
associated with immobilisation of an enzyme, the thermostability being of 
particular concern in the context of the FBB. 
 
3.5.  Conclusion 
During the culture of encapsulated HepG2 cells for use within a BAL device 
lactate can accumulate to concentrations which, if left unchecked, are 
detrimental to the growth, function and proliferation of the ELS. It has been 
demonstrated that LOx retains catalytic function, converting lactate to 
pyruvate when immobilised onto the surface of modified glass beads, as 
observed in the depletion of lactate spiked 10% FFP culture media. Thus the 
hypothesis has been proven that LOx can be immobilised onto a solid 
support and used to significantly reduce lactate concentrations to levels 
which are no longer detrimental to ELS cell growth, function or structural 
integrity of the alginate bead. The further characterisation of the 
immobilised LOx will be discussed in Chapter 5, where the kinetics of both 
the free and immobilised enzyme will be investigated. 
 
Having demonstrated that LOx can be immobilised to reduce lactate 
concentrations, the next research aim is to apply an appropriate 
immobilisation technique to harness enzymatic activity to degrade 
circulating DNA from the Bio-Artificial liver assist device. In the following 
chapter, the degradation of DNA using enzyme immobilisation technology 
will be addressed. 
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Chapter 4. DNA Removal 
 
 
Methods of immobilising Deoxyribonuclease I are explored, including the 
effect of cross linker and support on the extent of enzymatic degradation of 
HepG2 DNA.  
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4.  DNA Removal 
4.1.  Introduction 
The Liver Group BAL is based on the premise that alginate encapsulated 
HepG2 cells will take on a surrogate role of performing the metabolic, 
detoxifying and synthetic functions of the liver, until the patient’s own liver 
has recovered or until transplantation becomes possible. However, there is a 
potential risk of tumorgenesis and initiation of an immune response 
associated with the use of HepG2 cells, should HepG2 DNA be released 
from the cells and enter the patient’s circulation. This chapter concerns the 
elimination of this potential risk to patient safety by utilising enzyme 
technology to degrade circulating DNA fragments. 
 
4.1.1. DNA removal in the Liver Group BAL 
There are currently intended to be two approaches utilised for the removal 
of extraneous DNA; physical removal of DNA by filtration, and removal by 
enzymatic degradation. Together, these methods will allow compliance with 
FDA guidelines for DNA levels arising from extracorporeal support 
devices. These currently stand at 10-100 ng of DNA of host cell origin per 
parenteraly administered dose for vaccine based therapies. The worst case 
scenario in the BAL, whereby cell death and DNA release occurs in all of 
the 7x10
10
 cells (which represent 30% of the adult male liver mass and thus 
the critical cell number required for treatment), would result in 66 µg/ml 
HepG2 DNA in the 7L BAL volume. (Calculations based on there being 
6.64 x 10
-12
 g DNA in a diploid cell (134)). The amount of DNA released 
from encapsulated HepG2 cell spheroids in a typical scaled-down model of 
the BAL has been shown to be 68 ng/ml in 100% FFP over the course of 
eight hours (group data). Physical filtration has been shown to remove DNA 
to acceptable levels; therefore, the inclusion of immobilised DNase I will 
serve as a “fail-safe” mechanism for the BAL device. This thesis is 
concerned with the enzymatic branch of DNA removal and so no further 
reference will be made to the filtration approach. 
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4.1.2. Deoxyribonuclease I 
The mammalian phosphodiesterase Deoxyribonuclease I (DNase I), found 
mostly in the pancreas, is a glycoprotein with a molecular weight ranging 
from 31-35 kDa, depending on the tissue/species of origin and also the 
extent of glycosylation (135). It contains two disulfide bridges (136) one of 
which, between C173-C209 is essential for maintaining the structure and 
hence activity of DNase I (137). Adjacent to this is one of two calcium 
binding sites, which, when occupied, have been demonstrated to increase 
the stability of DNase I (a higher temperature is then required to denature 
the enzyme) and also protect against denaturation by entities such as urea 
(137;138). Within the active site of DNase I there are two further divalent 
ion binding sites to which Mg
2+
 binds in the presence of DNA (139). 
The enzyme hydrolyses and degrades DNA by endonucleolytically cleaving 
double or single stranded DNA depending on the divalent metal ion used 
(140;141). This occurs via a nucleophilic attack mechanism (142) 
preferentially at phosphodiester linkages adjacent to pyramidine nucleotides 
to generate 3’OH and 5’P oligonucleotides (Figure 4-1) comprising at least 
two nucleotides (142;143). 
 
         
      
 
                               
Figure 4-1 – Equation depicting the role of DNase I in DNA degradation. 
 
It has been reported that the carboxylate groups H134-E78 and H252-D212 
are crucial for binding to the minor groove of DNA molecules (144;145). 
Interestingly, although the DNA molecule undergoes a conformational 
change following DNase I binding, the enzyme maintains an almost 
unchanged configuration (145). The pH optimum for DNase I activity is 
between 7 and 8.2 (135;146). 
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DNase I also has a very high affinity for G-actin (147), and when so bound 
the nuclease activity of DNase I is inhibited (148;149). Glu13 of DNase I is 
involved in the binding of both DNA and actin which is possible due to the 
binding site of actin being very close to the active site (150). It is therefore 
postulated that actin inhibits DNase I activity by a mode of steric hindrance, 
physically blocking the accessibility of the active site to the DNA substrate. 
A further role for divalent cations has been proposed, as there is data to 
suggest that Mg
2+
 concentration can influence the equilibrium point of the 
ratio of F-actin and the inhibitory G-actin; with decreasing Mg
2+
 more 
G-actin is present and a greater extent of DNase I inhibition is observed 
(142). However, divalent cations can also be detrimental to DNase I 
activity, as the enzyme is inhibited by Zn
2+
 (146). 
 
There have been particular difficulties when engineering a support for the 
immobilisation of DNase I owing to the large size of DNA molecules (151); 
the support must permit efficient mass transfer of the substrate whilst also 
ensuring sufficient contact between the enzyme and the support structure. 
 
4.1.3. Existing methods of DNase I immobilisation 
4.1.3.1. Nylon microspheres 
Early studies into the use of DNase I for the removal of circulating DNA in 
systemic lupus erythematosus (SLE) patients (151) utilised activated nylon 
microspheres with an approximate diameter of 1.1 mm as a support for 
DNase I immobilisation. The beads were chosen owing to their low patient 
toxicity, the large surface area available for binding enzyme, structural 
stability and importantly, because they exhibited minimal thrombogenicity, 
thus lowering the likelihood of reducing circulating platelet concentrations. 
The microspheres were gently hydrolysed with 3 M HCl at 30°C for 
607minutes at a flow rate of 30 ml/min before undergoing treatment with 
4% glutaraldehyde for 15 minutes to activate the surface for enzyme 
attachment (enzyme retention on microspheres was calculated to be between 
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26.8-31.5%). DNase I was immobilised by immersing the beads in a buffer 
solution containing MgCl2 and 15 mg enzyme for 60 minutes. Following 
introduction to an extracorporeal circulation system in dogs, immobilised 
DNase I was shown to accelerate the degradation of circulating DNA in 
vitro and in vivo whilst no detectable release of enzyme into the host was 
observed. The microsphere immobilised DNase I was housed in a chamber 
where the flow rate of plasma was 200 ml/min. Although this method 
demonstrates great potential for the use within the BAL, there is the caveat 
that the nylon microspheres would be very difficult to make or produce in 
sterile conditions which is a critical practicality for the BAL application. 
 
4.1.3.2. Magnetic hydrophilic polymer particles 
Rittich et al. (152) successfully immobilised DNase I onto magnetic poly 
(HEMA-co-EDMA) microspheres, which had a diameter of 1.2 µm and 
were synthesised in the presence of magnetite powder (ferrous-ferric oxide 
Fe3O4). The advantages of these microspheres included bio-compatibility, 
low non-specific protein adsorption and furthermore, the magnetic property 
allowed for easy removal/isolation of the immobilised enzyme from the 
reaction solution. The immobilisation process was carried out for four hours 
at room temperature before lyophilising the microspheres, to yield an 
average of 13.9 mg enzyme per gram of carrier. Interestingly, activity 
analysis of immobilised enzyme microspheres showed that the degree of 
activity is dependent upon the identity of the divalent cation used to activate 
DNase I; these were, as a percentage of original, native enzyme activity 
3.4% (Ca
2+
), 20.5% (Mg
2+
), 72.2% (Mn
2+
) and 91.2% (Co
2+
), when used at 
concentrations of 10 mM. However, it would not be possible to provide 
these ions at the required concentration in vivo should this immobilisation 
protocol be utilised within the BAL. 
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4.1.3.3. Epoxy groups of methacrylate monoliths 
Epoxy groups inherently present on macroporous poly (glycidyl 
methacrylate-co-ethylene dimethacrylate) (GMA-EDMA) monolith 
columns were used by Bencina et al. (140) to immobilise DNase I for use in 
a bioreactor. These groups form covalent bonds with either amines, 
sulphydryl groups or hydroxyl groups on the amino acids of DNase I. This 
immobilisation support system benefits from a large porosity and high 
mechanical and chemical stability, making it well suited to supporting 
reactions where high molecular mass analytes (i.e. DNA) are present. The 
system was observed to function well at flow rates of both 0.6 ml/min and 
9-ml/min. However, it is to be noted that flow rates within the BAL system 
are typically in great excess of these tested values, up to 600 ml/min. 
DNase I was immobilised by either a static method where the column was 
immersed in enzyme solution, or by a dynamic method where the enzyme 
solution was drawn through the column at 15 minute increments for a total 
duration of two hours. It was concluded that greater enzyme activity could 
be gained by increasing the duration of the immobilisation procedure and, 
furthermore, that the speed of immobilisation can be increased by using a 
dynamic rather than a static method. In terms of physical conditions, the 
results suggested that pH7 and 22°C were optimal, likely due to a better 
stability of DNase I. 
 
Despite there having been degrees of success with the above mentioned 
methods of DNase I immobilisation, the conditions under which the 
immobilisations and enzyme performance assays were conducted are not 
suitable for use within the BAL. For this reason, alternative methods had to 
be developed. 
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4.2.  Materials & Methods 
4.2.1. Preparation of Dynabeads® 
The high affinity DNA has for binding to glass prompted the use of an 
alternative immobilisation support matrix. Hydrophilic Dynabeads® 
M-270 Amine beads (average diameter of 2.8 µm) were chosen for their 
magnetic property, which would facilitate the removal of the beads from the 
BAL as well as allowing greater control over the localisation and 
containment of the beads within the operational BAL. Furthermore, these 
beads have a low risk of initiating an immunological response, and they 
could be manufactured in sterile conditions, further minimising the potential 
risk to the patient. The exposed amine binding site on the beads allowed for 
simple covalent cross-linking of DNase I onto the beads. 
 
Materials: 
Hydrophilic Dynabeads® M-270 Amine beads (Invitrogen, 14307D) 
DNase I (0.2 mg/ml aliquot, as described in section 2.13) 
0.2 ml polypropylene microcentrifuge tube 
Magnetic microcentrifuge rack (Dynabeads®) 
Super-fine flat ended gel loading pipette tips (StaLabs, I 1022-2600) 
 
HEPES Buffer (pH7.4): 
10 mM HEPES (pH 7-7.6, Sigma, HO887) 
1 mM CaCl2 
1 mM MgCl2  
 
The basic preparation method was modified slightly from the 
manufacturers’ published protocol in order to minimise the total quantity of 
enzyme used by scaling down the process, and was as follows: Stock 
suspension of Dynabeads® was vortexed thoroughly for two minutes to 
ensure as near as homogenous suspension as possible, before transferring 
7.7 µl of the bead suspension to a 200 µl microcentrifuge tube. Each tube 
was placed within a magnetic rack and left for four minutes to allow the 
beads to precipitate out of the solution. The liquid phase was carefully 
aspirated using super-fine flat ended gel loading pipettes and the tubes then 
removed from the rack and washed by resuspending in 7.7 µl 10 mM 
HEPES buffer. The tubes were once again applied to the magnet for four 
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minutes to precipitate the beads; this process was repeated twice. The final 
wash solution was aspirated and replaced with 10 µl of 0.2 mg/ml DNase I 
solution (total 2 µg DNase I protein) and the beads incubated at room 
temperature for 24 hours. 
 
4.2.2. Immobilisation of DNase I onto glass beads 
Materials: 
100 mg glass beads (750-1000 µm diameter, (Kisker-Biotech, PGB-075) 
Methanol 
Isopropyl alcohol 
Sonicator 
1,3-benzenedisulfonyl chloride (97%, Aldrich, 444642) 
Toluene, anhydrous (99.8%, Sigma-Aldrich 244511) 
N,N-dimethylacetamide (DMAd) (≥99.5%, Sigma-Aldrich, 38840) 
10 mM phosphate buffer 
Ethanol 
3- aminopropyltriethoxysilane (≥98%, Sigma A3648) 
Ceramic mortar 
Plate shaker 
Miniature blow torch 
 
HEPES Buffer (pH7.4): 
10 mM HEPES (pH 7-7.6, Sigma, HO887) 
1 mM CaCl2 
1 mM MgCl2  
0.2 mg/ml DNase I 
 
The method for immobilising DNase I onto glass beads was modified from 
the methodology described in section 3.2.3 to covalently bind LOx onto 
glass beads; all steps were as described for LOx immobilisation up to the 
addition of a cross-linker molecule. For the cross linking stages in this 
method, the beads were treated with 100 mg benzene 1,3 disulfonyl chloride 
dissolved in 10 ml DMAd at room temperature for 15 minutes. They were 
washed twice with 10 ml ethanol and then rinsed in 10 ml 10 mM HEPES 
(pH7.4) or 50 mM TrisHCl (pH7.4) before applying 100 µl of 0.02 mg/ml 
DNase I (made with 10 mM HEPES or 50 mM TrisHCl and a 10 µl aliquot 
of 0.2 mg/ml DNase I) and incubated at room temperature for 24 hours. This 
was based on published literature which demonstrated a longer incubation 
time at ambient temperature is optimal for DNase immobilisation (140). The 
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cross-linked enzyme beads were rinsed three times in 500 µl 10 mM HEPES 
pH7.4 or 50 mM TrisHCl (pH7.4) buffer before use in subsequent 
applications. 
 
4.2.3. Western blot analysis of samples 
Materials: 
Blocking buffer: 
5% non –fat dehydrated milk powder 
1 x PBS (without Ca
2+
 or Mg
2+
) 
10% Tween 20 
 
5 x sample buffer (20 ml): 
4 ml 1.5 M TrisHCl (pH6.8) 
10 ml glycerol 
5 ml β-mercaptoethanol 
2 g sodium dodecyl sulphate (SDS) 
1 ml 1% bromophenol blue 
iBlot® Gel Transfer Device (Invitrogen) 
Nitrocellulose iBlot® transfer stack (Invitrogen) 
 
1/20 000 Anti-rabbit HRP 
1/7000 Anti-DNase I (rabbit monoclonal antibody) 
Criterion® pre-cast gradient (4-12%) gel (BioRad) 
Full-range Rainbow molecular weight marker (GE Healthcare Life 
Sciences, RPN800E) 
ECL detection kit (Milipore) 
 
For the protein gel, 5 µl 5 x sample buffer was added to 20 µl of the sample 
and heated at 90⁰C for 10 minutes to denature protein (i.e. DNase I) which 
would otherwise prevent the process of protein separation by 
electrophoresis. Once cooled, 20 µl of this was applied to each well of a 
gradient gel, loading Full Range Rainbow Marker as a reference for 
molecular weight. Running buffer was added to the reservoir and the gel run 
at 250 volts for 45 minutes. The gel was removed and applied to the iBlot® 
transfer device as per the manufacturer’s guidelines and transferred for four 
minutes. The membrane was blocked overnight at 4⁰C in blocking buffer to 
minimise non-specific antibody binding. Anti-DNase I antibody, diluted 
1/7000 in blocking buffer, was applied to the membrane and incubated with 
gentle agitation at room temperature for one hour. The membrane was 
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washed four times for five minutes in 1 x PBS (with 0.1% Tween 20) before 
applying anti-rabbit antibody diluted 1/20 000 in blocking buffer. This was 
incubated with gentle agitation as before at room temperature for one hour. 
The membrane was rinsed four times in 1 x PBS (with 0.1% Tween 20) 
before adding equal volumes of the chemiluminescent reagents as per the 
manufacturer’s guidelines for five minutes. Blots were developed using 
x-ray film for an appropriate exposure time. 
 
4.2.4. Removal of DNA: a time-course study 
Materials: 
100 mg DNase I beads 
HepG2 DNA solution (0.85 mg/ml) 
Rotating sample mixer 
Liquid nitrogen 
HEPES Buffer (pH7.4): 
10 mM HEPES (pH7-7.6, Sigma, HO887) 
1 mM CaCl2 
1 mM MgCl2  
 
An initial spike of 20 µl 40 ng/ml HepG2 DNA in 1 ml 10 mM HEPES 
buffer solution was added to 100 mg DNase I conjugated glass beads and 
the tubes incubated at 37⁰C on a rotational mixer for a total period of 24 
hours. Samples of 20 µl were taken initially and hourly for the first four 
hours and then after 24 hours. Additional samples were taken immediately 
after a second spike administration (dosage as before) two hours into the 
experiment. Samples were snap frozen in liquid nitrogen prior to analysis. 
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4.2.5. NHS PEG cross-linking of DNase I 
Materials: 
100 mg O,O’-Bis[2-(N-Succinimidyl-succinylamino)ethyl] polyethylene 
glycol (Mr ≈ 2 000, Aldrich, 713783-500MG) 
DMSO (anhydrous ≥99.9%, Sigma-Aldrich, 76855)  
PBS 
 
100 mg functionalised glass beads (section 3.2.3) 
 
HEPES buffer (pH7.4): 
10 mM HEPES (pH7-7.6, Sigma, HO887) 
1 mM CaCl2 
1 mM MgCl2  
 
100 mg functionalised glass beads were prepared as described in section 
3.2.3 up to and including the air drying of the beads following treatment 
with 3- aminopropyltriethoxysilane in dry toluene. After this, each batch of 
beads was treated with 1 ml of a solution comprising 100 mg O,O’-Bis[2-
(N-Succinimidyl-succinylamino)ethyl] polyethylene glycol (NHS PEG) 
dissolved in 6 ml DMSO, and incubated for 15 minutes. The supernatant 
was aspirated and the beads rinsed twice in 1 ml DMSO, twice in 2 ml PBS 
and finally with 2 ml of 10 mM HEPES buffer (pH 7.4). DNase I was cross-
linked and all further steps performed as described in section 4.2.2 (100 µl 
of 0.02 mg/ml DNase I per 100 mg beads (made with 10 µl of 0.2 mg/ml 
DNase I in 90 µl 10 mM HEPES buffer). 
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4.3. Results 
4.3.1. Immobilised DNase I activity 
In order to establish the extent of DNase I activity the enzyme was 
incubated with plasmid DNA, which should be a simple substrate, being a 
smaller, circular molecule rather than the large complex molecule that is 
eukaryotic genomic DNA. However, the BAL application requires that 
genomic DNA be removed, which could likely be much longer in length 
than a simple bacterial plasmid. Calf thymus DNA was used as a 
preliminary measure to test the ability of DNase I to break down larger and 
more complex DNA molecules. 
Glass beads were prepared and DNase I immobilised as described in section 
4.2.2. Free enzyme activity on genomic DNA was compared with that of 
immobilised DNase I in a 50 µl TrisHCl (with 1 mM MgCl2 and 1 mM 
CaCl2 pH7.4) solution spiked with 5 µl genomic (10 mg/ml calf thymus, 
diluted in water to 170 ng/µl) or plasmid DNA (170 ng/µl pEGFP (3.4 kb)). 
Unconjugated glass beads were included for each DNA condition as a 
negative control. 
 
Figure 4-2– Activity of free / immobilised DNase I on plasmid or genomic DNA. 
Key: (1) Plasmid DNA + immobilised DNase I; (2) Genomic DNA + immobilised 
DNase I; (3) Genomic DNA + free DNase I; (4) Plasmid DNA + glass beads only; 
(5) Genomic DNA + glass beads only. Samples incubated at 37⁰C for 10 minutes in 
50 µl TrisHCl (with 1 mM MgCl2 and 1 mM CaCl2 pH7.4) prior to running on a 2% 
agarose ethidium bromide gel. Marker = HyperLadder III (Bioline). 
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Samples were incubated for 10 minutes at 37⁰C, after which the 
supernatants were removed and enzymatic activity inactivated by heating 
for 10 minutes at 75⁰C. Samples were run on an ethidium bromide stained 
2% agarose gel, as described in section 2.12. From this gel (Figure 4-2) it is 
apparent that free DNase I acts upon genomic DNA and that immobilisation 
of the enzyme does not completely inhibit this process. 
 
4.3.2. DNA degradation time for immobilised DNase I 
Samples of free and immobilised DNase I were prepared and incubated with 
10 µl calf thymus DNA (10 mg/ml) in a total reaction volume of 200 µl 
TrisHCl (with 1 mM MgCl2 and 1 mM CaCl2 pH7.5) at 37⁰C. Individual 
experiments were stopped in a time-wise fashion after 0 – 32 minutes, 
samples taken, heated at 75⁰C for 10 minutes to inactivate the enzyme in 
order to ensure a definitive end point to enzymatic activity, and run on a 2% 
agarose gel as described in section 2.12. 
 
Figure 4-3 – Time required for genomic (calf thymus) DNA degradation by free /  
immobilised DNase I. 
Samples incubated at 37⁰C for 0-32 minutes in 50 µl TrisHCl (with 1 mM MgCl2 
and 1 mM CaCl2 pH7.5) prior to separating on a 2% agarose ethidium bromide gel. 
Lanes 1 & 2 = molecular weight ladders. Lane 3 = Uncut genomic DNA. - = unused 
lane. “I” = Immobilised DNase I + genomic DNA; “F” = Free DNase I + genomic 
DNA. Subscript numbers denote enzyme and DNA incubation time, in minutes. 
400 bp _  
 
1      2       3     -      I2    F2     I4    F4    I8    F8    I16   F16   I32   F32 
100 bp ¯  
 
300 bp -  
 
200 bp ¯ 
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As predicted, free DNase I brought about a more rapid and more complete 
degradation of genomic DNA than did immobilised DNase I, with an 
apparent plateau of activity having been reached after four minutes of 
incubation with DNA. A similar trend was observed also with immobilised 
DNase I, although this occurred later, after approximately eight minutes 
incubation with DNA. 
Although useful for ascertaining whether or not DNA had been degraded 
and allowing a comparison between conditions to be made, the DNA gel  
method only permits a qualitative assessment of the data; in order to gain a 
greater insight into the activity of immobilised DNase I compared to the free 
enzyme a quantitative method of analysis was required. Therefore, analysis 
of DNA depletion following incubation with DNase I was performed using 
the PicoGreen assay. 
 
4.3.3. PicoGreen as a DNA detection method 
HepG2 DNA was incubated with glass beads in TrisHCl (with 1 mM MgCl2 
and 1 mM CaCl2 pH7.4) at 37⁰C for 15 minutes. Following this the 
supernatants were removed for further analysis. The PicoGreen assay was 
utilised to quantify the amount of DNA remaining following treatment with 
bead-conjugated or free DNase I. This data indicated that virtually no DNA 
was degraded in the presence of DNase I linked beads and furthermore, that 
the free enzyme showed little activity (Figure 4-4a). As previous 
experiments had demonstrated that the immobilisation procedure is effective 
(Figure 4-2, Figure 4-3), the supernatants following DNA incubation with 
free and immobilised DNase I were separated on a 2% agarose gel to 
investigate whether that particular immobilisation had been successful and 
importantly, whether HepG2 DNA is a suitable substrate for DNase I under 
experimental conditions. The presence of smeared bands in the DNA gel 
demonstrated that free DNase I removed more DNA than immobilised 
DNase I, but that both bands were comparable to those obtained when calf 
thymus DNA was used as the substrate (Figure 4-4b). An experiment to 
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determine the suitability of the PicoGreen assay as a means to quantifying 
enzymatic degradation of HepG2 DNA was thus conducted. 
 
 
4.3.3.1. Linearity of the PicoGreen assay 
By plotting the concentration of DNA applied against the concentration of 
DNA detected, a standard curve demonstrating the linearity of the 
PicoGreen assay was obtained (Figure 4-5). DNA levels below 
approximately 25 ng/ml were indistinguishable from each other and were no 
longer linear. Therefore, this method is not suitable for detecting low levels 
of DNA. As the detection of low levels of HepG2 DNA is a fundamental 
requirement of this investigation, the PicoGreen assay method was replaced 
by Q-PCR for the detection of genomic DNA. 
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Figure 4-4 – DNA degradation by DNase I. 
Remaining HepG2 DNA determined by a) PicoGreen (n=6, +/- SD) and b) 
Western blot analysis (Samples separated at 90 v on a 2% agarose gel). 
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Figure 4-5 DNA detection by PicoGreen assay method. 
DNA range from 0-80 ng/ml). Assay performed in TTE buffer. Mean values for 
each data point plotted. n=3. 
 
The previously described immobilisation of DNase I onto glass beads was 
repeated, being treated with HepG2 DNA before applying the supernatants 
to Q-PCR. This time, it was evident that the immobilisation had been 
successful in so far as HepG2 DNA concentration was reduced following 
incubation with the enzyme linked beads. Furthermore, the free enzyme was 
shown to exhibit DNA clearance activity closer to that expected (Figure 
4-6). 
 
Figure 4-6 - DNA clearance of DNase I immobilised onto glass beads, determined 
by Q-PCR. 
Activity of enzyme determined from the concentration of DNA remaining in 
solution following incubation for 15 minutes at 37⁰C in 50 mM TrisHCl buffer 
(pH7.4) with DNase I, immobilised DNase I or glass beads alone.+/- SD, n=6. 
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However, it was also apparent that a proportion of DNA was being removed 
from solution in the absence of DNase I, approximately 50% (Figure 4-6), 
strongly implying that DNA was binding to the support material and being 
removed from solution in this non-specific manner. For this reason, an 
alternative immobilisation support was sought. 
 
4.3.4. Dynabeads® as the immobilisation matrix 
Whereas a reduction in DNA concentration was observed in conditions 
treated with free DNase I, enzyme conjugated to Dynabeads® did not have 
any effect upon the DNA concentration, compared to the enzyme-free 
control condition (Figure 4-7). Therefore, although the DNase I enzyme was 
active, it was hypothesised that this activity was severely compromised 
during the immobilisation procedure. Dynabeads® utilise amine groups to 
bind to their target conjugate and it was hypothesised that the buffer 
medium, TrisHCl, may be having a detrimental effect upon this cross 
linking chemistry. Consequently, the buffer was exchanged for HEPES, 
which would also have the advantage in that it is routinely used to buffer 
carbon dioxide at a physiological pH, which would be of great benefit when 
undertaking studies in more physiologically relevant conditions (e.g. in the 
presence of plasma, for extended periods of time). 
Exchanging the buffer was observed to improve the activity of Dynabeads® 
tethered DNase I (Figure 4-8). This was to such an extent that a direct 
comparison between the DNA removal capacity of enzyme linked to 
Dynabeads® and the original glass beads was deemed appropriate. 
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Figure 4-7 – DNA removal by DNase I Dynabeads® in TrisHCl. 
DNA digestion conducted in the presence of 50 mM TrisHCl buffer (pH7.4) for 15 
minutes at 37°C. Analysis was by q-PCR. +/- SD, n=6  
 
 
Figure 4-8 – DNA removal by DNase I Dynabeads® in the 10 mM HEPES buffer. 
HepG2 DNA digested by immobilised DNase I, free DNase I or the negative 
control (beads only) in 10 mM HEPES buffer (pH 7.4, with 1 mM MgCl2 and 
1 mM CaCl2) for 15 minutes at 37°C. Analysis was by q-PCR. +/- SD, n=6. 
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4.3.5. DNase I immobilised onto glass or Dynabeads® 
A second investigation allowed the direct comparison of DNase I activity 
when bound to either Dynabeads® or the original glass beads, with the 
immobilisation protocol for each now being conducted in 10 mM HEPES 
buffer (pH 7.4). It thus became apparent that DNase I conjugated onto glass 
beads evoked a more substantial reduction in DNA concentration than did 
their Dynabeads® counterparts. Furthermore, in experiments when glass 
beads were used more DNA remained in solution than when Dynabeads® 
were applied to the DNA solution. Combined data from four experiments 
demonstrated that DNase I immobilised onto glass beads are more effective 
at DNA removal than their Dynabead® tethered counterparts (Figure 4-9), 
with only 0.03 ng/ml DNA remaining after treatment with glass-
immobilised DNase I, compared to 0.76 ng/ml with Dynabead®. 
 
 
Figure 4-9 – Comparison of DNA degradation by DNase I immobilised onto glass 
beads or Dynabeads®. 
100 ng/ml HepG2 DNA incubated in 10 mM HEPES (with 1 mM MgCl2 and 
1 mM CaCl2) for 15 minutes at 37°C with either beads alone, free DNase I or 
DNase I immobilised onto glass or Dynabeads®. Mean +/- SD, n=12. 
 
Owing to the observation that DNA is removed in the presence of the glass 
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which had been inactivated by heating was cross-linked to glass beads, in 
addition to a standard experimental condition where active DNase I was 
cross linked. Following incubation in HepG2 DNA spiked buffer solution, 
the supernatants were removed before washing the remaining beads in a 
high pH solution in order to elute any DNA which may have bound to the 
bead surface. The PCR data in Figure 4-10 shows that although compared to 
free DNase I there was much DNA remaining in solution following 
treatment with DNase I conjugated beads, this was itself much less than the 
quantity remaining after incubation with beads cross linked with inactive 
enzyme. Analysis of the wash solutions demonstrates that more DNA was 
eluted from heat inactivated DNase I conjugated bead conditions than from 
active DNase I beads. Total DNA recovered from the HI DNase I eluent 
combined with DNA remaining in solution following treatment with HI 
DNase I beads was not found to be comparable to the initial start 
concentration of DNA (p=0.09, two-tailed T-test). 
 
 
Figure 4-10 – Extent of DNA binding to glass. 
Heat inactivated (HI) DNase I was immobilised to glass beads as a control for 
exposed surface area on glass beads available for DNA binding. DNA was eluted 
from the beads following DNA digestion (15 minutes at 37°C) with Tris pH 10 and 
this assayed for DNA content. Prior to applying to PCR, the eluent was pH 
neutralised to pH7.4 by the drop-wise addition of 0.1 M HCl. Error bars depict +/- 
SD, n=3. 
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4.3.6. Cross-linker effect on immobilised DNase I activity 
The extent of DNA clearance by DNase I conjugated to glass beads by 
either benzene 1,3 disulfonyl chloride or by the longer chain molecule, 
O,O’-Bis[2-(N-Succinimidyl-succinylamino)ethyl] polyethylene glycol 
(NHS PEG) was determined by Q-PCR analysis of the resulting HepG2 
DNA spiked buffer solution after incubation with each set of beads. Beads 
modified with the cross linking molecules but unconjugated to DNase I 
demonstrated a greater reduction in solution DNA concentration when 
exposed to NHS PEG beads than with benzene 1,3 disulfonyl chloride 
modified beads (Figure 4-11a). Overall, DNase I conjugated to beads with 
benzene 1,3 disulfonyl chloride brought about a greater extent of DNA 
depletion in solution than when the NHS PEG ester was used (Figure 
4-11b); spiked solutions where DNase I was conjugated to glass beads with 
NHS PEG had more DNA remaining after treatment than in solution treated 
by DNase I tethered to beads via benzene 1,3 disulfonyl chloride.  
 
  
109 
 
 
Figure 4-11 – Effect of cross-linker on DNase I activity. 
DNA depletion of spiked 10 mM HEPES buffer solution following incubation with 
glass beads with/ without DNase I immobilised via NHS PEG or benzene 1,3 
disulfonyl chloride (BDS CL) cross linkers. (a) Comparison of DNase I activity 
following immobilisation by the different cross linkers; (b) Effect of cross linker on 
DNA depletion in the absence of DNase I. Error bars depict +/- SD, n=3 for 
individual experiments (n=6 for each cross linking condition). Initial DNA spike of 
100 ng/ml administered to all conditions and incubated for 15 minutes at 37⁰C. 
Supernatants were removed and applied to Q-PCR. 
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1    2         3              4        5     6 
blank condition, to account for DNA being removed from solution by 
binding to the glass bead rather than by purely enzymatic means. The 
Western blot data (Figure 4-12) shows that more DNase I tends to be left in 
solution, i.e. is not bound to the glass beads, when benzene 1,3 disulfonyl 
chloride is used as the cross linking agent. Also, using NHS PEG seems to 
yield more variable levels of cross linking. Combining these data enabled a 
calculation of the specific activity of DNase I immobilised under each 
condition (Table 4-1). 
 
 
Figure 4-12 – Binding of DNase I to the cross linking molecule. 
a) Post-immobilisation supernatants from duplicate conditions loaded onto a 
gradient pre-cast gel and run for 45 minutes at 250 v. Ladder = Full range Rainbow 
molecular weight marker. Lanes 1 & 2 = Free DNase I; 3 & 4 = NHS PEG; 
 5& 6 = Benzene 1,3 disulfonyl chloride. b) Quantification of band intensity 
(Arbitrary units represent surface area of pixels from scanned blot image). Each 
condition was performed in duplicate. 
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Table 4-1 – Calculated activity of DNase I immobilised onto glass beads. 
Cross linking molecule used was either NHS PEG or benzene 1,3 disulfonyl 
chloride (BDS CL). Mean values of duplicate concurrent immobilisations shown. 
DNA clearance derived from Q-PCR data; Band intensity data obtained from 
western blot analysis of unbound DNase I following immobilisation. 
CONDITION 
Mean DNA 
Cleared 
(% of Start [DNA]) 
Mean Band 
Intensity 
(Arbitrary Units) 
Calculated 
Specific 
Activity 
NHS PEG 12.17 58312 2.09E-04 
BDS CL 35.50 98424 3.61E-04 
 
In light of these findings, the original cross linking protocol was utilised in 
subsequent investigations. 
 
4.3.7. DNase time-course in buffer 
Having established that DNase I can successfully be conjugated to glass 
beads and that these were then capable of DNA degradation, it was 
necessary to determine whether these DNase I beads can function in more 
physiologically relevant conditions. Therefore, DNase I beads were 
incubated with HepG2 DNA spiked HEPES buffer at 37⁰C and pH7.4 with 
continual rotational mixing for a period of 24 hours, and the extent of DNA 
depletion compared to that in control conditions (Figure 4-13). It was 
observed that DNA levels were greatly reduced following incubation with 
both free and immobilised DNase I. 
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Figure 4-13 – DNA depletion in spiked 10 mM HEPES at 37⁰C over 24 hours. 
Samples spiked initially and after two hours with 20 µl of 0.95 µg/ml HepG2 
DNA. Empty beads = glass beads without DNase I (negative control). START 
DNA = DNA spiked buffer, no beads. DNA concentration determined by q-PCR. 
 
4.3.8. DNase I activity in plasma 
The BAL requires that immobilised DNase I be able to effectively degrade 
DNA in the presence of plasma. In order to quantify the extent of DNA 
degradation and hence determine the efficacy of the DNase I beads, a 
suitable Q-PCR protocol had to be established. The difficulties in 
performing Q-PCR in the presence of plasma are well documented, the 
various constituents interfering with components of the PCR reaction, such 
as Taq polymerase. By diluting samples 1/5000 and treating with Proteinase 
K it was however possible to gain a linear five-point standard curve (Figure 
4-14). 
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Figure 4-14 – Standard curve of BioLine DNA in FFP. 
FFP diluted 1/5000 in dH2O, spiked with human DNA in a range of concentrations 
(to give a final range from 1 pg / reaction to 0.0001 pg/reaction) and treated with 
Proteinase K prior to Q-PCR. n=3. 
 
The enzymatic activity of DNase I was investigated for both free and 
immobilised DNase I in the presence of plasma, over a period of 48 hours, 
to determine whether the enzyme can function for extended periods of time 
in the presence of plasma components which may affect activity. An 
inactivated form of DNase I, created by heating DNase I for 15 minutes at 
75⁰C and vortexing thoroughly, was included to control for the binding of 
DNA to available space on the glass bead support. FFP was spiked to a 
concentration of 100 ng/ml with HepG2 DNA and incubated for 48 hours at 
37⁰C prior to analysing the samples using the plasma Q-PCR protocol. It 
was surprising to note that the extent of DNA degradation by immobilised 
DNase I was much closer to that achieved by the free enzyme (Figure 4-15), 
demonstrating 50% the activity of the free enzyme, compared to the 
approximate 60-fold reduction in DNA clearance observed when 
incubations were previously performed in 10 mM HEPES buffer for a 
shorter period of time. 
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Figure 4-15 – DNA degradation by DNase I in 100% FFP. 
FFP was spiked with HepG2 DNA to give a concentration of 100 ng/ml. This was 
applied to free, immobilised or immobilised heat inactivated (HI) DNase I and 
incubated for a total of 48 hours at 37⁰C with continuous rotational mixing. 
Samples of 20 µl were taken and analysed by Q-PCR. n=6. 
 
 
4.4. Discussion 
4.4.1. DNase I immobilisation onto glass beads 
Initial experiments with plasmid and calf thymus DNA revealed that 
immobilisation of DNase I onto glass beads yielded a satisfactory degree of 
DNA degradation, as illustrated by DNA gel analysis. Whereas free DNase I 
unequivocally had brought about a greater extent of degradation on genomic 
DNA, DNase I immobilised onto glass beads also greatly reduced the 
average molecular length of both plasmid and genomic DNA compared to 
the corresponding negative controls (glass beads without DNase I). As the 
immobilised enzyme had degraded less DNA within the incubation period 
than had the free enzyme, the question to be next addressed was whether the 
immobilisation procedure had limited the rate at which DNase I can break 
down DNA or whether the affinity for the substrate had been reduced. This 
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degradation is observed with increasing incubation time. A more 
comprehensive investigation of this is discussed in Chapter 5. 
 
To investigate this, a range of incubation periods for free and immobilised 
DNase I with DNA were compared. The resulting data can be interpreted to 
signify that immobilised DNase I may still have the potential to deplete a 
solution of DNA to the same extent as the free enzyme, but that it requires a 
greater length of time to do so. This could be due to physical restriction of 
the enzyme by the cross-linking molecules utilised in the immobilisation 
procedure, or simply that by no longer being able to freely diffuse through 
solution, the immobilised enzyme is less likely to encounter and thus 
interact with the substrate. Although not ideal, an immobilised enzyme with 
a slow turnover rate may not be of detriment to the BAL system, providing 
that DNA is cleared efficiently, and importantly, that the enzyme does not 
lose activity during the extended incubation period required to achieve this. 
This could be a real issue in the BAL, which is required to function in the 
presence of plasma, rather than an enzyme-friendly Tris or HEPES based 
buffer, due to the plethora of plasma components which have been observed 
to be detrimental to DNase I activity, examples including proteinases and 
actin molecules. 
Investigations into the extent of DNA removal due to binding to the glass 
bead support, rather than through enzymatic degradation, revealed that this 
phenomenon does occur. Figure 4-10 demonstrates that after incubation 
with DNA, washing glass beads in a high pH solution eluted the bound 
DNA, confirming that a degree of DNA will inevitably bind to the support. 
Interestingly, heat inactivated DNase I beads released much more DNA than 
the active DNase I beads. This could give an insight into the method of 
DNA clearance by immobilised DNase I; the data could suggest that DNA 
binds to the glass support and it is from there that the tethered enzyme 
interacts with and consequently degrades DNA. For this reason the quantity 
of DNA eluted from DNase I cross linked beads is much lower than that for 
the inactive immobilised enzyme, as the glass-bound DNA had been mostly 
removed already by the action of DNase I. Alternatively, less HI DNase I 
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may have bound to the glass bead, thus providing a greater surface area to 
which DNA could bind. 
4.4.2. DNA detection methods 
When developing a system for removing DNA contaminants from the BAL 
it is crucial to have a satisfactory means of determining and quantifying how 
much DNA was present initially and then what proportion of this remains 
following treatment with the system. There is hence a great emphasis on 
selecting a suitable detection method; it must be sensitive, robust, and 
reliable even in the presence of plasma constituents. Initially, the PicoGreen 
assay was utilised. Although Q-PCR is a highly sensitive method of DNA 
detection, PicoGreen was chosen as a) unlike PCR, it does not rely upon 
enzymatic activity which may be compromised in the presence of plasma, 
and b) is less likely to bias (the nature of PCR means there is a tendency to 
disproportionally amplify smaller DNA sequences). However, the 
PicoGreen assay was discovered to not be sensitive enough in the detection 
of lower DNA concentrations, and so Q-PCR was henceforth used for the 
quantitative detection of DNA. The issue of interference from plasma 
constituents was overcome by modifying the PCR pre-treatment protocol 
and diluting samples from incubations conducted in plasma 1 / 5000 and 
treating with Proteinase K to remove protein contaminants which may 
compromise PCR reliability. This approach has been shown by our group to 
be a robust and reliable method for detecting and quantifying HepG2 DNA. 
 
4.4.3. DNase I immobilisation onto Dynabeads® 
Due to the observed phenomenon of DNA binding to glass, an alternative 
support matrix was investigated. Dynabeads® are small magnetic spheres, 
pre-modified with an amine group for binding the target protein. It was their 
pre-modified, ready to use state along with their magnetic nature which 
made them an ideal choice for an immobilisation support for DNase I; being 
magnetic, they would allow greater control of the containment of DNase I 
should the approach be utilised within the BAL. 
  
117 
 
Initial difficulties in terms of a lack of enzymatic activity were overcome by 
performing the immobilisation in 10 mM HEPES instead of the TrisHCl 
buffer. The rationale behind this decision was based on the chemistry of the 
reactive group on both the Dynabeads® and DNase I. Tris contains amine 
groups which can compete for binding sites and so interfere with the 
conjugation of enzyme and support. Exchanging the buffer solution lead to 
improved performance of cross linked DNase I, although this was then 
shown to be inferior to the levels of DNA degradation achieved when glass 
beads were used as the immobilisation support. Therefore, subsequent 
investigations into optimising DNase I immobilisation utilised glass beads 
rather than pursuing Dynabeads® any further. 
 
4.4.4. Cross-linker effect on immobilised DNase I activity 
For the immobilisation of DNase I onto glass beads two cross linking 
molecules were investigated. The first, 1,3-benzenedisulfonyl chloride, is a 
relatively small, aromatic molecule, comprising two sulfonyl chloride 
moieties attached to a benzene ring. 
 
 
Figure 4-16 – Molecular structure of cross-linking molecules. 
a) 1,3-benzenedisulfonyl chloride and b) O,O’-Bis[2-(N-Succinimidyl-
succinylamino)ethyl] polyethylene glycol. “n” depicts a repeating polyethylene 
glycol (PEG) unit, generating a cross linker molecule with a molecular weight of 
approximately 2000 Daltons. (Images taken from www.sigmaaldrich.com) 
a) b) 
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The second is a homobifunctional molecule, containing two succinimidyl 
termini separated by a polyethylene glycol repeating unit, or spacer arm, 
with a MW of 2 000 daltons. Both target primary amines, which are present 
on the N-terminus of peptide chains and also on lysine residues, which are 
usually on the outer surface of proteins owing to their charged and 
hydrophilic nature (137). This therefore makes them ideal targets for cross 
linking; it is unlikely that the enzyme would be denatured following 
structural changes, which may be the case if the target residue was more 
internally located. DNase I has nine lysine residues (137) and so the 
potential for a successful cross linking reaction is reasonably high. It would 
seem that the reaction had been successful when 1,3-benzenedisulfonyl 
chloride was used to tether DNase I to glass beads, as the resulting enzyme 
complex was observed to reduce DNA concentration in a spiked solution. 
However, as this was significantly less than the activity of the free enzyme, 
it was hypothesised that a large proportion of the enzyme was not being 
bound and so a more effective method of cross linking was investigated. 
The NHS PEG ester was chosen because succinimidyl esters are an 
established means of binding primary amines, and furthermore, the long 
spacer arm was hypothesised to increase the activity of bound DNase I by 
permitting greater scope for movement of the enzyme and thus facilitating 
an interaction with DNA. 
However, subsequent investigation revealed that this was not the case; using 
NHS PEG as the cross linking agent actually saw less DNase I activity than 
when the original method of cross linking was employed. An explanation 
for this could be that the NHS PEG bound DNase I at multiple sites, thus 
holding it in a rigid conformation and preventing substrate interactions. This 
becomes particularly relevant when taking into account the DNase I active 
site. This comprises an exposed loop region which interacts with the minor 
groove of DNA, whilst positively charged residues on either side of the loop 
interact with phosphate groups of the DNA strands; one of the required loop 
region residues is Lysine 74. It is therefore apparent that should this residue 
become involved in tethering the enzyme to a physical support, the 
properties of the lysine, and hence those of the active site would be altered, 
hence affecting the affinity, formation and interaction of the 
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enzyme - substrate complex. However, it must be considered that there are a 
total of nine lysine residues, all of which are accessible, i.e. found on the 
outer regions of DNase I (137), and so theoretically there stands an 11% 
chance that this residue will be targeted – assuming that the enzyme is 
cross-linked by only one cross-linking molecule. Although this scenario 
could account for an overall reduction in DNase I activity following 
immobilisation, it does not address the issue of why the longer cross linking 
agent was less effective than the shorter molecule. 
Alternatively, the long length of the NHS PEG cross linker may likely have 
become detrimental rather than beneficial to DNase I activity. For example, 
it may possibly have allowed sufficient flexibility in the orientation of the 
enzyme that it was able to twist around so that the active site faced the glass 
support, thus vastly decreasing the possibility of a successful interaction 
with DNA. It is also plausible that the length of NHS PEG (having a 
molecular weight of over 2 000 Daltons) made it possible for both ends of 
this homobifunctional cross linking molecule to bind different NH2 
modified sites on the glass bead support, rather than binding to DNase I.  
This may have limited the available cross-linking sites for DNase I and thus 
reduced the overall potential efficacy of any given bead. Moreover, the 
resulting “mesh” of double-bound cross-linker may have created a matrix 
within which DNA could become caught, or, acted as a barrier between 
DNA and DNase I, therefore preventing its interaction with immobilised 
DNase I. 
 
4.4.5. DNase I activity in plasma 
It was unexpected to observe that DNase I immobilised onto glass beads 
demonstrated levels of DNA clearance only 50% lower than those of free 
DNase I in the presence of 100% FFP; this had not previously been the case 
when investigating DNase I activity in buffer solutions, where free DNase I 
typical degraded from 60 up to 200 times more DNA within the given 
incubation time than the immobilised enzyme. It must be noted that this 
change is not due to increased activity of immobilised DNase I, but rather a 
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marked reduction in DNA degradation by free DNase I, compared to 
digestions carried out in buffer. An explanation for this could be that the 
process of immobilisation confers stability to DNase I, by protecting it from 
detrimental effects of interactions with plasma constituents; without this 
protection, the free enzyme is compromised, possibly by inactivation 
following binding with inhibitor molecules such as G-actin. If 
immobilisation is having a beneficial effect upon DNase I activity in 
plasma, the potential use of the DNase I glass beads in the BAL to reduce 
circulating DNA over an extended treatment period is feasible. This will be 
addressed in Chapter 6, where a scaled-down model of the BAL will be 
used to assess the efficacy of immobilised enzymes to remove DNA in 
physiologically relevant conditions.  
 
4.5. Summary 
There is a potential risk to the patient from circulating HepG2 DNA when 
undergoing treatment with the BAL. One approach to eliminate this risk is 
to utilise DNase I to degrade DNA. It has been demonstrated in this chapter 
that DNase I can be immobilised onto glass beads which, when incubated 
with DNA spiked solution, results in a reduction of the DNA concentration. 
Although the extent of DNA degradation in spiked buffer solution was less 
when treated with immobilised DNase I than with the free enzyme, it has 
been shown that the immobilised DNase I beads also reduce DNA 
concentration in spiked FFP. The next logical question to be addressed is 
therefore whether the immobilised DNase I can reduce DNA concentration 
in a more physiologically relevant model, at 37⁰C, in the presence of 
plasma, for periods of up to eight hours – essentially reproducing the 
working conditions of the BAL during patient treatment. 
 
In order to determine the length of time required by immobilised DNase I to 
clear a given amount of DNA, the kinetic profile of both the free and bead 
conjugated enzyme must be deduced. This will be addressed, along with that 
of lactate oxidase in the following chapter. 
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Chapter 5. Enzyme Kinetics 
 
 
Kinetic data is calculated for the activity of free and immobilised 
Deoxyribonuclease I and Lactate oxidase, enabling an estimation of the 
DNA and lactate clearance capacity of the systems in the BioArtificial Liver 
Device / Fluidised Bed Bioreactor.  
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5.  Enzyme Kinetics 
5.1. Introduction 
In order to fully comprehend and assess the usefulness and practicality of 
using the immobilised enzyme preparations it is necessary to determine their 
functionality compared to the original, non immobilised enzyme. For this to 
be possible, the determination of the rate at which the enzyme catalysed 
reaction occurs is required. This chapter seeks to address this question. 
 
Enzymes can be referred to as highly specific “biological catalysts”; they 
increase the rate at which a reaction occurs by lowering the activation 
energy (Ea) threshold which must be exceeded in order for the reaction to 
occur. For this to be possible, the enzyme must have a greater affinity for 
the transient state form of the substrate rather than the uncomplexed 
substrate molecule, so that a progression from enzyme + substrate to an 
enzyme-substrate complex to the formation of product(s) can occur (153). It 
is to be noted that the addition of a catalyst does not affect the relative 
quantity of product formed by the reaction; the ratio of product to substrate 
remains unchanged from that encountered in the absence of any catalyst, 
only the number of successful reactions per unit time is increased. In other 
words, the rate at which the reaction occurs is affected but the position of 
the equilibrium between substrate and product concentrations is not. 
 
It has been frequently demonstrated that the affinity an enzyme has for its 
substrate and/or the rate at which the reaction takes place is altered by 
immobilising the enzyme. Typically, both will be lower in the immobilised 
version of the enzyme as the quaternary structure of the protein is tethered 
in such a way that the active site is restricted and thus less likely to adopt 
the conformational change often required to correctly interact with its 
substrate. Furthermore, binding the enzyme to a bulky support matrix will 
frequently have a negative impact on the diffusion and accessibility of 
substrate to the enzyme. However, there are of course advantages to 
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immobilisation; other than conferring greater stability to the enzyme 
(thermal, structural and even chemical), instances have been reported 
whereby enzymatic activity is in fact improved following immobilisation 
(87). 
 
5.1.1. Determination of enzyme kinetics 
The efficacy of an enzyme to catalyse a particular chemical reaction is 
determined by two main factors; how readily the enzyme forms a complex 
with its substrate and how transient this interaction is. 
 
In the most simple scenario, a graph depicting an enzyme catalysed reaction 
would demonstrate that with increasing time the substrate concentration is 
depleted whilst the concentration of the product formed increases, until the 
curve plateaus when the substrate is depleted and becomes rate limiting. In 
terms of the velocity of an enzyme catalysed rate of reaction, plotting the 
rate of reaction as a function of the substrate concentration will often 
produce a curve. This represents that the rate of reaction rapidly increases 
with increasing substrate concentration until the curve levels off, indicating 
that increasing the substrate concentration will no longer increase the rate of 
reaction as the enzyme is functioning at its maximum capacity. This point is 
referred to as the Vmax, or the maximum velocity at which a particular 
enzyme catalysed reaction can occur. It is related to the “turnover number”, 
(as this value is expressed as Vmax divided by the product of total enzyme 
concentration and time) representing the number of substrate molecules 
converted to product by each enzymatic active site per unit time. The Km of 
a reaction is the Michaelis-Menten constant and refers to the concentration 
of substrate which causes a rate of reaction half that of the Vmax. It describes 
the dependence of the initial rate of reaction on the availability of the 
Figure 5-1 – Schematic representation of an enzyme catalysed reaction. 
ES = Enzyme-substrate complex; E = regenerated enzyme; P = product formed. 
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substrate, and in simple enzymatic reactions is equal to the dissociation 
constant of the enzyme-substrate complex, hence describing the affinity an 
enzyme has for its substrate (153). 
 
5.1.1.1. Criteria for calculating Km 
It is not always possible to deduce the Km of an enzyme for its substrate in a 
given context. This most often occurs when one or more of the key 
assumptions which are necessary in order to calculate the Km cannot be 
reasonably made. These criteria are: 
 
 The production of product is linear with time during the time interval 
used 
 The concentration of the substrate is greatly in excess; i.e. is not limiting 
the maximum rate at which the reaction can occur 
 The product is formed only by a single enzyme and formation of the 
product in the absence of that enzyme is negligible 
 Substrate binding to an active site of an enzyme has no effect upon the 
activity or affinity of an adjacent site 
 Enzyme activity is neither affected by the substrate nor by the product. 
 
It is not possible to confidently assume that the immobilisation of an 
enzyme onto a solid support will have no effect upon the affinity of the 
enzyme for its substrate, nor that multiple enzymes may be bound onto the 
support or to each other in such a way as to influence the formation of 
enzyme-substrate complexes in their immediate environment. Furthermore, 
it has been demonstrated in previous chapters that DNA binds to the glass 
immobilisation support; in this manner, both DNase I and its substrate are in 
effect immobilised. Therefore, the proceeding experiments sought to 
determine an estimation of the Km and Vmax of immobilised DNase I and 
LOx – referred to as the “apparent Km”( Km[app]). 
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5.2. Materials & Methods 
5.2.1. Lactate oxidase 
Materials: 
Phosphate Buffer (pH7.4): 
10 mM potassium phosphate 
0.01 mM Flavin Adenine Dinucleotide (FAD) (≥95%, Sigma, F6625) 
 
0.02 U/ml LOx (0.02 U in 1 ml 10 mM phosphate buffer) 
Plate reader at 570 nm wavelength 
96-well plate (Nunc) 
Immobilised LOx glass beads (see section 3.2.3) 
 
For the free LOx enzyme, a modified version of the lactate oxidase activity 
assay described in section 3.2.1 was performed. 20 µl of 0.02 U/ml LOx 
solution was added to each well of a 96 well plate, containing 80 µl assay 
reagent mix (as described in section 3.2.1) and a range of lactate 
concentrations prepared from a serial dilution of a freshly prepared lactate 
stock. The plate was incubated at 37⁰C and a total of 40 single end point 
measurements for each well were taken at 570 nm wavelength using the 
Anthos HTIII plate reader coupled with Manta software. Final substrate 
concentrations used per well were 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125 
and 0 mM. Each series of substrate concentrations was replicated three 
times. 
Methodology for immobilised LOx was as described previously, using LOx 
glass beads prepared as in section 3.2.3. Four glass beads were used per well 
in place of 20 µl of 0.02 U/ml LOx solution, the volume being substituted 
by 10 mM potassium phosphate buffer. 
 
5.2.2. Deoxyribonuclease I 
Materials: 
HEPES buffer solution (pH7.4): 
10 mM HEPES (pH 7-7.6, Sigma, HO887) 
1 mM MgCl2 
1 mM CaCl2 
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Figure 5-2 – Equation for the Determination of Km. 
4 U/µl Deoxyribonuclease I (Type II from bovine pancreas, Sigma Aldrich 
D4527) (from 25 µl frozen aliquots of 21.8 µg/µl (40 U/ µl) DNase I 
(original stock of 1836 U/mg protein)). 
 
Assay Reagent: 
500 µl 1M sodium acetate buffer pH5 
250 µl 100 mM magnesium sulphate 
3.65 ml purified water 
600 µl 0.033% (w/v) DNA solution: 
 
2 mg calf thymus DNA (Sigma, D3664) 
dH2O 
96-well plate (UV Transparent, ThermoFisher) 
FLUOstar OMEGA plate reader (BMG Labtech) 
 
To individual wells of a 96-well plate 125 µl assay reagent was applied. 
Calf thymus DNA diluted in purified water was used at the following range 
of concentrations: 0, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, and 5 mg/ml. For 
each condition a further 3.65 ml purified water was added to complete the 
reaction mixture. This was incubated for five minutes at 25⁰C after which 
25 µl 10 mM HEPES buffer or 25 µl DNase I enzyme (resuspended in 
HEPES buffer) was added to each well (total 100 U DNase I per well). 
Absorbance measurements were taken continually at the 260 nm wavelength 
over a 10 minute period at 37˚C using the OMEGA plate reader. 
 
5.2.3. Enzyme kinetics calculations 
All calculations were performed using non-linear regression and the 
Michaelis-Menten formula on GraphPad PRISM® 4 software programme. 
The Michaelis-Menten equations are as follows, where υ = reaction rate, 
d = the derivative function, P =  product, Ѕ = substrate, and t = time: 
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5.3. Results 
5.3.1. Lactate oxidase 
Free lactate oxidase was found to have a Km value of 0.01911 mM and a 
Vmax of 0.07523 mM/min. Immobilised lactate oxidase enzyme exhibited an 
apparent Km of 0.01491 mM and a Vmax[app] of 0.003172 mM/min 
respectively (Table 5-1). 
 
 
Figure 5-3 – Change in absorbance at different lactate concentrations (Free LOx). 
20 µl of LOx (0.02 U/ml in 10 mM phosphate buffer) used per 120 µl reaction 
volume. Samples incubated and absorbance measurements taken continuously at 
570 nm at 37⁰C. n=3 for each substrate concentration condition. 
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Figure 5-4 – Rate of lactate clearance with Free LOx. 
20 µl LOx (0.02 U/ml) used per 120 µl reaction volume. Samples incubated at 
37⁰C and absorbance measurements taken continuously (570 nm). Lactate 
concentrations from 2-0 mM. Line of best fit modelled by non-linear regression. 
n=3 
 
 
 
Figure 5-5 – Rate of lactate clearance by immobilised LOx. 
4 LOx beads used per 120 µl reaction volume. Samples incubated at 37⁰C and 
absorbance measurements taken continuously (570 nm). Lactate concentrations 
from 2-0 mM. Line of best fit modelled by non-linear regression. n=3 
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Table 5-1 – Vmax and Km data for free and immobilised LOx. 
Calculated using GraphPad Prism4 software. 
 
Vmax 
(mM/min) 
Km 
(mM) 
Std.Error 
Vmax 
(mM/min) 
Std.Error 
Km 
(mM) 
Free LOx 0.075 0.019 0.005 0.004 
Immobilised LOx 0.003 0.015 0.0004 0.006 
 
5.3.2. Deoxyribonuclease I 
In contrast to traditional kinetic studies which measure the rate of product 
formation to determine kinetic data, it was necessary to perform kinetic 
studies on the rate of substrate depletion for DNase I; since DNase I 
catalyses a degradation reaction, there is no product formation per se. For 
this reason a time course experiment was prepared, using fluorescence to 
compare the amount of remaining DNA after increasing time exposed to 
DNase I. However, the change in absorbance was very slight and tended to 
fluctuate (Figure 5-6), particularly at lower substrate concentrations, and so 
establishing a rate of enzymatic activity proved challenging. 
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Figure 5-6 – Change in absorbance at 260 nm of DNase I treated solutions. 
DNA concentration of solutions were 1000, 500, 100, 50 and 10 µg/ml. 1.77 Units 
free DNase I incubated with each condition for 10 minutes at 37⁰C prior to the start 
of the time course, where absorbance readings were taken continuously for a total 
of 624 seconds using the OMEGA plate reader at a wavelength of 260 nm at 37⁰C. 
n = 3 for each substrate concentration. 
 
However, an approximation was possible for free DNase I by plotting the 
difference in absorbance at 260 nm between 0 and 624 seconds, using a 
higher quantity of enzyme; 1000 Units per reaction rather than the original 
1.77 Units as used in all previous experiments with free and immobilised 
DNase I. In this manner a Km of 54.02 µg/ml and a Vmax of 228.7 µg/ml/min 
were obtained. 
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Figure 5-7 – Rate of DNA degradation by 1000 U free DNase I with increasing 
substrate concentration. 
DNA degradation determined by a decrease in absorbance at the 260 nm 
wavelength.  10 00 Units free DNase I incubated with DNA (500, 100, 50 and 10 
µg/ml)  for 10 minutes at 37⁰C prior to the start of the time course. Absorbance 
readings were taken continuously for a total of 624 seconds using the OMEGA 
plate reader at 260 nm wavelength at 37⁰C. n = 6 for each substrate concentration. 
 
 
Table 5-2 – Rate of DNA depletion by 1000 U DNase I. 
Km and Vmax values, as calculated using non-linear regression with GraphPad 
Prism 4 software, are also included. 
DNA Concentration (µg/ml) DNA Cleared (µg/minute) 
500 109.821 
100 37.837 
50 15.521 
10 6.750 
5 1.8750 
1 1.859 
0 0.000 
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Determination of true kinetic values for immobilised DNase I was not only 
theoretically impossible due to the failure to meet the Michaellis-Menten 
criteria, but also on a practical level, as the observed change in absorbance 
of a DNA containing solution over time was very slight (Figure 5-6). This is 
illustrated in Figure 5-8, where the activity rate of immobilised DNase I is 
compared to that of the free enzyme. 
 
Figure 5-8 – Rate of DNA depletion by DNase I at varying substrate 
concentrations. 
DNase I incubated with DNA (500, 100, 50 and 10 µg/ml) for 10 minutes at 37⁰C 
prior to the start of the time course. Absorbance detected using OMEGA plate 
reader (260 nm) at 37⁰C. Change in absorbance units calculated from T=0-T = 624 
seconds. Data for free and immobilised DNase I are both shown. n=3 for each 
condition. 
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5.4. Discussion 
For immobilised enzymes the true Km and Vmax could not be obtained and so 
the apparent values for these were derived. This was necessary as the state 
of being immobilised rendered the traditional model unsuitable for the 
bound enzymes; as described previously, part of the assumed criteria when 
calculating enzyme kinetics is that both enzyme and substrate are freely 
diffusible in solution, which is clearly not going to be the case when dealing 
with enzymes immobilised to a physical support. 
It is evident from the gradient of the curve generated by the activity of 
lactate oxidase on a range of substrate concentrations that the immobilised 
enzyme is not as efficient at degrading lactate as is the free enzyme. 
However, it is to be noted that although there is a great difference between 
the Vmax/Vmax{app} of these conditions (0.07523 mM/min and 
0.003172 mM/min for free and immobilised LOx respectively), somewhat 
surprisingly the Km values are similar (0.01911 mM for free and 
0.01491 mM for immobilised lactate oxidase). This can be interpreted to 
signify that there is a large decrease in activity, but that there is no change in 
the affinity the enzyme has for its substrate; although the process of 
immobilisation results in the enzyme being unable to catalyse as many 
reactions per unit time as its free counterpart, physically tethering lactate 
oxidase to a support does not seem to have affected the ability of the 
enzyme to form a complex with its substrate molecule via the active site. 
Therefore, the immobilised enzyme could catalyse the conversion of lactate 
once it has bound its substrate, but perhaps mass transfer issues are 
hindering the frequency of an interaction between substrate and immobilised 
enzyme. As it stands, using the Vmax of immobilised LOx 
(0.003172 mM/min), 100 mg of immobilised enzyme would require 
2362 minutes (almost 39.4 hours) to clear 7.5 mM of lactate. However, 
increasing the quantity of immobilised LOx beads to just 1 gram could 
theoretically clear 7.5 mM lactate in under four hours. 
Although the Km obtained for an enzyme can vary between batches of 
isolated protein from the same source, it is of use to know what typical 
values could be expected to be yielded, in particular for the free, unaltered 
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enzyme. It has been reported elsewhere that for Pediococcus LOx, a Km 
value of 2.3 x 10
-4
 M and Vmax of 0.11 µmole/minute can be obtained (131). 
In the same study, LOx was immobilised onto alkylamine glass beads with a 
conjugation yield of 3.2 mg per gram of support and Km and Vmax values of 
3.6 x 10
-4
 M and 0.22 µmol/minute respectively were calculated. This is in 
comparison to the data obtained in this study, with Km of 1.91 x 
-5
 M and 
Vmax of 75.2 µmol/min for the free enzyme and Km of 1.49 x 10
-5
 M and 
Vmax of 3.7 µmol/min for the immobilised LOx, indicating that the 
immobilisation conducted in this study resulted in a more active LOx than 
by the alkylamine glass method. 
 
Issues surrounding mass transfer limitations could be countered when the 
immobilised LOx complexes are introduced into the FBB circuit – a 
continuous flow system, rather than the static conditions used in the assay to 
deduce the kinetic data, will very likely increase the frequency of substrate 
presentation. The implications for this, in terms of the suitability and 
practical considerations of using immobilised lactate oxidase within the 
bioreactor, are unclear based on this data alone. It could be hypothesised 
that if given adequate time the immobilised enzyme will be sufficient to 
reduce lactate concentrations within the bioreactor, without having to 
increase the total quantity of protein (and hence the number of beads) 
compared to the hypothetical amount of free lactate oxidase that would be 
required. However, this will have to be deduced experimentally, identifying 
a compromise point between time of treatment and the number of 
immobilised LOx beads required within the FBB chamber. Furthermore, the 
kinetic data was deduced in 10 mM phosphate buffer, and so may not reflect 
the kinetic profile of LOx in the presence of plasma constituents. 
The determination of kinetic data for DNase I proved more problematic than 
for LOx. The major obstacle was that the criteria could not be met which 
was required for modelling Km and Vmax; not only was the enzyme no longer 
freely diffusible once immobilised, but there was also evidence to imply that 
the substrate, DNA, was also not entirely free in solution, as it too tended to 
bind to the glass beads. Therefore it was not possible to assign a true Km to 
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immobilised DNase I. Nevertheless, an approximation of enzyme activity 
was possible by taking the specific activities of free and immobilised 
DNase I and comparing the typical extent of DNA clearance from a spiked 
solution for each enzyme condition. In this manner, a rough approximation 
of how much DNA could be expected to be cleared per unit time by 
immobilised DNase I was calculated. 
Attention is drawn to Figure 4-12 of section 4.3.6 (page 110) which 
concerns the determination of the specific activity of immobilised DNase I. 
From the blot quantification it was possible to approximate the proportion of 
DNase I bound to the glass beads. By dividing the percentage degradation of 
a known quantity of DNA in a given time by the proportion of bound 
enzyme, an activity value could be designated per immobilised DNase I 
molecule per unit time, as well as per unit of activity (Table 5-3). Although 
these values are by no means a representation of actual Km or Vmax data, 
they can provide a guideline as to the proportion of DNA that could 
potentially be cleared by immobilised DNase I within a given time period. 
Our laboratory data has demonstrated that typically in a 10 litre working 
volume (containing 7 x 10
10
 cells) over an eight hour treatment period with 
ALF plasma, 47 µg/ml DNA can be detected after eight hours. The 
hypothetical calculations suggest that (assuming a linear rate of increase) a 
single 100 mg batch of immobilised DNase I would be able to clear 
3.5 ng/ml/min DNA; extrapolating this further indicates that 100 times more 
beads, 10 grams of glass beads would require just 12.3 minutes to clear this 
concentration of DNA. However promising this seems, it must be 
remembered that these figures are hypothetical, having extrapolated existing 
data in the absence of strong kinetics data. Moreover, the kinetic analyses 
were conducted using standardised calf thymus DNA, whereas a crude 
extraction from HepG2 cells has been used for the majority of DNase I work 
in this thesis, as this represents the most probable form of DNA present in 
the BAL. Owing to the inhomogeneous identity of the HepG2 DNA extract 
it would not have been practical to utilise this for determining DNase I 
kinetic data. Therefore, the rate of HepG2 DNA digestion, particularly in 
plasma, may vary from the Km and Vmax values calculated in this chapter.
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Table 5-3 – Hypothetical rates of immobilised DNase I activity, compared to free 
DNase I. 
 * = Based on the use of 100 µl 0.02 mg/ml DNase I for the immobilisation 
procedure, as described in section 4.2.2. ** = Data derived from analysis of Q-PCR 
analysis of samples incubated at 37˚C for 10 minutes with immobilised / free 
DNase I in a 200 µl reaction volume spiked to give a HepG2 DNA concentration of 
100 ng/ml. ***= the DNase I powder (Sigma, D4527) comprised 2.8 mg of 
3533 U/mg protein. Working solutions were diluted in 10 mM HEPES buffer to 
give a stock of 70.6 U/ml (0.02 mg/ml). 
 Free DNase I Immobilised DNase I 
Total protein / reaction* 
(µg) 
2 0.28 
DNA cleared in 10 minutes** 
(ng/ml) 
99.99 35.50 
DNA cleared in 1 minute 
(ng/ml) 
9.99 
 
3.55 
 
DNA cleared / µg protein 
(ng/ml/min) 
4.99 
 
12.62 
 
Units DNase I / reaction*** 
7.06 
 
2.10 
 
DNA cleared / DNase I Unit 
(ng/ml/min) 
1.42 
 
1.69 
 
 
5.5.  Summary 
Irrespective of the method used to approximate the kinetic profile of 
immobilised DNase I and LOx, it is apparent that the activity of the 
immobilised enzyme is reduced following immobilisation. However, the 
data acquired suggests that this residual activity may still be enough to clear 
circulating DNA and reduce sufficient lactate from the BAL, although the 
effects of plasma constituents and a dynamic, rather than static, reaction 
environment must be considered. This will be investigated in the following 
chapter, where a scaled-down representation of the BAL is used to model 
the conditions within the BAL device. 
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Chapter 6. Immobilised Enzymes in the BAL 
 
 
The efficacy and practicality of using immobilised Deoxyribonuclease I and 
Lactate oxidase in the BioArtifical Liver Device / Fluidised Bed Bioreactor 
is investigated, careful consideration being given to downstream effects on 
encapsulated HepG2 cells and circulating protein concentration. 
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6. Immobilised Enzymes in the BAL. 
6.1.  Introduction 
It has been demonstrated in previous chapters that enzymatic activity can 
successfully be harnessed by immobilising these biological catalysts onto a 
solid support. The motivation for this is the desire to utilise immobilised 
enzymes within a Bio-Artificial liver assist device (BAL), both in the cell 
production stage of the fluidised bed bioreactor (FBB) and in the actual 
patient treatment stage, in order to optimise the efficacy and safety of this 
device in the alleviation of ALF. However, although both immobilised LOx 
and DNase I have been investigated under conditions reminiscent of those to 
be encountered in the intended application (physiological pH and 
temperature, and in the presence of human plasma) there are other factors 
and challenges to be considered before it can be more accurately determined 
whether these complexes will function well in the proposed BAL system. 
Both enzymes must be able to withstand any potential sheer stress induced 
by the constant fluidisation of the BAL/FBB circuit; in terms of resistance 
to denaturation by physical forces, as well as ensuring that the immobilised 
enzyme beads are in an appropriate setting to actually encounter their target 
substrate and more importantly, catalyse its degradation. 
 
6.1.1. Protein depletion 
There is also the matter of the glass support interacting unfavourably with 
and sequestering plasma proteins; it is of high importance that any measure 
introduced to enhance BAL productivity does not compromise either its 
function or patient safety. ALF patients typically present with depleted 
levels of liver synthesised proteins circulating in their plasma, such as 
clotting factors (38). The purpose of treating with a BAL, rather than a 
purely artificial (filtration) approach, is to replace this loss of function by 
utilising a liver derived cell line to perform the metabolic and synthetic 
functions of the patient’s damaged liver. Therefore, it is critical to the 
success of the BAL that the newly synthesised proteins are not being 
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sequestered or in any other way reduced in functionality by either the BAL 
itself or by any component of the device. 
 
6.1.2. Hydrogen peroxide production 
There is a potential issue with the equimolar generation of H2O2 from the 
degradation of lactate by LOx (122). H2O2 is a known inducer of oxidative 
stress in cells and so it follows that elevated concentrations within the BAL 
system should be avoided. However, it has been previously reported that 
ELS show upregulated production of the enzyme catalase, which is naturally 
present in the liver and catalyses the breakdown of H2O2. Therefore, it may 
be that the BAL ELS can metabolise an elevation in H2O2 concentration, 
although the extent, if any, of this must be thoroughly assessed. 
 
6.1.3. Small-scale BAL experiment 
Having demonstrated the efficacy of immobilised LOx and DNase I to 
reduce levels of lactate and DNA respectively in physiologically relevant 
conditions, the next logical step would be to apply these technologies 
simultaneously in a system which mimics the BAL as closely as possible. In 
addition to incubating for up to eight hours at a physiological pH, 
temperature and in the presence of plasma, immobilised enzymes were 
applied to a mini-column system, in order that the effects of flow rate and 
sheer stress, if any, could be investigated. 
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6.2.  Materials & Methods 
6.2.1. Protein depletion 
Materials: 
Enzyme conjugated glass beads (see sections 3.2.3 and 4.2.2) 
FBB conditioned media 
15 ml polypropylene tubes (Corning®) 
1.5 ml microcentrifuge tubes 
Liquid nitrogen 
Incubator 
Rotational mixer 
 
Enzyme linked beads were prepared, as described in previous sections, in 
100 mg batches and each applied to 10 ml of conditioned media, taken from 
the media change on Day 7 of encapsulated HepG2 spheroids cultured in the 
FBB. Control samples contained conditioned media only. These were 
incubated at 37⁰C for eight hours with constant mixing to mimic the BAL 
environment. Samples of 100 µl were taken at hourly intervals and frozen 
prior to assaying for alpha fetoprotein by ELISA (see section 2.6 for 
detailed methodology). 
 
6.2.2. Effect of H2O2 on ELS 
Materials: 
Day 10 ELS 
10% FFP media 
Hydrogen peroxide (VWR, 23615.261) 
6-well plate (Nunc) 
1 M HEPES (pH 7-7.6, Sigma, HO887) 
 
For this experiment, ELS which had been growing in the FBB for ten days 
were used. 1 ml of cells were transferred to a well of a 6-well plate 
containing a total volume of 4 ml fresh 10% FFP media spiked with H2O2. 
Two concentrations of H2O2 (Mr = 34) were tested; 7 mM and 0.07 mM, 
obtained by adding 28.6 µl of 979 mM stock or 9.79 mM pre-diluted H2O2 
respectively to the FFP media. To the control cells, H2O2 was substituted 
with 28.6 µl H2O. For each condition, a cell-free counterpart was also in 
place as a negative control for H2O2 degradation. All wells received 40 µl 
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1M HEPES to buffer pH to 7.4. Plates were incubated at 37⁰C for 
10 minutes, after which the supernatants were removed and retained for 
subsequent analysis. Cell samples were also taken to compare their viability 
with those prior to experimentation. 
 
6.2.3. Siliconisation of glassware 
The process of siliconisation utilises dichlorodimethylsilane to replace the 
hydrophilic hydroxyl groups on the surface of glass, resulting in a 
hydrophobic surface which is far less likely to interact and bind via 
hydrogen bonding with molecules such as proteins and DNA. 
 
Materials: 
Dichlorodimethylsilane (Sigma, 33009) 
Dichloromethane (Sigma-Aldrich, 270997) 
Ethanol 
dH2O 
 
A 5% solution of pre-chilled dichlorodimethylsilane was made in 
dichloromethane, working in a fume cupboard as HCl vapour is liberated 
during this procedure. Glassware was immersed in the solution for 
30 minutes, whereupon it was rinsed in dichloromethane, ethanol and then 
dH2O. Treated glassware was allowed to air dry and stored in clean 
autoclave bags until required. 
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6.2.4. Mini-column experiment 
A miniaturised working model of the BAL allowed small scale experiments 
into the effectiveness of various measures to improve functionality of the 
system. 
  
Materials: 
Glass columns of length 185 mm and internal diameter 10 mm (15 ml 
volume) 
Polypropylene screw cap, diameter 15 mm with an 8 mm circular opening in 
the top 
Tapered glass fitting (12 mm base, 1 mm apex) 
200 micron mesh filters (comprised of two rubber O-rings, diameter 12 mm) 
Silicon tubing of length 75 cm and 50 cm 
Pump tubing (2.7 mm bore size, 0.5 mm thickness) 
250 ml polypropylene reservoir chamber bottle 
Watson-Marlow 520Du peristaltic pump with ten channel pump 
Sampling septum 
Sterile 5 ml needle 
100 mg DNase conjugated glass beads 
100 mg LOx conjugated LOx beads 
FBB conditioned medium / FFP with 40 IU/ml heparin 
Lactate  
HepG2 DNA 
 
All glassware was siliconised prior to use, as previously described. Each 
mini-column circuit was arranged as shown in Figure 5-9. In summary, for 
each mini-column circuit: filter discs (comprising a 200 micron nylon mesh 
adhered with silicone glue between two 12 mm rubber O-rings) were 
positioned at either end of the glass tube, held in place by polypropylene 
caps which also housed the tapered glass connectors. To the connector on 
the top section of the column one end of a 75 cm silicone tube was attached, 
the other being connected to a luer fitting in the lid of a 250 ml bottle (the 
reservoir). From another luer fitting in the lid a T-piece was joined, to which 
a septum and a section of 50 cm silicone tubing was connected. The pump 
tubing was connected to the terminus of this tubing, which was threaded 
into a multichannel pump. On leaving the pump, the tubing was joined to 
the 75 cm silicone tubing, thus completing the circuit. 
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A solution comprising 0.864 g lactate dissolved in 10 ml dH2O and pH 
adjusted to 7.4 was added to 800 ml Day 10 FBB media, giving a final 
lactate concentration of 12 mM. To this 5.2 µl heparin and 150 µl HepG2 
DNA were added and 200 ml of the resulting solution transferred to each 
mini-column circuit. 100 mg each of DNase / LOx conjugated glass beads 
were prepared as described previously and the total 200 mg transferred to 
each glass column. For the control, 200 mg treated but non-enzyme 
conjugated glass beads were used. The pump was run at a rate of 18 ml/min 
for six hours at 37⁰C. Samples were taken from the septum using a needle 
and 2 ml syringe every hour and snap frozen in liquid nitrogen to await 
analysis. 
 
Figure 6-1 – Schematic diagram of the mini column circuit. 
For clarity only one column is depicted; multiple column circuits were included by 
attaching their tubing to the pump at points (i) and (ii). Enzyme cross-linked glass 
beads were housed in the base of the column (a). A reservoir of 10% FFP 
media / 100 FFP (b) fed the system which was drawn through the column by a 
multichannel pump. Samples were taken using a syringe from the septum in the 
reservoir lid (c). 
PUMP 
(a) 
(ii) (i) 
(c) 
(b) 
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6.3.  Results 
6.3.1. Protein depletion 
In order to determine the extent to which plasma proteins are sequestered by 
the immobilised enzyme beads, 100 mg of these beads were incubated in 
Day 5 conditioned media and the protein content after a six hour incubation 
with constant mixing at 37⁰C compared with that of the initial, pre-
treatment value. Media samples without any added beads were also 
incubated, to control for any loss of protein which may occur as a 
consequence of external factors such as heat, time and the affects of the 
plastic-ware utilised. Results are shown in Figure 6-2. 
 
 
Figure 6-2– Effect of immobilised enzyme beads on plasma protein content. 
100 mg enzyme linked glass beads (DNase I and LOx) were incubated for a period 
of six hours with 10 ml conditioned media which was obtained from the media 
change on Day 5 of encapsulated HepG2 cell growth in the FBB. Hourly samples 
of 100 µl were snap frozen prior to screening for AFP in an ELISA. Samples also 
taken from conditions where conditioned media alone was incubated (“Media 
Only” – negative control). Conditions run in duplicate, n=3 for each. Error bars 
denote standard deviation of the mean. 
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6.3.2. Effect of H2O2 on ELS 
The data, particularly from the higher H2O2 dose condition, demonstrates 
that H2O2 levels were lower when incubated with ELS for 10 minutes than 
when incubated in the absence of cells (Figure 6-3). 
 
Figure 6-3 - Intrinsic hydrogen peroxide clearance by encapsulated HepG2 cells. 
Key to labels: BLANK = assay reagent only (equivalent hydrogen peroxide volume 
substituted with water); + = 0.07 mM hydrogen peroxide dose; ++ = 7 mM 
hydrogen peroxide dose. Control condition contained reaction solution only. n=3 
for each condition Error bars depict +/- SD. 
 
MTT assay data shows that although ELS subjected to H2O2 showed 
reduced mitochondrial activity, suggestive of metabolic stress, there was 
little difference between the high and the low H2O2 dosed conditions. 
However, once this data was corrected for by normalising to protein 
concentration determined by BCA assay, there was no statistical difference 
between cells from the two H2O2 conditions. It is to be noted that the 
untreated ELS demonstrated slightly better metabolic activities than their 
H2O2 treated counterparts. 
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Figure 6-4 – Metabolic function of encapsulated HepG2 cells following hydrogen 
peroxide treatment. 
Normalised to protein concentration, determined by BCA assay. Key to conditions: 
- = no hydrogen peroxide administered; + = 0.07 mM dose; ++ = 7 mM dose. n=3 
for all conditions, +/- SD. T-Test (two-tailed, equal variance) *p<0.05 *^= value 
obtained of 0.0505 
 
Fluorescent microscopy of ELS before and after the treatment shows that 
although the proportion of viable cells was lower after H2O2 exposure, the 
viability of untreated ELS was also lower than before the commencement of 
the experiment, suggesting that at least a proportion of cell death was due to 
factors other than exposure to H2O2 (Figure 6-5). 
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Figure 6-5 – Effect of H2O2 on encapsulated HepG2 cell viability. 
Day 11 encapsulated HepG2 cells were assayed for viability before and after 
treatment with hydrogen peroxide spiked 10% FFP culture medium. Viability 
determined using fluorescent microscopy with propidium iodide (excitation filter 
of 510-560 nm, emission filter of 590 nm) to mark non-viable and fluorescein 
diacetate (excitation filter of 465-495 nm, emission filter of 515-555 nm) to mark 
viable cells. Samples were imaged using Lucia imaging software with a DX1200 
camera on a Nikon Eclipse microscope. Images were taken at 4x on phase contrast, 
live FDA and dead PI settings. Key to conditions: - = no hydrogen peroxide 
administered; + = 0.07 mM dose; ++ = 7 mM dose; T = 0 = viability of cells before 
commencing the experiment. n=3 for all conditions, +/- SD. 
 
 
6.3.3. Small-scale BAL experiment 
The first mini-column experiment was conducted as a representation of the 
conditions likely to be found in the BAL during patient treatment, although 
for this initial experiment, ELS beads were not included. Conditioned 10% 
FFP media from Day 10 of an FBB experiment was used, as this had been 
exposed to growing ELS beads for a period of three days and so would 
contain protein and molecular components, including some DNA, of HepG2 
origin. DNA was not added as human plasma is known to contain some 
background levels of DNA (typically 10.2 ng/ml (61)). Together, these 
factors should be representative of the majority of DNA likely to be 
presented to the DNase I beads during an eight hour BAL treatment period, 
assuming minimal cell damage and hence negligible DNA release into the 
circulation. A lactate spike was added to the media in order to fully 
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investigate the lactate clearance capacity of immobilised LOx in the mini-
columns; although such high lactate levels are unlikely to be encountered in 
the BAL, the LOx beads would have first had to catalyse the conversion of 
lactate from the FBB, where lactate concentrations would be much higher 
than in the BAL, and so lactate was added to mimic this earlier role. 
 
 
Figure 6-6 – DNA concentration in 10% FFP media mini-column experiment. 
100 mg DNase I conjugated glass beads (“Enzyme Beads”) or 100 mg glass beads 
(“Beads Only”) were housed in the base of individual mini-column circuits 
containing Day 10 conditioned FBB media (10% FFP) buffered with HEPES to 
pH7.4 and treated with heparin to prevent coagulation of plasma proteins. Samples 
incubated at 37⁰C for a total of six hours with a flow rate of 18 ml/min. 500 µl 
samples were taken initially and then at hourly intervals. DNA concentration 
determined by Q-PCR analysis. Mean values plotted for each condition, n=3. 
 
The same samples were also analysed for lactate concentration, in order to 
establish whether the LOx conjugated glass beads were effective under the 
mini-column conditions. 
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Figure 6-7 Lactate concentration of samples taken from the mini-column 
experiment. 
500 µl samples of lactate spiked Day 10 FBB culture media were taken initially 
and then every two hours from each mini-column system. “Empty Beads” denotes 
the negative control, of glass beads without enzyme; “Enzyme Beads” refer to 
conditions where 100 mg each of DNase I and LOx conjugated beads were housed 
within the mini-column. Mini-columns were maintained at 37⁰C at a flow rate of 
18 ml/ min. Media was treated with HEPES and heparin to buffer to pH7.4 and 
prevent clotting, respectively. Mean values shown for each data point, n=3. 
 
In the next experiment, 5 ml of ELS beads were included with the 
immobilised enzyme beads in the mini-column, with 100% FFP, to 
represent the closest imitation of the BAL conditions. All other 
methodology and analysis was as previously described, except that samples 
were taken at T=0, after one hour, and then at 30 minute intervals up to four 
hours, after which hourly samples were taken. The results of this 
investigation are shown in Figure 6-8. 
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Figure 6-8 - DNA concentration in the mini-columns – with ELS. 
500 µl samples of lactate spiked FFP were taken initially, after one hour and then 
every 30 minutes up to four hours, after which hourly samples were then taken 
from each mini-column system and assayed for DNA content by q-PCR. “Empty 
Beads” = negative control (glass beads without enzyme); “Enzyme Beads” = 100 
mg each of DNase I and LOx conjugated beads were housed within the mini-
column. Mini-columns were maintained at 37⁰C at a flow rate of 18 ml/ min. FFP 
was treated with HEPES and heparin to buffer to pH7.4 and prevent clotting, 
respectively. Mean values shown for each data point, n=3. 
 
Samples were also assayed for lactate concentration, the data for which is 
shown below. 
 
Figure 6-9 - Lactate concentrations within the mini-column with ELS. 
From the 500 µl samples taken during the mini-column experiment 3.5 µl were 
assayed for lactate using the Analox® apparatus. Readings were taken in at least 
duplicate per sample. Mean values of readings which fell within 0.1 mM of each 
other are shown. 
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Once plotted, the lactate concentrations revealed that there was great 
fluctuation and variation of the data points both within and between 
samples. To better visualise this change, the cumulative lactate removed 
from the system between all time points was plotted for each sample (Figure 
6-10). Furthermore, as lactate appeared to have been added to the system 
over time, the difference in lactate concentration between the start and end 
of the experiment was plotted (Figure 6-11). 
 
 
Figure 6-10 – Cumulative reduction in lactate concentration. 
In calculating the cumulative lactate cleared, only positive differences between 
sample times (i.e. representative of a reduction rather than an increase in lactate 
concentration) were included. 
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Figure 6-11 – Increase in lactate concentration after the experimental period. 
Values obtained by subtracting T=7 hours lactate concentrations from those at T=0 
for each condition. Negative values, as in “Enzyme Beads 2”, represent an overall 
reduction in lactate concentration. 
 
 
 
 
 
6.4.  Discussion 
6.4.1. Protein depletion 
A significant advantage that the BAL would have over a purely artificial 
method of liver failure support is that in addition to removing hazardous 
components, the plasma can also be supplemented with metabolites and 
proteins synthesised by the encapsulated HepG2 cell spheroids. Therefore, it 
is essential that the inclusion of immobilised enzymes into the BAL device 
does not have a detrimental impact upon the protein content of the 
plasma / growth media. Alpha fetoprotein (AFP) was chosen to represent 
plasma protein content as previous analysis undertaken by the Liver Group 
has demonstrated that encapsulated HepG2 cells synthesise detectable levels 
of AFP during FBB culture, which is not usually found in normal human 
plasma, thus permitting even small background levels to be measured. 
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The data demonstrated two key phenomena: firstly, that no significant 
difference in AFP levels can be seen between control and immobilised 
enzyme conditions, and secondly, that after two hours, there is no longer a 
significant difference between the T=0 and subsequent hourly samples, 
indicating that AFP is not being sequestered by the enzyme linked glass 
beads. This investigation also revealed that there is a degree of variability 
between replicates of the same experimental condition; this could represent  
the non-specific manner of protein adhering randomly to the plastic-ware. 
 
6.4.2. Effect of H2O2 on ELS 
The degradation of lactate is required in order to ensure lactate 
concentrations in the FBB do not accumulate to such an extent that they 
have detrimental effects on ELS proliferation or compromise the integrity of 
the alginate beads themselves. The use of immobilised LOx is an elegant 
approach to achieving this, as from the conversion of lactate, pyruvate is 
generated, which could be used as a metabolic substrate by HepG2 cells. 
However, in the enzymatic conversion of lactate, hydrogen peroxide, a 
known agent of oxidative stress, is also produced in a stoichiometric 
fashion. For this reason, it was crucial to determine whether this would 
prove detrimental to cell performance. When incubated with a relatively 
high dose of H2O2, the addition of ELS saw a reduction in supernatant H2O2, 
indicative of an active catalase function in these cells. The significance of 
this finding is that the intrinsic catalase activity of HepG2 cells may well be 
sufficient to clear any additional H2O2 produced as a by-product of 
immobilised LOx driven lactate conversion. Although metabolic activity 
decreased in cells in the presence of the lower H2O2 dose, there was no 
significant difference between cells given the higher H2O2 dose and the 
negative control, implying that HepG2 cells would unlikely be affected by 
the presence of 7 mM H2O2. 
 
 
  
154 
 
6.4.3. Small-scale BAL & immobilised enzyme efficacy 
Despite performing the mini-column experiment on two separate occasions, 
both investigations suffered from inconsistent results. It was observed that, 
for the first experiment, one sample replicate for each parameter, lactate or 
DNA concentration, generated results which would have been expected 
based on previous work, yet the partner replicate did not. For both 
parameters, the negative control “Beads Only 1” and the test condition 
“Enzyme Beads 2” appeared to follow the general trend expected of those 
conditions; namely, DNA and lactate levels remained mostly unchanged in 
the negative control and were reduced when immobilised enzyme beads 
were present. However, the replicate condition for each did not follow this, 
nor any, pattern. This could, in part, be due to the low levels of DNA 
present in the test conditions; having normalised the data by subtracting the 
NTC (i.e. plasma only condition) the values obtained were very low, often 
running into the negative value range. It is therefore unlikely that there was 
any real difference in DNA concentrations between the four mini columns; 
on such a small scale, even the apparent peak of the “Beads Only 1” 
condition could potentially be an artefact of PCR and low level DNA 
“noise”.  
The apparent decrease in lactate concentration in the “Enzyme Beads 2” 
column is more likely to be a genuine result, as the value falls comfortably 
within the limit of detection of the analysis method used. Nevertheless due 
to the frequent leaking of solution from the mini-columns, fair test 
conditions could not be adhered to as some columns had to be removed 
from the circuit for repair work, thus altering the duration of treatment and 
also the volume of solution to be treated by the immobilised enzyme or 
empty glass beads. The inter-condition, and indeed, inter-sample variation 
(see fluctuation of data points in Figure 6-6 and Figure 6-7) is likely a result 
of the assembly of the mini-columns themselves and the technical 
difficulties they presented. All four mini-column circuits were subject to 
leakage of varying degrees; notably, for the circuit assigned “Enzyme Beads 
1”, the pump had to be stopped on multiple occasions, for periods of up to 
30 minutes, in order to try to stop leaks from either the base or top of the 
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glass column chamber. As a consequence, it would be unjustified and 
impossible to conclude that the immobilised enzymes had any benefit over 
the negative control in this experimental situation. 
 
The mini-column experimental protocol underwent some modification for 
the second experiment; notably, the inclusion of 5 ml encapsulated HepG2 
cells. However, the experimental set up once again proved problematic and 
leaking mini columns meant that uniform experimental conditions could not 
be maintained. Furthermore, it was observed that seven hours into the 
experiment, almost complete depolymerisation of the alginate beads had 
occurred. This was likely due to citrate, which was added to the FFP during 
collection from the human donor; citrate is a potent chelator of divalent 
ions, and so in this fashion sequestered calcium away from the alginate 
matrix, leading to bead depolymerisation. Another consequence of this 
chelation, is that DNase I activity could likely have been negatively 
affected, by removing the calcium and magnesium ions upon which the 
enzyme is dependent for catalytic activity. Hence, should this experiment be 
repeated, calcium should be titrated into the FFP to negate the action of 
citrate. It should be noted that during the course of treatment with the BAL, 
the patient would not be treated with citrate as an anticoagulant, but heparin, 
thus avoiding this situation. 
A loss of volume due to a leak would result in a lower pressure within the 
mini column circuit, hence decreasing the extent of fluidisation of the ELS 
and so subjecting them to stressful conditions. The delay caused when the 
pump had to be stopped in order to repair columns is likely to have 
contributed to the rising lactate levels demonstrated in Figure 6-9; when no 
longer fluidised the HepG2 spheroids would not have sufficient oxygenation 
and so would rely more upon glycolytic respiration, generating lactate. The 
extent of fluidisation, and hence oxygenation would have been affected by 
the time for which the pump was stopped and also the extent of leaking, 
which would vary between columns and hence could account for at least 
some of the inter sample variation in trend for the same condition. 
Interestingly, by studying the cumulative lactate removed from each column 
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during the treatment period, it would seem that the LOx beads are 
functional, as both enzyme bead conditions show greater lactate clearance 
than the negative controls (Figure 6-10). It is clear that the ELS were 
producing lactate as a response to poor fluidisation, as lactate levels rose 
above that of the initial spike. Yet, plotting the overall rise in lactate over 
the experimental period reveals that this was less so, or indeed, lactate was 
reduced, in the columns containing immobilised enzyme beads, again 
indicating that they were functional in this context. However, this was not 
sufficient to reduce lactate levels below the ~ 10 mM threshold. 
It must be considered that this does not necessarily imply that LOx beads 
would be ineffective in the BAL; rather that more than the seven hour 
treatment time is required to clear 15 mM lactate. This experiment 
represented a “worst case scenario”, in other words, the treatment of a 
critically ill patient with exceptionally elevated lactate levels; however, the 
LOx beads would only be absolutely required to clear lactate during the 
10 day growth phase of the encapsulated HepG2 cells, which would see 
gradual lactate production and thus much more likely to be cleared by the 
LOx beads (note the results shown in Chapter 3 which demonstrated an 
appropriate reduction in lactate concentration). During the treatment phase 
of the BAL, should such high lactate levels be present in the patient’s 
plasma, other, traditional treatments (such as the addition of buffering 
agents) could be administered to prevent the depolymerisation of the 
alginate beads. 
A rise in DNA levels seen in the negative control columns is also likely due 
to cellular stress, damage and death caused by the lack of fluidisation, and 
also physical cell damage when passing through the cap filters once the cells 
were no longer within the alginate beads. It is interesting to note that DNA 
concentrations remained much lower in columns which contained 
immobilised DNase I than in the negative controls (Figure 6-8) strongly 
suggesting that the DNase I is effective, if not functioning optimally under 
these unintentionally harsh experimental conditions. However, as in the 
previous mini column experiment, the very lowest DNA values run into the 
negative values. This demonstrates a limitation of Q-PCR as a means of 
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DNA detection in plasma; in order to avoid reaction inhibition, it was 
necessary to dilute all samples 1/5000 prior to applying to the PCR. Whilst 
possible to compensate for this when generating the standard curve by 
adding more DNA prior to dilution, this is not only practically unfeasible to 
do with samples (the amount of DNA required to spike the total volume of 
each mini column circuit to the concentration used in the previous DNase I 
experiments (100 ng /ml) would be in excess of 20 µg) but also defeat the 
purpose of trying to determine whether the immobilised enzyme can clear 
levels of DNA typically released from HepG2 cells under normal BAL 
conditions. Having been so heavily diluted, small values are distorted, 
particularly after normalisation against the NTC, and so any pattern 
observed may be an artefact. 
 
In conclusion, the data generated by this series of experiments cannot 
empirically support nor reject the hypothesis that enzyme immobilised 
beads can reduce levels of DNA and lactate in a BAL context. Before this 
can be addressed, it is first critical that the mini-column apparatus and 
methodology is fine-tuned and improved in order that it can be assured that 
the experiment will not be compromised by technical errors and 
inaccuracies. Only then can the experimental protocol be repeated and the 
efficacy of DNase I and LOx conjugated beads truly tested in conditions as 
reminiscent as possible of those in the BAL device. 
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7.  General Discussion & Future Work 
The aims of this thesis were to develop a means of reducing concentrations 
of lactate and circulating DNA of non-patient origin. An enzymatic 
approach was chosen whereby the chemical tethering of the enzyme onto a 
variety of solid supports was investigated and the extent of substrate 
clearance used as an indicator of the efficacy of the immobilised enzyme 
complex. As these complexes would be required to function in the presence 
of plasma constituents within a physiological temperature and pH range, 
experimental situations were devised to mimic such conditions as closely as 
possible. 
 
7.1. Lactate Clearance 
Lactate is produced by HepG2 cells as a by-product of glycolytic 
respiration, which, unless measures of intervention are taken, could 
accumulate within the BAL chamber to concentrations in excess of 15 mM. 
At these elevated levels of lactate a detrimental effect is observed upon cell 
proliferation rates (group data). Additionally, in 10 mM lactate, ELS beads 
visibly swell, indicative of a loss of integrity due to chelation of calcium 
ions, thus compromising the integrity of the alginate beads used to house 
populations of HepG2 spheroids. In order to maintain the proliferative 
potential and structural integrity of the ELS, and hence maximise efficiency 
of the BAL unit, it is therefore desirable to employ a means of ensuring 
lactate concentration does not exceed a critical threshold. One approach 
would be to perform frequent media changes of the FBB; however, this may 
be considered wasteful of media, and is both time and labour intensive. 
In this study an enzymatic approach was elected to bring about a “real time” 
reduction in lactate, by utilising the enzyme lactate oxidase to catalyse the 
conversion of lactate in the presence of oxygen to pyruvate. It has been 
demonstrated in this thesis that LOx immobilised onto glass beads retains 
enzymatic activity in the presence of plasma and over a period of at least 
11 days to reduce lactate levels below the 10 mM threshold, whereby it no 
longer poses a threat to the integrity of alginate encapsulated HepG2 cells. 
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7.1.1. Role of LOx in the BAL 
Although lactate oxidase was immobilised for use within the BAL primarily 
in the cell growth phase of ELS culture in the FBB in order to overcome 
detrimental effects on the alginate encapsulated cell spheroids, there exists a 
potential for this technology in other applications. The second phase of BAL 
treatment, whereby the patient’s plasma is passed through the BAL device, 
could in particular benefit from incorporating immobilised lactate oxidase to 
reduce lactate concentrations in the plasma before returning it to the patient. 
Lactate concentration is an established prognostic tool in the determination 
of patient outcome in Acute Liver Failure (ALF), particularly in 
acetaminophen-induced cases (154). In healthy individuals lactate is 
converted by the process of gluconeogenesis in the liver but in ALF a net 
splanchnic release of lactate is observed (155). Elevated lactate 
concentration is strongly correlated with increased mortality rates; patients 
with serum lactate levels above 2 mmol/L which persist for over 24 hours, 
have been shown to have a 70% increased mortality rate (156). Lactic 
acidosis occurs following accumulation of lactate, produced via the 
anaerobic metabolism of glycolysis in hypoperfused tissue; with prolonged 
oxygen deficit, acidosis ensues and the body’s buffering capacity is 
exceeded (157;158). Although a mode of providing glucose rapidly, 
anaerobic glycolysis (utilising the glycolytic pathway) is much less efficient 
than standard aerobic respiration, generating just two molecules of ATP, 
compared to the 15 generated in aerobic respiration, per glucose molecule 
(159). It is therefore in the interest of the patient to repay the oxygen debt 
and restore lactate concentrations to the normal range of 0.5-1 mmol/L. 
However, the situation is exacerbated in liver failure patients; the liver 
normally converts blood lactate via gluconeogenesis to glucose, which is 
then used as an energy source for the hepatic cells. Yet the ability of the 
liver to take up lactate is concentration dependent, the extent of uptake 
being negatively proportional to the blood lactate concentration. Therefore, 
by removing less lactate from the blood, a failing liver not only limits its 
own energy supply, but also contributes to the progression of hyperlactemia. 
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Historically, bicarbonate has been used to buffer the excess anions in 
patients presenting with lactic acidosis, but this has now been phased out 
since it frequently proved more harmful than beneficial, owing to an 
increase in carbon dioxide and a further lowering of pH. Carbicarb, an 
equimolar mix of sodium bicarbonate and sodium carbonate, is used to 
buffer blood serum ions, and hemodialysis is another option for restoring 
lactate levels. However, the inclusion of immobilised LOx within the BAL 
unit would permit the restoration of normal serum lactate levels as part of 
the complete approach, negating the need for separate treatments and thus 
potentially having time, economic and patient comfort benefits, contributing 
to an improved QUALY (quality adjusted life years) score. 
Moreover, including LOx in the BAL could potentially provide a means of 
preventing a loss of function of the immobilised DNase I, by keeping lactate 
levels as low as possible and thus minimising the possibility of divalent ions 
being sequestered and made unavailable to DNase I, the activity of which is 
highly dependent upon calcium and magnesium ions. 
 
The benefits of using immobilised LOx to reduce lactate levels in patients 
would need to be clinically assessed, to investigate whether any 
improvement in prognosis could be observed by lowering lactate 
concentration in isolation of the plethora of other complications that a 
failing liver would present. One way of determining this could be to 
investigate the levels of ATP synthesis as a marker for improved cellular 
respiration, which would at least ameliorate the burden on a failing liver. 
 
7.2.  DNA Removal 
There is the potential risk to patient safety if HepG2 DNA is released from 
damaged cells and then enters the circulation via the BAL system. A 
physical barrier is planned to be used within the BAL circuit to prevent this 
but as a fail-safe method, this project sought to immobilise the DNA 
degrading enzyme, DNase I, to minimise this risk to become practically 
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negligible. It has been demonstrated in this work that DNase I immobilised 
onto glass beads retains catalytic activity in physiologically relevant 
conditions (pH7.4 and at 37⁰C) although not to the same extent as the 
native, free enzyme. 
DNA removal occurs naturally within the body, with several strategies 
being utilised to clear superfluous DNA, particularly from damaged and 
apoptotic / necrotic cells. In addition to the action of macrophages, DNase I 
is intrinsic to plasma where it acts to scavenge and degrade circulating 
DNA. Another example is that of serum amyloid P component (SAP), a 
pentraxin protein which has been shown to bind to chromatin (160), 
extracellular accumulations of which are coated with SAP (161). SAP has 
been suggested to play a role in facilitating endocytosis in macrophages, 
thus contributing to the extracellular clearance of DNA (162). Moreover, the 
protein contains a nuclear localisation sequence, leading to the proposal that 
SAP can enter the nucleus of a damaged cell (i.e. a compromised plasma 
membrane) to bind DNA before it is released from the cell (163). Despite 
this, it would not be acceptable to assume that these intrinsic methods of 
DNA removal would be sufficient to remove completely and hence 
minimize risk from any additional DNA of non-patient origin. For this 
reason, taken with the data that immobilised DNase I functions well in 
plasma, the inclusion of immobilised DNase I beads will be a suitable 
measure to ensure that patient safety is maintained during treatment with the 
BAL device. 
 
7.2.1. DNase I immobilisation 
As DNase I is intended to be used within the BAL device itself, it was 
appealing to elect an immobilisation platform such as magnetic 
Dynabeads® which could be easily retained and recovered, as this would 
minimise the possibility of the enzyme linked beads entering other 
components of the BAL and potentially causing a blockage in the circuit. 
However, experiments showed poor activity of the subsequent immobilised 
enzyme, and so the same basic protocol was used as had been previously 
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demonstrated to be successful with LOx immobilisation. The lysine 
targeting approach appears to successfully cross-link DNase I to the glass 
bead support, although a reduction in activity is observed. A reduction in 
activity is not uncommon after immobilisation, as the process of 
immobilisation often distorts the physical conformation of the enzyme, thus 
affecting the ease and mode of interaction with its target substrate (164), 
although the large size of DNA, the substrate, could also have played a role. 
In the catalysis of DNA and the formation of the enzyme-substrate complex, 
it is, unusually, DNA which undergoes a conformational change, not 
DNase I (165). It is not improbable that the “mesh” of cross-linker, 
particularly in the case of the long NHS-PEG ester, formed an impermeable 
barrier between immobilised enzyme and DNA, or created an environment 
in which DNA could become entangled and thus prevented from having the 
degree of flexibility required to form a successful interaction with DNase I. 
An interesting alternative mode of immobilisation would be to engineer a 
tagged form of DNase I, such as has been done recently for lactate 
dehydrogenase (166); in this way, the orientation and site of cross-linking 
would be certain, minimising the need for long cross linking molecules and 
thus reducing the steric hindrance effects upon DNA. 
 
7.2.2. Additional clinical uses for immobilised DNase I 
The use of immobilised DNase I as a therapeutic for the treatment of other 
diseases is a possibility. There exists already much research into the use of 
DNase I as a means of reducing circulating DNA levels in SLE patients and 
thus ameliorating the symptoms of an autoimmune response (141;151), and 
also for removing DNA deposits in cystic fibrosis patients (141;142;167). 
Recently, it has been demonstrated that administration of RNase and 
DNase I can bring about an almost complete elimination of metastases in 
tumour bearing mice and also leads to an immunomodulatory effect (168). 
However, before research into these areas could go ahead, it would be 
necessary to devise first a mode, rather than passing the plasma over the 
DNase I beads, which is far less invasive and thus more practical and 
feasible for use within these particular clinical contexts. 
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7.3.  Existing Clinical Applications for Enzyme 
Immobilisation 
The majority of investigations have used enzymes in solution to be 
administered either orally or as an injectable, with relatively few studies into 
the use of immobilised enzyme complexes as a potential therapeutic agent. 
Immobilised enzymes are frequently found in the bio-clinical field as an 
analytical tool, most often in the form of biosensors, but less often as 
therapeutics in their own right. However, a selection of prominent examples 
will now be discussed, demonstrating that there is a need and a role for 
immobilised enzymes in therapeutic strategies. 
 
7.3.1. Glucocerebrosidase & Gaucher’s Disease. 
Type I Gaucher’s Disease is a lysosomal storage disease (LSD) defined by a 
deficiency in the enzyme glucocerebrosidase (GCR) (169) which is required 
for the metabolism of glycosphingolipids (170;171). In this disease, the 
sphingolipid accumulates in macrophages which infiltrate primarily the 
viscera and bone marrow where the major symptoms are manifested, 
namely anaemia, an increased risk of infection due to low leukocyte 
numbers, and a low platelet count (170;172). It has been demonstrated that 
GCR can be successfully immobilised into spherical microspheres by pre-
adsorbing GCR onto a calcium titanium phosphate powder before mixing 
this enzyme conjugated ceramic powder with a sodium alginate solution 
(173). This was then polymerised into spherical microspheres of a 
homogenous size which exhibited a steady release of the enzyme. Although 
this has not yet been tested in vivo, it serves as a promising start to a role as 
a drug delivery mechanism for immobilised GCR as a treatment for a range 
of glycosphingolipidoses, not just Gaucher’s Disease (174). 
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7.3.2. Deoxyribonuclease I & cystic fibrosis 
Cystic fibrosis (CF) is one of the most common autosomal recessive genetic 
disorders, affecting 1 in 2000 Caucasian live births. It affects endothelial 
cells’ ability to clear pulmonary secretions, which accumulate to create an 
environment prone to infection. It is the retention of pulmonary secretions 
which give the disease its characteristic symptom of a thick, viscous 
sputum, a result of neutrophil derived DNA (167;175). 
Deoxyribonuclease I, an endonuclease which degrades double stranded 
DNA, has been utilised for some time in the management of CF. 
Traditionally, it has been administered as a “raw” enzyme suspension via 
nebulisation, but a recent study encapsulated the enzyme within poly(lactic-
co-glycolic acid) nanoparticles (176). The results demonstrated that the 
nanoparticles had no significant cytotoxic effects and had a satisfactory 
level of nebulising efficiency, but immobilised DNase I activity decreased 
by a third in comparison to the original enzyme. Intended as a carrier for 
drug delivery, this approach remains to be tested in a clinical trial situation. 
 
7.3.3. L-asparaginase & acute lymphoblastic leukaemia 
The use of L-asparaginase (ASP) to treat Acute Lymphoblastic Leukaemia 
(ALL) has been implemented for over 40 years (177), aiming to reduce 
abnormal lymphoblast numbers by depriving them of L-asparagine via 
catalysis of its breakdown into aspartic acid and ammonia (178). However, 
to overcome issues with immuno-incompatibility when injected, a recent 
study has developed a method for immobilising ASP within a glycidyl 
methacrylate-co-ethylene glycol dimethacrylate (GMA-co-EDMA) 
monolithic column as part of an extracorporeal shunt system (179). The 
proposed treatment would be to pass patients’ plasma through an 
extracorporeal circuit containing ASP where levels of L-asparagine would 
be depleted before the plasma is returned to the patient. Thus direct contact 
between ASP and cells of the patient’s immune system would be eliminated, 
therefore avoiding an immune response. Preliminary data showed that 
following an incubation period of eight hours, ASP was successfully 
immobilised onto the monolith, with kinetic data demonstrating that the 
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conjugated enzyme actually had a lower Km value than the free enzyme, 
indicative of an increased affinity for the substrate molecule (179;180). The 
remarkable finding however, was that when human serum spiked with 
L-asparagine was applied to this system, a rapid increase in serum aspartic 
acid and an almost complete absence of L-asparagine was detected after 
30 minutes (179), and that no significant decrease in immobilised ASP 
activity was apparent after a period of 21 days. This indicates that the use of 
immobilised ASP is a promising alternative to traditional ALL 
chemotherapy treatments, benefiting patients whilst avoiding many of the 
common detrimental side effects including hepatic toxicity, errors with 
blood clotting factors and adverse immunological reaction (181). 
 
7.3.4. Urease in artificial kidney devices 
Urease catalyses the conversion of urea to ammonia and carbon dioxide and 
has been utilised in an immobilised form in several artificial kidney device 
designs, where it is contained within an extracorporeal circuit to cleanse the 
plasma of urea. Non toxic and biocompatible polymers (xanthan and 
alginate) have been used to entrap urease into microspheres, an approach 
which saw the retention of 75% the activity of the original enzyme (182). 
The protocol called for polymerisation of the alginate-urease mixture in a 
Ca
2+
 solution containing gelatine, which was subsequently used to cross-link 
urease using glutaraldehyde. The immobilised enzyme demonstrated greater 
stability to pH and temperature in vitro, and the physical integrity of the 
microspheres was not compromised after multiple uses. Furthermore, only 
25% activity was lost following the reuse of the microspheres for a total of 
20 times over a period of 40 days, indicating that the urease microspheres 
are suitable for use over a prolonged period, a phenomenon which would 
hold potential at the theoretical level for use in a therapeutic device. 
A more recent study also utilised an alginate-urease suspension to form 
microspheres which did not exhibit enzyme leaching after 48 hours (183). 
Although some activity was lost during immobilisation, when applied to a 
urea-containing solution, designed to mimic blood, the concentration of urea 
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was reduced to 25% of the initial concentration after five hours of perfusion 
(183), again demonstrating the potential that alginate microspheres have for 
clearing urea in renal failure patients. 
 
Chen at al. utilised a poly(vinyl)alcohol (PVA) membrane to immobilise  
urease (184) which, with an ion-exchange membrane, formed a membrane 
reactor-separator, for the removal of urea from solution. In vitro studies 
demonstrated that this system effectively reduced pre-treatment levels of 
urea in citrate buffer whilst preventing the backflow of ammonium ions into 
the pre-treatment solution. 
 
One approach which has been tested experimentally in vivo (in sheep 
models) saw the co-encapsulation of PEG derived urease and alanine 
dehydrogenase within ovine erythrocytes (185). Once injected into sheep on 
a urea supplemented diet, the enzyme-packed erythrocytes continued to 
retain activity for six days (compared to two days when not encapsulated), 
effectively lowering urea concentration directly in the blood stream, without 
evoking an immune response. The longevity of immobilised enzymes in this 
treatment is probably associated with the production of NADH and pyruvate 
by erythrocyte metabolism, molecules which are required for the 
regeneration and hence continued use of the encapsulated enzymes. 
 
7.3.5. Bilirubin oxidase & liver failure 
One common symptom of liver failure is jaundice, attributed to the 
accumulation of bilirubin due to substantial hepatocyte depletion and hence 
a deficit of bilirubin degrading enzymes. To alleviate this, a potential 
therapy has been proposed whereby bilirubin oxidase is conjugated to 4% 
Sepharose beads within a packed bed bioreactor (186) through which the 
patient’s blood would be passed as part of an extracorporeal circuit. This 
system was shown to convert more than 90% bilirubin to biliverdin in vivo 
in rat models and although a 20% reduction in red blood cell number was 
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observed, no significant decrease in white blood cell or platelet number was 
recorded. Also, the products formed were not found to have any tumour 
inducing or cytotoxic effects. This was also the case for human blood tested 
in vitro, demonstrating a potential role for this strategy in the management 
of liver failure. 
 
7.4. Future Work 
The work presented in this thesis has demonstrated the proof of principle 
behind utilising immobilised enzymes to convert undesirable molecules into 
harmless or potentially useful substrates for the ELS of the BAL. However, 
were more time and resources available, there remain a number of questions 
which must be addressed before this approach can be fully incorporated into 
the BAL for patient treatment. These are outlined and discussed in the 
following sections. 
 
7.4.1. Determination of efficiency of LOx immobilisation 
Antibodies against DNase I have been used in this study to determine the 
extent of enzyme immobilisation to the glass bead support. However, this 
information has not been possible to directly ascertain for immobilised LOx, 
owing to the lack of a suitable antibody. Should time and funding have 
permitted, it would have been desirable to create such an antibody, to allow 
for an optimisation of the immobilisation procedure. 
 
7.4.2. Pyruvate utilisation by ELS 
The enzymatic degradation of lactate leads to the synthesis of hydrogen 
peroxide and pyruvate. Although it has been herein demonstrated that the 
hydrogen peroxide produced does not appear to have a significant 
detrimental effect upon the survival or synthetic activity of ELS, it remains 
to be seen whether the pyruvate generated bestows any growth advantage to 
the cells, compared to growth rates in media in the absence of 
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supplementary energy substrates. In theory, the availability of additional 
pyruvate, which is a substrate for the citric acid cycle (also Krebs cycle), 
could mean that there would be a greater availability of energy sources to 
the ELS. However, it is likely that any growth advantage would only 
become apparent were the glucose availability limited in some way; as the 
media in which the ELS are cultured is currently supplemented with a high 
glucose concentration, it would follow that this would rarely be the case, but 
the glucose balance could be investigated and optimised further. Indeed, 
recent data from our group suggests that a lower glucose concentration in 
fact promotes cell proliferation. 
 
7.4.3. Storage stability of immobilised enzyme complexes 
The nature of Acute Liver Failure (ALF) necessitates a mode of treatment 
which can be made readily available, as and when a case is presented. In 
order to achieve this, the BAL device is being developed so that the entire 
chamber, containing sufficient numbers of functional ELS, can be frozen for 
storage and then thawed and utilised when required, in effect providing an 
“off the shelf” service. Therefore, it would be desirable that the immobilised 
enzyme cartridge also be frozen or prepared in another manner for mid- to 
long-term storage; although the immobilisation process is not as time 
consuming as is the culture of functional ELS, this nevertheless imposes a 
significant delay in patient treatment which could prove fatal. 
Although it has often been reported that immobilisation confers a degree of 
structural stability to an enzyme, the extent of damage incurred by the 
process of freezing and thawing the enzymes must be determined 
empirically. A proposed method to determine this would be to compare the 
enzymatic activity of immobilised enzyme complexes after storage in frozen 
conditions for varying periods of time with freshly prepared immobilised 
enzyme beads. 
Furthermore, deamination of asparagines and glutamine residues on 
DNase I is known to occur over time when stored in vials and is often 
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concurrent with a decrease in enzyme activity (143). This is another factor 
which should be investigated in future work. 
 
7.4.4. Full-scale system of lactate / DNA removal 
In an attempt to assess the usefulness and efficacy of using immobilised 
LOx and DNase I within the BAL, scaled-down models of the BAL were 
utilised, using a mini-column circuit within which ELS and both 
immobilised LOx and DNase I were cultured in human plasma for a period 
of eight hours (representative of the proposed patient treatment time). 
Another factor for consideration is the optimal positioning of the 
immobilised enzyme complexes within the BAL unit. Current mini-column 
experiments have been simplified models of the full-scale BAL chamber 
and its circuit; issues of practicality meant that it was most appropriate to 
house the beads in the glass column, in order to ensure sufficient flow that 
the immobilised enzymes were exposed to as much of the substrate as 
possible. This meant sharing space with the ELS in the second mini-column 
experiment; although no mixing of immobilised enzyme beads and ELS was 
observed, as the former (being much denser) were not fluidised and 
remained at the base of the column, this would not be ideal in the more 
complex, full-scale BAL system. Therefore, a series of further experiments 
would be required to account for the relative effects upon flow rate and 
pressure that introducing a cartridge to house the immobilised enzyme 
complexes would incur. In terms of the positioning of this cartridge, it 
would be logical to have this after the chamber containing the ELS, 
although as the BAL system is based upon a double circuit, it may also be 
possible to have this cartridge elsewhere, if necessitated by issues of 
pressure, space and other practical considerations. 
Before moving the current model to a full-scale BAL chamber experiment it 
would first be necessary to devise a protocol for the scaled-up production of 
the immobilised enzymes. Currently, 100 mg of glass beads have been 
required per “dose” when treating a 200 ml total volume within the mini-
column circuit. These beads are produced in individual 100 mg batches (as 
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described in the General Materials & Methods chapter); however, although 
it would not be feasible to prepare multiple batches simultaneously using 
this current methodology to produce the total quantity of immobilised 
enzymes which would be required in a full-scale BAL experiment, a scale-
up process of immobilisation would permit this. Alternatively, recent 
research has demonstrated that the use of UV light may be a practical and 
effective way of immobilising enzymes in larger quantities (187), which 
would also have the advantage of being a “green” method of 
immobilisation, as the use of harsh chemicals for immobilisation is vastly 
reduced. This would represent an interesting line of research, in terms of 
optimisation of the immobilisation process for LOx and DNase I. 
 
7.4.5. Optimisation of immobilised enzyme activity 
The covalent immobilisation of DNase I and LOx onto glass beads has been 
demonstrated in this thesis to be an effective mode of reducing DNA and 
lactate concentrations in 10% FFP media and human plasma. In both 
circumstances, the activity of the immobilised enzyme was found to be less 
than that of the corresponding free enzymes, although sufficient activity was 
retained in order to bring about a significant reduction in substrate 
concentrations, compared to the relevant negative control. Nevertheless, in 
order to optimise the efficacy and efficiency of treatment with immobilised 
LOx and DNase I, an investigation into the use of modified variants of the 
enzymes and/or alternative cross-linking strategies would have been 
conducted had time permitted. For example, it has been frequently stated in 
the literature that LOx is an unstable enzyme, owing to its lack of thermal 
stability even when immobilised (188;189), a phenomenon which was also 
observed in this study, as exemplified in Figure 3-4 (page 60). To overcome 
this, an approach of using directed evolution has been used by others, for 
example, comprising a random mutagenesis step followed by error prone 
PCR and DNA shuffling, to generate a mutated form of LOx which 
exhibited a half life 36-times greater than that of the wild type enzyme 
(190). Manipulation of the enzyme prior to immobilisation in order to 
improve functionality has also been used to generate a galactose oxidase 
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variant with a ~four-fold improvement in Km and Vmax, by a process of error 
prone PCR and subsequent screening (191). 
Moreover, by modifying the enzyme, for example by introducing a cysteine 
mutation (192) or by incorporating a peptide tag at a region unlikely to 
affect the enzyme’s active site, which is specific for the immobilisation 
support (166) – termed “orientated immobilisation” – greater retention of 
enzymatic activity can be observed following immobilisation. Another 
example demonstrating the merits of orientated immobilisation is a 
cytochrome c reductase assay which revealed that enzymes tethered in an 
orientated manner displayed three-fold greater activity levels compared to 
randomly immobilised enzyme controls (193). 
In the light of this data, it could thus be possible to achieve a more efficient 
immobilised LOx and DNase I enzyme by genetically altering the initial 
enzyme. In addition to potentially improving specific activity of the 
enzyme, another advantage of engineering would be that a specific antibody 
against the enzyme could be generated, facilitating quality control measures; 
of particular interest for LOx, as to date, no antibody is readily available. 
 
7.5. Conclusion 
The aim of this thesis was to devise a means of immobilising enzymes to 
address the deleterious effects of high lactate levels and DNA of non-patient 
origin from a Bio-Artificial Liver support device. Through the experiments 
undertaken, it has been demonstrated that by using glass beads as an 
immobilisation support, Deoxyribonuclease I and Lactate oxidase can be 
covalently attached to the matrix. The process of immobilisation in both 
instances does have a negative impact upon the Vmax, the rate at which 
enzymatic catalysis of the substrate occurs, compared to the native free 
enzyme. However, both enzymes have been shown to retain an acceptable 
level of activity, leading to significant reductions in both lactate and DNA 
concentrations in spiked solutions. This is also the case when in the 
presence of human plasma and in physiological conditions reminiscent of 
those likely to be encountered in the FBB / BAL. Although investigations 
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conducted on a small-scale replica of the BAL failed to provide any 
conclusive evidence that the immobilised enzyme complexes improve 
lactate and DNA levels, it is probable that flaws in the methodology 
prevented a true indication of what was actually occurring in these 
conditions. In spite of this, from the data it can be postulated that, although 
more verification work needs to be undertaken using improved methodology 
for confirmation, enzyme immobilisation is a viable approach to reducing 
lactate and circulating DNA levels within the BAL, in order to improve the 
safety and efficacy of this device as a therapy for patients with acute liver 
failure. 
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